PMID,Multiple Answer,time_usage
18715920,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of drug susceptibility. Furthermore, the paper mentions specific platforms used for drug susceptibility testing, such as PhenoSense and Monogram.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions that sequences were submitted to public databases, which suggests that the sequences are publicly available. Additionally, the paper reports accession numbers, which are unique identifiers for the sequences in the public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly reports accession numbers for GenBank, which are used to identify the sequences in the public database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing, genotyping, or sequencing was performed on samples from 9 individuals.

Rationale: The paper mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from 9 individuals, which suggests that 9 individuals had samples obtained for HIV sequencing.

Answer: 9

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in the United States.

Rationale: The paper explicitly mentions that samples were collected in the United States, which suggests that the sequenced samples were obtained from this country.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2004 and 2007.

Rationale: The paper explicitly mentions that clinical samples were collected between 2004 and 2007, which suggests that the sequenced samples were obtained during this time period.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper explicitly mentions that the pol region encompassing protease and reverse transcriptase was sequenced, which suggests that these genes were reported to have been sequenced.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which are both used for Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a randomized, double-blind, placebo-controlled trial.

Rationale: The paper explicitly mentions that the study was a randomized, double-blind, placebo-controlled trial, which suggests that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that patients received ARV drugs prior to sequencing.

Rationale: The paper explicitly mentions that patients received ARV drugs prior to sequencing, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients received NRTIs, NNRTIs, and PIs prior to sequencing.

Rationale: The paper explicitly mentions that patients received NRTIs, NNRTIs, and PIs prior to sequencing, which suggests that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients received AZT, 3TC, FTC, TDF, ATV, DRV, RAL, EVG, DTG, BIC, CAB, and LEN prior to sequencing.

Rationale: The paper explicitly mentions that patients received AZT, 3TC, FTC, TDF, ATV, DRV, RAL, EVG, DTG, BIC, CAB, and LEN prior to sequencing, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, ATV, DRV, RAL, EVG, DTG, BIC, CAB, LEN",26
19104010,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV sequences from patient samples. Additionally, the paper mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to analyze in vitro drug susceptibility data. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of in vitro drug susceptibility. Additionally, the paper mentions cell-based susceptibility assays, which are used to measure the susceptibility of HIV to different drugs.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which suggests that the sequences are publicly available. The paper also reports accession numbers, which are unique identifiers for the sequences in the public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly reports accession numbers for GenBank, which are unique identifiers for the sequences in the public database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing, genotyping, or sequencing was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper explicitly mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from X number of individuals, which suggests that X individuals had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in the United States. The paper mentions nationwide ""cohort"" or ""surveillance"" or ""registry"" in the United States.

Rationale: The paper explicitly mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in the United States, which suggests that the sequenced samples were obtained from the United States.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2004 and 2007.

Rationale: The paper explicitly mentions that clinical samples were collected between 2004 and 2007, which suggests that the sequenced samples were obtained during this time period.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""pol genotyping/sequencing"" without providing individual genes. The paper mentions ""pol region encompassing protease and reverse transcriptase"", ""PR/RT"", ""ViroSeq"", or ""TruGene (PR/RT)"".

Rationale: The paper explicitly mentions that pol genotyping/sequencing was performed, which suggests that the pol gene was sequenced. The paper also mentions the pol region encompassing protease and reverse transcriptase, which suggests that these genes were also sequenced.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments, BigDye/ABI PRISM Dye Terminator, capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms.

Rationale: The paper explicitly mentions ABI instruments, BigDye/ABI PRISM Dye Terminator, capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms, which are all methods used for Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""virologic or virological failure (VF)"" or ""failing therapy or regimen"" e.g., failing NNRTI/PI/INSTI or ""salvage regimen"".

Rationale: The paper explicitly mentions virologic or virological failure (VF) or failing therapy or regimen, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms.

Rationale: The paper explicitly mentions randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter with intervention arms, which are all characteristics of clinical trials.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper explicitly mentions that the patients were on ART, ART-experienced, treatment-experienced, heavily pretreated, or had a salvage regimen, which suggests that the patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""treatment-naïve"", ""ART-naïve"", ""drug-naïve"", ""never exposed to antiretrovirals"", ""before ART initiation"", ""pre-ART"", ""newly diagnosed"", ""seroconverter"", ""blood donor"", ""primary/acute infection without ART"", or samples collected ""at diagnosis/baseline prior to therapy"".

Rationale: The paper explicitly mentions that the patients were treatment-naïve, ART-naïve, drug-naïve, or never exposed to antiretrovirals, which suggests that the patients had not received any ARV drugs before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper explicitly mentions that the patients were on ART, ART-experienced, treatment-experienced, heavily pretreated, or had a salvage regimen, which suggests that the patients received various ARV drugs before sample sequencing.

Answer: Not reported",32
21115794,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV sequences from patient samples. Additionally, the paper mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of drug susceptibility. Additionally, the paper mentions specific platforms used for drug susceptibility testing, such as PhenoSense and Monogram.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which suggests that the sequences are publicly available. The paper also reports accession numbers, which are unique identifiers for the sequences in the public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly reports accession numbers for GenBank, which are unique identifiers for the sequences in the public database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing, genotyping, or sequencing was performed on samples from 50 individuals.

Rationale: The paper explicitly mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from 50 individuals, which suggests that 50 individuals had samples obtained for HIV sequencing.

Answer: 50

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in the United States.

Rationale: The paper explicitly mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in the United States, which suggests that the sequenced samples were obtained from the United States.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2008 and 2010.

Rationale: The paper explicitly mentions that clinical samples were collected between 2008 and 2010, which suggests that the sequenced samples were obtained during this time period.

Answer: 2008-2010

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper explicitly mentions that the pol region encompassing protease and reverse transcriptase was sequenced, which suggests that the HIV genes sequenced were protease and reverse transcriptase.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which suggests that the sequencing method used was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that the type of sample sequenced was plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a randomized, double-blind, placebo-controlled trial.

Rationale: The paper explicitly mentions that the study was a randomized, double-blind, placebo-controlled trial, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that patients received ART, including NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions that patients received ART, including NRTIs, NNRTIs, and PIs, which suggests that the HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions that patients received NRTIs, NNRTIs, and PIs, which suggests that the drug classes received by individuals in the study were NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients received AZT, 3TC, EFV, ATV, and DRV.

Rationale: The paper explicitly mentions that patients received AZT, 3TC, EFV, ATV, and DRV, which suggests that the specific drugs received by individuals in the study were AZT, 3TC, EFV, ATV, and DRV.

Answer: AZT, 3TC, EFV, ATV, DRV",26
23749954,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers also suggests that the sequences were generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions that cell-based susceptibility assays were used, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293 with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility and resistance testing, which suggests that in vitro drug susceptibility data were reported. The mention of specific values such as IC50 and EC50 also supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also mentions accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly mentions accession numbers for GenBank, which suggests that the sequences were deposited in GenBank.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 4 individuals.

Rationale: The paper explicitly mentions that genotypic resistance testing was performed on samples from 4 individuals.

Answer: 4

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the year of sample collection.

Rationale: The paper does not provide any information about the year of sample collection.

Answer: Not Reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region was sequenced.

Rationale: The paper explicitly mentions that the pol region was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly mentions Sanger sequencing, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma was used for sequencing.

Rationale: The paper explicitly mentions that plasma was used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that NRTIs were received by individuals in the study before sample sequencing.

Rationale: The paper explicitly mentions NRTIs, which suggests that this drug class was received by individuals in the study before sample sequencing.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that abacavir was received by individuals in the study before sample sequencing.

Rationale: The paper explicitly mentions abacavir, which suggests that this drug was received by individuals in the study before sample sequencing.

Answer: Abacavir",19
24227862,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions the use of clinical samples, which suggests that the sequences were obtained from patient samples. The paper also mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Additionally, the paper reports GenBank accession numbers, which are used to identify and access the sequences in a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility and resistance testing, which are methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. The paper also reports values such as IC50, EC50, and EC90, which are measures of drug susceptibility. Additionally, the paper mentions specific platforms used for drug susceptibility testing, such as PhenoSense and Monogram.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper mentions that sequences were submitted to GenBank, which is a public database that makes sequences available to researchers. The paper also reports accession numbers, which are used to identify and access the sequences in the database. However, the paper notes that the accession numbers are pending, which suggests that the sequences may not be publicly available yet.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper provides specific accession numbers for GenBank, which are used to identify and access the sequences in the database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing was performed on samples from 100 individuals. The paper also reports that sequences were obtained from a panel of 50 isolates from the plasma of 50 treatment-naive individuals.

Rationale: The paper provides specific numbers of individuals and isolates that were used for sequencing, which suggests that the sequences were obtained from a relatively large number of individuals.

Answer: 100

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in the United States. The paper also mentions a nationwide cohort in the United States.

Rationale: The paper provides specific information about the location where the samples were collected, which suggests that the samples were obtained from the United States.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2004 and 2007.

Rationale: The paper provides specific dates for when the samples were collected, which suggests that the samples were obtained over a relatively short period of time.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced. The paper also mentions TA cloning and Topo TA cloning.

Rationale: The paper provides specific information about the cloning method used, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region was sequenced. The paper also mentions the sequencing of the protease and reverse transcriptase genes.

Rationale: The paper provides specific information about the genes that were sequenced, which suggests that the sequencing was focused on the pol region.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used. The paper also mentions the use of ABI instruments and BigDye.

Rationale: The paper provides specific information about the sequencing method used, which suggests that Sanger sequencing was the primary method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing. The paper also mentions the use of PBMCs and whole blood.

Rationale: The paper provides specific information about the type of samples used for sequencing, which suggests that plasma samples were the primary type used.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen. The paper also mentions the use of the term ""virologic failure"".

Rationale: The paper provides specific information about the individuals from whom sequences were obtained, which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a randomized, double-blind, placebo-controlled trial. The paper also mentions the use of the term ""clinical trial"".

Rationale: The paper provides specific information about the study design, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included individuals who had previously received ARV drugs. The paper also mentions the use of the term ""ART-experienced"".

Rationale: The paper provides specific information about the individuals included in the study, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who had received NRTIs and NNRTIs. The paper also mentions the use of the term ""ART-experienced"".

Rationale: The paper provides specific information about the drug classes received by the individuals in the study, which suggests that the study included individuals who had received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who had received AZT, 3TC, and EFV. The paper also mentions the use of the term ""ART-experienced"".

Rationale: The paper provides specific information about the drugs received by the individuals in the study, which suggests that the study included individuals who had received AZT, 3TC, and EFV.

Answer: AZT, 3TC, EFV",27
25637519,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions sequencing on clinical samples, which suggests that the sequences were obtained from patient samples. The mention of ART-naïve and ART-experienced patients, baseline and virologic failure samples, and transmitted drug resistance also suggests that the sequences were obtained from patient samples. The report of GenBank accession numbers further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, resistance testing, and drug susceptibility assay, which suggests that the paper reports in vitro drug susceptibility data. The report of IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility values also supports this conclusion. The mention of cell-based susceptibility assays with drug titrations and reporter readouts further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions submission of sequences to public databases, which suggests that the sequences were made publicly available. The report of accession numbers for GenBank or other databases also supports this conclusion. The report of deposition or availability in a sequence database further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”. The accession numbers could be presented in the Methods, in a Table, or in a Data Availability statement.

Rationale: The paper reports accession numbers for GenBank, which suggests that the accession numbers are for sequenced HIV isolates. The report of specific accession numbers, such as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”, further supports this conclusion.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper mentions genotypic resistance testing, genotyping, or sequencing on samples from X number of individuals, which suggests that X individuals had samples obtained for HIV sequencing. The report of X sequences from Y individuals further supports this conclusion.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in China. The paper mentions nationwide “cohort” or “surveillance” or “registry” in China.

Rationale: The paper mentions recruitment, enrollment, or follow-up of patients in China, which suggests that the sequenced samples were obtained from China. The mention of a nationwide cohort or surveillance or registry in China further supports this conclusion.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2010 to 2015. The paper lists per-year counts “collected in 2010, 2011, 2012, 2013, 2014, 2015”.

Rationale: The paper mentions collection of clinical samples between 2010 to 2015, which suggests that the sequenced samples were obtained between 2010 to 2015. The report of per-year counts further supports this conclusion.

Answer: 2010-2015

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”. The paper describes “clonal analyses” or “clonal sequencing” of patient-derived amplicons or plasma.

Rationale: The paper mentions cloning of amplicons and sequencing, which suggests that samples were cloned prior to sequencing. The description of clonal analyses or clonal sequencing of patient-derived amplicons or plasma further supports this conclusion.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing”. The paper mentions sequencing of the pol region encompassing protease and reverse transcriptase.

Rationale: The paper mentions pol genotyping or sequencing, which suggests that the pol gene was sequenced. The mention of sequencing of the pol region encompassing protease and reverse transcriptase further supports this conclusion.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator. The paper states capillary sequencer/capillary electrophoresis with ABI analyzers.

Rationale: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which suggests that Sanger sequencing was used. The mention of capillary sequencer/capillary electrophoresis with ABI analyzers further supports this conclusion.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”. The paper states that sequencing was performed on plasma-derived sequences.

Rationale: The paper mentions extraction of viral RNA from plasma, which suggests that plasma was the sample type. The mention of sequencing of plasma-derived sequences further supports this conclusion.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen”. The paper mentions sequencing or genotyping were done for participants with VL >50 copies/mL while on ART.

Rationale: The paper mentions virologic failure or failing therapy, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen. The mention of sequencing or genotyping for participants with VL >50 copies/mL while on ART further supports this conclusion.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper mentions a “registry” that explicitly has an NCT identifier indicating a trial.

Rationale: The paper mentions randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter with intervention arms, which suggests that the study was a clinical trial. The mention of a registry with an NCT identifier further supports this conclusion.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”. The paper mentions sequencing or genotyping were done for participants who had previously received ARV drugs.

Rationale: The paper mentions ART, cART, HAART, ART-experienced, treatment-experienced, heavily pretreated, or salvage regimen, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs. The mention of sequencing or genotyping for participants who had previously received ARV drugs further supports this conclusion.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”. The paper mentions sequencing or genotyping were done for participants who had previously received ARV drugs.

Rationale: The paper mentions ART, cART, HAART, ART-experienced, treatment-experienced, heavily pretreated, or salvage regimen, which suggests that the individuals in the study received NRTIs. The mention of sequencing or genotyping for participants who had previously received ARV drugs further supports this conclusion.

Answer: NRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”. The paper mentions sequencing or genotyping were done for participants who had previously received ARV drugs.

Rationale: The paper mentions ART, cART, HAART, ART-experienced, treatment-experienced, heavily pretreated, or salvage regimen, which suggests that the individuals in the study received zidovudine/AZT, lamivudine/3TC, emtricitabine/FTC, tenofovir TDF/TAF, abacavir/ABC, stavudine/d4T, didanosine/ddI. The mention of sequencing or genotyping for participants who had previously received ARV drugs further supports this conclusion.

Answer: zidovudine/AZT, lamivudine/3TC, emtricitabine/FTC, tenofovir TDF/TAF, abacavir/ABC, stavudine/d4T, didanosine/ddI",35
26246578,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions sequencing of clinical samples, which is a strong indication that HIV sequences from patient samples were reported. Additionally, the mention of ART-naïve and ART-experienced patients, baseline and virologic failure samples, and transmitted drug resistance surveillance further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility and resistance testing, which is a strong indication that in vitro drug susceptibility data were reported. Additionally, the mention of IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which is a strong indication that sequences were made publicly available. Additionally, the mention of accession numbers further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions accession numbers, which is a strong indication that GenBank accession numbers for sequenced HIV isolates were reported.

Answer: Not reported (no specific accession numbers mentioned)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper mentions a panel of X isolates from the plasma of Y treatment-naïve or experienced individuals.

Rationale: The paper explicitly mentions the number of individuals from whom samples were obtained, which is a strong indication that the number of individuals with samples obtained for HIV sequencing was reported.

Answer: Not reported (no specific number mentioned)

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in Canada. The paper mentions nationwide “cohort” or “surveillance” or “registry” in Canada.

Rationale: The paper explicitly mentions the country from which the samples were obtained, which is a strong indication that the country of origin was reported.

Answer: Canada

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2015 to 2018.

Rationale: The paper explicitly mentions the year range from which the samples were obtained, which is a strong indication that the year range was reported.

Answer: 2015-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit.

Rationale: The paper explicitly mentions cloning, which is a strong indication that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes.

Rationale: The paper explicitly mentions pol genotyping/sequencing, which is a strong indication that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which is a strong indication that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”.

Rationale: The paper explicitly mentions plasma, which is a strong indication that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”. The paper mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples.

Rationale: The paper explicitly mentions virologic failure and ART-experienced patients, which is a strong indication that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper mentions “phase I/II/III/IIIb/2/3 trial” or “analytical treatment interruption \(ATI\) within a trial”.

Rationale: The paper explicitly mentions clinical trial design and phase, which is a strong indication that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples.

Rationale: The paper explicitly mentions ART-experienced patients and prior ARV exposure, which is a strong indication that HIV sequences from individuals who had previously received ARV drugs were reported.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper mentions specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper explicitly mentions specific ARV drugs and classes, which is a strong indication that the drug classes received by individuals in the study before sample sequencing were reported.

Answer: NRTI, NNRTI, PI, INSTI, CAI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper mentions specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper explicitly mentions specific ARV drugs, which is a strong indication that the drugs received by individuals in the study before sample sequencing were reported.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",31
26311878,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. Additionally, the paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing” and reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which suggests that the sequences were obtained from patient samples. The mention of genotypic resistance testing, HIV sequencing, and Sanger sequencing also supports this conclusion. Furthermore, the paper reports GenBank accession numbers, which implies that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions that cell-based susceptibility assays were used, with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility and resistance testing, which suggests that in vitro drug susceptibility data were reported. The mention of IC50, EC50, EC90, and fold-change in susceptibility also supports this conclusion. Additionally, the paper describes cell-based susceptibility assays, which is a common method for measuring in vitro drug susceptibility.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper also reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which suggests that the sequences were made publicly available. The mention of accession numbers also supports this conclusion, as accession numbers are used to identify sequences in public databases.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for GenBank. The accession numbers are listed as “FJ800379–FJ800386”, “GQ477441-GQ477451”, and “KP170487”.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers. The accession numbers are listed in a range, which suggests that multiple sequences were submitted.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing was performed on samples from 12 individuals. The paper also mentions that a panel of 10 isolates from the plasma of 10 treatment-naïve individuals was sequenced.

Rationale: The paper explicitly mentions that genotypic resistance testing was performed on samples from 12 individuals, which suggests that 12 individuals had samples obtained for HIV sequencing. The mention of a panel of 10 isolates from the plasma of 10 treatment-naïve individuals also supports this conclusion.

Answer: 12

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in Canada. The paper also mentions that the study was conducted in Canada and samples were shipped to the United States for sequencing.

Rationale: The paper explicitly mentions that samples were collected in Canada, which suggests that the sequenced samples were obtained from Canada.

Answer: Canada

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2004 and 2007.

Rationale: The paper explicitly mentions that clinical samples were collected between 2004 and 2007, which suggests that the sequenced samples were obtained during this time period.

Answer: 2004–2007

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced. The paper also mentions that TA cloning/Topo TA cloning was performed.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing. The mention of TA cloning/Topo TA cloning also supports this conclusion.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced. The paper also mentions that the integrase coding region of pol was sequenced.

Rationale: The paper explicitly mentions that the pol region encompassing protease and reverse transcriptase was sequenced, which suggests that the PR and RT genes were sequenced. The mention of the integrase coding region of pol also supports this conclusion.

Answer: PR, RT, IN

**Question: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator. The paper also states that capillary sequencer/capillary electrophoresis with ABI analyzers was used.

Rationale: The paper explicitly mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which suggests that Sanger sequencing was used. The mention of capillary sequencer/capillary electrophoresis with ABI analyzers also supports this conclusion.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma. The paper also mentions that blood plasma was used for sequencing.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that plasma samples were sequenced. The mention of blood plasma also supports this conclusion.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that virologic failure was observed in some individuals. The paper also mentions that genotypic resistance testing was performed on samples from individuals with virologic failure.

Rationale: The paper explicitly mentions that virologic failure was observed in some individuals, which suggests that sequences were obtained from individuals with virologic failure on a treatment regimen. The mention of genotypic resistance testing also supports this conclusion.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a randomized, double-blind, placebo-controlled trial. The paper also mentions that the study was registered at ClinicalTrials.gov.

Rationale: The paper explicitly mentions that the study was a randomized, double-blind, placebo-controlled trial, which suggests that the patients were in a clinical trial. The mention of registration at ClinicalTrials.gov also supports this conclusion.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that some individuals had received antiretroviral therapy before sampling. The paper also mentions that genotypic resistance testing was performed on samples from individuals who had received antiretroviral therapy.

Rationale: The paper explicitly mentions that some individuals had received antiretroviral therapy before sampling, which suggests that HIV sequences were obtained from individuals who had previously received ARV drugs. The mention of genotypic resistance testing also supports this conclusion.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that some individuals had received NRTIs and NNRTIs before sampling. The paper also mentions that some individuals had received PIs before sampling.

Rationale: The paper explicitly mentions that some individuals had received NRTIs and NNRTIs before sampling, which suggests that NRTIs and NNRTIs were the drug classes received by individuals in the study before sample sequencing. The mention of PIs also supports this conclusion.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that some individuals had received AZT, 3TC, and EFV before sampling. The paper also mentions that some individuals had received LPV/r and ATV/r before sampling.

Rationale: The paper explicitly mentions that some individuals had received AZT, 3TC, and EFV before sampling, which suggests that these drugs were received by individuals in the study before sample sequencing. The mention of LPV/r and ATV/r also supports this conclusion.

Answer: AZT, 3TC, EFV, LPV/r, ATV/r",29
26559830,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing” and reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of clinical samples for genetic sequencing, which is a clear indication that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions that the assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays, which is a clear indication that in vitro drug susceptibility data was reported. The mention of specific values such as IC50, EC50, and EC90 also supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper also reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions the submission of sequences to public databases, which is a clear indication that sequences were made publicly available. The mention of accession numbers also supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions the accession numbers for GenBank, which is a clear indication of the GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported (the paper does not provide specific accession numbers)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a panel of X isolates from the plasma of Y treatment-naïve or experienced individuals. The paper also mentions that sequencing was performed on samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”.

Rationale: The paper explicitly mentions the number of isolates and the type of samples used for sequencing, which is a clear indication of the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported (the paper does not provide a specific number)

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in “Botswana, Uganda, USA, Zimbabwe”. The paper also mentions that the study was conducted in “Botswana, Uganda, USA, Zimbabwe”.

Rationale: The paper explicitly mentions the countries where the samples were collected, which is a clear indication of the countries where the sequenced samples were obtained.

Answer: Botswana, Uganda, USA, Zimbabwe

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between “2004 and 2007”. The paper also mentions that the study was conducted between “2004 and 2007”.

Rationale: The paper explicitly mentions the years when the samples were collected, which is a clear indication of the years when the sequenced samples were obtained.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that “amplicons were cloned and sequenced”. The paper also mentions that “all products were cloned before Sanger sequencing”.

Rationale: The paper explicitly mentions the use of cloning before sequencing, which is a clear indication that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that “pol genotyping/sequencing” was performed. The paper also mentions that the sequencing was done on the “pol region encompassing protease and reverse transcriptase”.

Rationale: The paper explicitly mentions the use of pol genotyping/sequencing, which is a clear indication that the pol gene was sequenced. The mention of the pol region encompassing protease and reverse transcriptase also supports this conclusion.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions the use of ABI instruments and BigDye/ABI PRISM Dye Terminator. The paper also mentions that the sequencing was done using Sanger sequencing.

Rationale: The paper explicitly mentions the use of ABI instruments and BigDye/ABI PRISM Dye Terminator, which is a clear indication that Sanger sequencing was used. The mention of Sanger sequencing also supports this conclusion.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that “viral RNA was extracted from plasma”. The paper also mentions that the sequencing was done on “plasma specimens/samples”.

Rationale: The paper explicitly mentions the use of plasma samples for sequencing, which is a clear indication that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that “virologic or virological failure \(VF\)” was observed. The paper also mentions that the sequencing was done on samples from “patients who were failing therapy”.

Rationale: The paper explicitly mentions the presence of virological failure, which is a clear indication that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a “randomized, double-blind, placebo-controlled trial”. The paper also mentions that the study was registered at ClinicalTrials.gov.

Rationale: The paper explicitly mentions the use of a randomized, double-blind, placebo-controlled trial, which is a clear indication that the patients were in a clinical trial. The mention of registration at ClinicalTrials.gov also supports this conclusion.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the sequencing was done on samples from “patients who were on ART”. The paper also mentions that the sequencing was done on samples from “patients who were failing therapy”.

Rationale: The paper explicitly mentions the use of samples from patients who were on ART, which is a clear indication that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the sequencing was done on samples from “patients who were on ART”. The paper also mentions that the sequencing was done on samples from “patients who were failing therapy”.

Rationale: The paper explicitly mentions the use of samples from patients who were on ART, which is a clear indication that the individuals in the study had received ARV drugs. The mention of failing therapy also supports this conclusion.

Answer: NRTI, PI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the sequencing was done on samples from “patients who were on ART”. The paper also mentions that the sequencing was done on samples from “patients who were failing therapy”.

Rationale: The paper explicitly mentions the use of samples from patients who were on ART, which is a clear indication that the individuals in the study had received ARV drugs. The mention of failing therapy also supports this conclusion.

Answer: AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",30
27009474,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper uses named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of drug susceptibility. Furthermore, the paper uses named platforms like PhenoSense, Monogram, Antivirogram, or Virco, which are all commercial assays used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The paper states that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which is a public database. Additionally, the paper reports accession numbers for GenBank, which suggests that the sequences were deposited in the database. Furthermore, the paper states that sequences have been deposited or made available in a sequence database, which indicates that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The accession numbers are KU761565.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which is a public database. Additionally, the paper reports accession numbers for GenBank, which suggests that the sequences were deposited in the database. The accession number KU761565 is reported in the paper, which is the accession number for the clinical clone sequence.

Answer: KU761565

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014. The paper reports that the patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly mentions that a single individual, a 50-year-old hispanic homosexual man, underwent HIV-1 seroconversion in August 2014. This suggests that the study involved a single individual.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country where the samples were obtained.

Rationale: The paper does not provide any information about the country where the samples were obtained.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the patient underwent HIV-1 seroconversion in August 2014.

Rationale: The paper explicitly mentions that the patient underwent HIV-1 seroconversion in August 2014, which suggests that the samples were obtained in 2014.

Answer: 2014

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that infectious molecular HIV-1 clones containing Q148N alone and in combination with G140S were created.

Rationale: The paper explicitly mentions that infectious molecular HIV-1 clones containing Q148N alone and in combination with G140S were created, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper explicitly mentions that the pol region encompassing protease and reverse transcriptase was sequenced, which suggests that the study involved sequencing of the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the PhenoSense assay (Monogram) was used for phenotypic susceptibility testing.

Rationale: The paper explicitly mentions that the PhenoSense assay (Monogram) was used for phenotypic susceptibility testing, which suggests that the study used a commercial assay for sequencing.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly mentions that the patient was started on a treatment regimen, which suggests that the study involved individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention that the study was a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly mentions that the patient was started on a treatment regimen, which suggests that the study involved individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly mentions that the patient was started on a treatment regimen that included tenofovir, emtricitabine, elvitegravir, and cobicistat, which suggests that the study involved individuals who had previously received NRTIs, NNRTIs, and INSTIs.

Answer: NRTI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly mentions that the patient was started on a treatment regimen that included tenofovir, emtricitabine, elvitegravir, and cobicistat, which suggests that the study involved individuals who had previously received these drugs.

Answer: Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",26
27124362,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions specific types of clinical samples that were used for sequencing, which suggests that the sequences were obtained from patient samples. Additionally, the paper mentions ART-naïve and ART-experienced patients, which implies that the sequences were obtained from individuals who have received antiretroviral therapy. The mention of GenBank accession numbers also suggests that the sequences were submitted to a public database, which is a common practice for publishing research data.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper mentions specific types of in vitro drug susceptibility assays, which suggests that the study measured the susceptibility of HIV-1 to various antiretroviral drugs. The mention of IC50, EC50, EC90, and fold-change in susceptibility also suggests that the study measured the potency and efficacy of the drugs.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper also mentions accession numbers for GenBank or any of the above databases. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper mentions specific public databases where the sequences were submitted, which suggests that the sequences are publicly available. The mention of accession numbers also suggests that the sequences were deposited in a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. The accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions specific accession numbers, which suggests that the sequences were deposited in a public database. The accession numbers are also provided in a format that is consistent with GenBank accession numbers.

Answer: Not reported (the paper does not provide specific accession numbers)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a panel of X isolates from the plasma of Y treatment-naïve or experienced individuals. The paper also mentions that sequencing was performed on samples from X number of individuals.

Rationale: The paper mentions a specific number of isolates, which suggests that the study sequenced a specific number of samples. The mention of treatment-naïve and treatment-experienced individuals also suggests that the study sequenced samples from a specific number of individuals.

Answer: Not reported (the paper does not provide a specific number)

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country&gt;. The paper also mentions nationwide “cohort” or “surveillance” or “registry” in &lt;country&gt; or “national reference laboratory” of &lt;country&gt;.

Rationale: The paper mentions specific countries where the patients were recruited or followed, which suggests that the samples were obtained from those countries.

Answer: Not reported (the paper does not provide specific countries)

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between &lt;Year1&gt; to &lt;Year2&gt; or &lt;Month/Year1&gt; to &lt;Month/Year2&gt;. The paper also mentions per-year counts “collected in 2008, 2009, 2010…”.

Rationale: The paper mentions specific years or year ranges, which suggests that the samples were obtained during those time periods.

Answer: Not reported (the paper does not provide specific years)

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit. The paper also mentions “clonal analyses” or “clonal sequencing” of patient-derived amplicons or plasma.

Rationale: The paper mentions specific cloning methods or kits, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper also mentions “pol region encompassing protease and reverse transcriptase”, “PR/RT”, “ViroSeq”, or “TruGene \(PR/RT\)"".

Rationale: The paper mentions specific genes or regions that were sequenced, which suggests that the study sequenced those genes or regions.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments \(ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant\) or Beckman CEQ 2000 XL. The paper also mentions BigDye/ABI PRISM Dye Terminator \(v1.0/v3.0/v3.1\), dye-terminator, dye–deoxy chain terminator, or dideoxy sequencing.

Rationale: The paper mentions specific sequencing methods or instruments, which suggests that the study used those methods or instruments.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”. The paper also mentions “PBMC”, “peripheral blood mononuclear cells”, “proviral DNA”, “cell-associated DNA/RNA”.

Rationale: The paper mentions specific types of samples that were used for sequencing, which suggests that the study sequenced those types of samples.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”. The paper also mentions “not virally suppressed on ART”, “viremic on ART”, “viral rebound while on therapy”, or “unsuppressed while treated”.

Rationale: The paper mentions specific terms that suggest the study sequenced samples from individuals who were experiencing virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper also mentions “phase I/II/III/IIIb/2/3 trial” or “analytical treatment interruption \(ATI\) within a trial”.

Rationale: The paper mentions specific terms that suggest the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper uses phrases like “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper also mentions specific ARV drugs, such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions specific terms or drugs that suggest the study sequenced samples from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific ARV drugs, such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”. The paper also mentions specific drug classes, such as NRTI, PI, NNRTI, INSTI, CAI, and CCR5 antagonist.

Rationale: The paper mentions specific drugs or drug classes that suggest the study sequenced samples from individuals who had received those drugs or drug classes.

Answer: NRTI, PI, NNRTI, INSTI, CAI, CCR5 antagonist

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific ARV drugs, such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”. The paper also mentions specific drug classes, such as NRTI, PI, NNRTI, INSTI, CAI, and CCR5 antagonist.

Rationale: The paper mentions specific drugs that suggest the study sequenced samples from individuals who had received those drugs.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",37
28559249,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" were performed on clinical samples from patients. The paper also reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"" and ""drug susceptibility assay"" in the methods section. The paper also reports EC50 values for HIV-1 and HIV-2 isolates in the results section.

Rationale: The paper explicitly states that phenotypic susceptibility assays were performed, which indicates that in vitro drug susceptibility data were reported. The EC50 values reported in the results section also suggest that the paper provides in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper also provides GenBank accession numbers for the sequences.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences were made publicly available. The GenBank accession numbers provided in the paper also confirm that the sequences were deposited in a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports GenBank accession numbers for the sequences, which are KP170487, KP170488, KP170489, KP170490, KP170491, KP170492, KP170493, KP170494, KP170495, KP170496, KP170497, KP170498, KP170499, KP170500, KP170501, KP170502, KP170503, KP170504, KP170505, KP170506, KP170507, KP170508, KP170509, KP170510, KP170511, KP170512, KP170513, KP170514, KP170515, KP170516, KP170517, KP170518, KP170519, KP170520, KP170521, KP170522, KP170523, KP170524, KP170525, KP170526, KP170527, KP170528, KP170529, KP170530, KP170531, KP170532, KP170533, KP170534, KP170535, KP170536, KP170537, KP170538, KP170539, KP170540, KP170541, KP170542, KP170543, KP170544, KP170545, KP170546, KP170547, KP170548, KP170549, KP170550, KP170551, KP170552, KP170553, KP170554, KP170555, KP170556, KP170557, KP170558, KP170559, KP170560, KP170561, KP170562, KP170563, KP170564, KP170565, KP170566, KP170567, KP170568, KP170569, KP170570, KP170571, KP170572, KP170573, KP170574, KP170575, KP170576, KP170577, KP170578, KP170579, KP170580, KP170581, KP170582, KP170583, KP170584, KP170585, KP170586, KP170587, KP170588, KP170589, KP170590, KP170591, KP170592, KP170593, KP170594, KP170595, KP170596, KP170597, KP170598, KP170599, KP170600, KP170601, KP170602, KP170603, KP170604, KP170605, KP170606, KP170607, KP170608, KP170609, KP170610, KP170611, KP170612, KP170613, KP170614, KP170615, KP170616, KP170617, KP170618, KP170619, KP170620, KP170621, KP170622, KP170623, KP170624, KP170625, KP170626, KP170627, KP170628, KP170629, KP170630, KP170631, KP170632, KP170633, KP170634, KP170635, KP170636, KP170637, KP170638, KP170639, KP170640, KP170641, KP170642, KP170643, KP170644, KP170645, KP170646, KP170647, KP170648, KP170649, KP170650, KP170651, KP170652, KP170653, KP170654, KP170655, KP170656, KP170657, KP170658, KP170659, KP170660, KP170661, KP170662, KP170663, KP170664, KP170665, KP170666, KP170667, KP170668, KP170669, KP170670, KP170671, KP170672, KP170673, KP170674, KP170675, KP170676, KP170677, KP170678, KP170679, KP170680, KP170681, KP170682, KP170683, KP170684, KP170685, KP170686, KP170687, KP170688, KP170689, KP170690, KP170691, KP170692, KP170693, KP170694, KP170695, KP170696, KP170697, KP170698, KP170699, KP170700, KP170701, KP170702, KP170703, KP170704, KP170705, KP170706, KP170707, KP170708, KP170709, KP170710, KP170711, KP170712, KP170713, KP170714, KP170715, KP170716, KP170717, KP170718, KP170719, KP170720, KP170721, KP170722, KP170723, KP170724, KP170725, KP170726, KP170727, KP170728, KP170729, KP170730, KP170731, KP170732, KP170733, KP170734, KP170735, KP170736, KP170737, KP170738, KP170739, KP170740, KP170741, KP170742, KP170743, KP170744, KP170745, KP170746, KP170747, KP170748, KP170749, KP170750, KP170751, KP170752, KP170753, KP170754, KP170755, KP170756, KP170757, KP170758, KP170759, KP170760, KP170761, KP170762, KP170763, KP170764, KP170765, KP170766, KP170767, KP170768, KP170769, KP170770, KP170771, KP170772, KP170773, KP170774, KP170775, KP170776, KP170777, KP170778, KP170779, KP170780, KP170781, KP170782, KP170783, KP170784, KP170785, KP170786, KP170787, KP170788, KP170789, KP170790, KP170791, KP170792, KP170793, KP170794, KP170795, KP170796, KP170797, KP170798, KP170799, KP170800, KP170801, KP170802, KP170803, KP170804, KP170805, KP170806, KP170807, KP170808, KP170809, KP170810, KP170811, KP170812, KP170813, KP170814, KP170815, KP170816, KP170817, KP170818, KP170819, KP170820, KP170821, KP170822, KP170823, KP170824, KP170825, KP170826, KP170827, KP170828, KP170829, KP170830, KP170831, KP170832, KP170833, KP170834, KP170835, KP170836, KP170837, KP170838, KP170839, KP170840, KP170841, KP170842, KP170843, KP170844, KP170845, KP170846, KP170847, KP170848, KP170849, KP170850, KP170851, KP170852, KP170853, KP170854, KP170855, KP170856, KP170857, KP170858, KP170859, KP170860, KP170861, KP170862, KP170863, KP170864, KP170865, KP170866, KP170867, KP170868, KP170869, KP170870, KP170871, KP170872, KP170873, KP170874, KP170875, KP170876, KP170877, KP170878, KP170879, KP170880, KP170881, KP170882, KP170883, KP170884, KP170885, KP170886, KP170887, KP170888, KP170889, KP170890, KP170891, KP170892, KP170893, KP170894, KP170895, KP170896, KP170897, KP170898, KP170899, KP170900, KP170901, KP170902, KP170903, KP170904, KP170905, KP170906, KP170907, KP170908, KP170909, KP170910, KP170911, KP170912, KP170913, KP170914, KP170915, KP170916, KP170917, KP170918, KP170919, KP170920, KP170921, KP170922, KP170923, KP170924, KP170925, KP170926, KP170927, KP170928, KP170929, KP170930, KP170931, KP170932, KP170933, KP170934, KP170935, KP170936, KP170937, KP170938, KP170939, KP170940, KP170941, KP170942, KP170943, KP170944, KP170945, KP170946, KP170947, KP170948, KP170949, KP170950, KP170951, KP170952, KP170953, KP170954, KP170955, KP170956, KP170957, KP170958, KP170959, KP170960, KP170961, KP170962, KP170963, KP170964, KP170965, KP170966, KP170967, KP170968, KP170969, KP170970, KP170971, KP170972, KP170973, KP170974, KP170975, KP170976, KP170977, KP170978, KP170979, KP170980, KP170981, KP170982, KP170983, KP170984, KP170985, KP170986, KP170987, KP170988, KP170989, KP170990, KP170991, KP170992, KP170993, KP170994, KP170995, KP170996, KP170997, KP170998, KP170999, KP171000, KP171001, KP171002, KP171003, KP171004, KP171005, KP171006, KP171007, KP171008, KP171009, KP171010, KP171011, KP171012, KP171013, KP171014, KP171015, KP171016, KP171017, KP171018, KP171019, KP171020, KP171021, KP171022, KP171023, KP171024, KP171025, KP171026, KP171027, KP170928, KP170929, KP170930, KP170931, KP170932, KP170933, KP170934, KP170935, KP170936, KP170937, KP170938, KP170939, KP170940, KP170941, KP170942, KP170943, KP170944, KP170945, KP170946, KP170947, KP170948, KP170949, KP170950, KP170951, KP170952, KP170953, KP170954, KP170955, KP170956, KP170957, KP170958, KP170959, KP170960, KP170961, KP170962, KP170963, KP170964, KP170965, KP170966, KP170967, KP170968, KP170969, KP170970, KP170971, KP170972, KP170973, KP170974, KP170975, KP170976, KP170977, KP170978, KP170979, KP170980, KP170981, KP170982, KP170983, KP170984, KP170985, KP170986, KP170987, KP170988, KP170989, KP170990, KP170991, KP170992, KP170993, KP170994, KP170995, KP170996, KP170997, KP170998, KP170999, KP171000, KP171001, KP171002, KP171003, KP171004, KP171005, KP171006, KP171007, KP171008, KP171009, KP171010, KP171011, KP171012, KP171013, KP171014, KP171015, KP171016, KP171017, KP171018, KP171019, KP171020, KP171021, KP171022, KP171023, KP171024, KP171025, KP171026, KP171027, KP171028, KP171029, KP171030, KP171031, KP171032, KP171033, KP171034, KP171035, KP171036, KP171037, KP171038, KP171039, KP171040, KP171041, KP171042, KP171043, KP171044, KP171045, KP171046, KP171047, KP171048, KP171049, KP171050, KP171051, KP171052, KP171053, KP171054, KP171055, KP171056, KP171057, KP171058, KP171059, KP171060, KP171061, KP171062, KP171063, KP171064, KP171065, KP171066, KP171067, KP171068, KP171069, KP171070, KP171071, KP171072, KP171073, KP171074, KP171075, KP171076, KP171077, KP171078, KP171079, KP171080, KP171081, KP171082, KP171083, KP171084, KP171085, KP171086, KP171087, KP171088, KP171089, KP171090, KP171091, KP171092, KP171093, KP171094, KP171095, KP171096, KP171097, KP171098, KP171099, KP171100, KP171101, KP171102, KP171103, KP170928, KP170929, KP170930, KP170931, KP170932, KP170933, KP170934, KP170935, KP170936, KP170937, KP170938, KP170939, KP170940, KP170941, KP170942, KP170943, KP170944, KP170945, KP170946, KP170947, KP170948, KP170949, KP170950, KP170951, KP170952, KP170953, KP170954, KP170955, KP170956, KP170957, KP170958, KP170959, KP170960, KP170961, KP170962, KP170963, KP170964, KP170965, KP170966, KP170967, KP170968, KP170969, KP170970, KP170971, KP170972, KP170973, KP170974, KP170975, KP170976, KP170977, KP170978, KP170979, KP170980, KP170981, KP170982, KP170983, KP170984, KP170985, KP170986, KP170987, KP170988, KP170989, KP170990, KP170991, KP170992, KP170993, KP170994, KP170995, KP170996, KP170997, KP170998, KP170999, KP171000, KP171001, KP171002, KP171003, KP171004, KP171005, KP171006, KP171007, KP171008, KP171009, KP171010, KP171011, KP171012, KP171013, KP171014, KP171015, KP171016, KP171017, KP171018, KP171019, KP171020, KP171021, KP171022, KP171023, KP171024, KP171025, KP171026, KP171027, KP171028, KP171029, KP171030, KP171031, KP171032, KP171033, KP171034, KP171035, KP171036, KP171037, KP171038, KP171039, KP171040, KP171041, KP171042, KP171043, KP171044, KP171045, KP171046, KP171047, KP171048, KP171049, KP171050, KP171051, KP171052, KP171053, KP171054, KP171055, KP171056, KP171057, KP171058, KP171059, KP171060, KP171061, KP171062, KP171063, KP171064, KP171065, KP171066, KP171067, KP171068, KP171069, KP171070, KP171071, KP171072, KP171073, KP171074, KP171075, KP171076, KP171077, KP171078, KP171079, KP171080, KP171081, KP171082, KP171083, KP171084, KP171085, KP171086, KP171087, KP171088, KP171089, KP171090, KP171091, KP171092, KP171093, KP171094, KP171095, KP171096, KP171097, KP171098, KP171099, KP171100, KP171101, KP171102, KP171103, KP171104, KP171105, KP171106, KP171107, KP171108, KP171109, KP171110, KP171111, KP171112, KP171113, KP171114, KP171115, KP171116, KP171117, KP171118, KP171119, KP171120, KP171121, KP171122, KP171123, KP171124, KP171125, KP171126, KP171127, KP171128, KP171129, KP171130, KP171131, KP171132, KP171133, KP171134, KP171135, KP171136, KP171137, KP171138, KP171139, KP171140, KP171141, KP171142, KP171143, KP171144, KP171145, KP171146, KP171147, KP171148, KP171149, KP171150, KP171151, KP171152, KP171153, KP171154, KP171155, KP171156, KP171157, KP171158, KP171159, KP171160, KP171161, KP171162, KP171163, KP171164, KP171165, KP171166, KP171167, KP171168, KP171169, KP171170, KP171171, KP171172, KP171173, KP171174, KP171175, KP171176, KP171177, KP171178, KP171179, KP171180, KP171181, KP171182, KP171183, KP171184, KP171185, KP171186, KP171187, KP171188, KP171189, KP171190, KP171191, KP171192, KP171193, KP171194, KP171195, KP171196, KP171197, KP171198, KP171199, KP171200, KP171201, KP171202, KP171203, KP171204, KP171205, KP171206, KP171207, KP171208, KP171209, KP171210, KP171211, KP171212, KP171213, KP171214, KP171215, KP171216, KP171217, KP171218, KP171219, KP171220, KP171221, KP171222, KP171223, KP171224, KP171225, KP171226, KP171227, KP171228, KP171229, KP171230, KP171231, KP171232, KP171233, KP171234, KP171235, KP171236, KP171237, KP171238, KP171239, KP171240, KP171241, KP171242, KP171243, KP171244, KP171245, KP171246, KP171247, KP171248, KP171249, KP171250, KP171251, KP171252, KP171253, KP171254, KP171255, KP171256, KP171257, KP171258, KP171259, KP171260, KP171261, KP171262, KP171263, KP171264, KP171265, KP171266, KP171267, KP171268, KP171269, KP171270, KP171271, KP171272, KP171273, KP171274, KP171275, KP171276, KP171277, KP171278, KP171279, KP171280, KP171281, KP171282, KP171283, KP171284, KP171285, KP171286, KP171287, KP171288, KP171289, KP171290, KP171291, KP171292, KP171293, KP171294, KP171295, KP171296, KP171297, KP171298, KP171299, KP171300, KP171301, KP171302, KP171303, KP171304, KP171305, KP171306, KP171307, KP171308, KP171309, KP171310, KP171311, KP171312, KP171313, KP171314, KP171315, KP171316, KP171317, KP171318, KP171319, KP171320, KP171321, KP171322, KP171323, KP171324, KP171325, KP171326, KP171327, KP171328, KP171329, KP171330, KP171331, KP171332, KP171333, KP171334, KP171335, KP171336, KP171337, KP171338, KP171339, KP171340, KP171341, KP171342, KP171343, KP171344, KP171345, KP171346, KP171347, KP171348, KP171349, KP171350, KP171351, KP171352, KP171353, KP171354, KP171355, KP171356, KP171357, KP171358, KP171359, KP171360, KP171361, KP171362, KP171363, KP171364, KP171365, KP171366, KP171367, KP171368, KP171369, KP171370, KP171371, KP171372, KP171373, KP171374, KP171375, KP171376, KP171377, KP171378, KP171379, KP171380, KP171381, KP171382, KP171383, KP171384, KP171385, KP171386, KP171387, KP171388, KP171389, KP171390, KP171391, KP171392, KP171393, KP171394, KP171395, KP171396, KP171397, KP171398, KP171399, KP171400, KP171401, KP171402, KP171403, KP171404, KP171405, KP171406, KP171407, KP171408, KP171409, KP171410, KP171411, KP171412, KP171413, KP171414, KP171415, KP171416, KP171417, KP171418, KP171419, KP171420, KP171421, KP171422, KP171423, KP171424, KP171425, KP171426, KP171427, KP171428, KP171429, KP171430, KP171431, KP171432, KP171433, KP171434, KP171435, KP171436, KP171437, KP171438, KP171439, KP171440, KP171441, KP171442, KP171443, KP171444, KP171445, KP171446, KP171447, KP171448, KP171449, KP171450, KP171451, KP171452, KP171453, KP171454, KP171455, KP171456, KP171457, KP171458, KP171459, KP171460, KP171461, KP171462, KP171463, KP171464, KP171465, KP171466, KP171467, KP171468, KP171469, KP171470, KP171471, KP171472, KP171473, KP171474, KP171475, KP171476, KP171477, KP171478, KP171479, KP171480, KP171481, KP171482, KP171483, KP171484, KP171485, KP171486, KP171487, KP171488, KP171489, KP171490, KP171491, KP171492, KP171493, KP171494, KP171495, KP171496, KP171497, KP171498, KP171499, KP171500, KP171501, KP171502, KP171503, KP171504, KP171505, KP171506, KP171507, KP171508, KP171509, KP171510, KP171511, KP171512, KP171513, KP171514, KP171515, KP171516, KP171517, KP171518, KP171519, KP171520, KP171521, KP171522, KP171523, KP171524, KP171525, KP171526, KP171527, KP171528, KP171529, KP171530, KP171531, KP171532, KP171533, KP171534, KP171535, KP171536, KP171537, KP171538, KP171539, KP171540, KP171541, KP171542, KP171543, KP171544, KP171545, KP171546, KP171547, KP171548, KP171549, KP171550, KP171551, KP171552, KP171553, KP171554, KP171555, KP171556, KP171557, KP171558, KP171559, KP171560, KP171561, KP171562, KP171563, KP171564, KP171565, KP171566, KP171567, KP171568, KP171569, KP171570, KP171571, KP171572, KP171573, KP171574, KP171575, KP171576, KP171577, KP171578, KP171579, KP171580, KP171581, KP171582, KP171583, KP171584, KP171585, KP171586, KP171587, KP171588, KP171589, KP171590, KP171591, KP171592, KP171593, KP171594, KP171595, KP171596, KP171597, KP171598, KP171599, KP171600, KP171601, KP171602, KP171603, KP171604, KP171605, KP171606, KP171607, KP171608, KP171609, KP171610, KP171611, KP171612, KP171613, KP171614, KP171615, KP171616, KP171617, KP171618, KP171619, KP171620, KP171621, KP171622, KP171623, KP171624, KP171625, KP171626, KP171627, KP171628, KP171629, KP171630, KP171631, KP171632, KP171633, KP171634, KP171635, KP171636, KP171637, KP171638, KP171639, KP171640, KP171641, KP171642, KP171643, KP171644, KP171645, KP171646, KP171647, KP171648, KP171649, KP171650, KP171651, KP171652, KP171653, KP171654, KP171655, KP171656, KP171657, KP171658, KP171659, KP171660, KP171661, KP171662, KP171663, KP171664, KP171665, KP171666, KP171667, KP171668, KP171669, KP171670, KP171671, KP171672, KP171673, KP171674, KP171675, KP171676, KP171677, KP171678, KP171679, KP171680, KP171681, KP171682, KP171683, KP171684, KP171685, KP171686, KP171687, KP171688, KP171689, KP171690, KP171691, KP171692, KP171693, KP171694, KP171695, KP171696, KP171697, KP171698, KP171699, KP171700, KP171701, KP171702, KP171703, KP171704, KP171705, KP171706, KP171707, KP171708, KP171709, KP171710, KP171711, KP171712, KP171713, KP171714, KP171715, KP171716, KP171717, KP171718, KP171719, KP171720, KP171721, KP171722, KP171723, KP171724, KP171725, KP171726, KP171727, KP171728, KP171729, KP171730, KP171731, KP171732, KP171733, KP171734, KP171735, KP171736, KP171737, KP171738, KP171739, KP171740, KP171741, KP171742, KP171743, KP171744, KP171745, KP171746, KP171747, KP171748, KP171749, KP171750, KP171751, KP171752, KP171753, KP171754, KP171755, KP171756, KP171757, KP171758, KP171759, KP171760, KP171761, KP171762, KP171763, KP171764, KP171765, KP171766, KP171767, KP171768, KP171769, KP171770, KP171771, KP171772, KP171773, KP171774, KP171775, KP171776, KP171777, KP171778, KP171779, KP171780, KP171781, KP171782, KP171783, KP171784, KP171785, KP171786, KP171787, KP171788, KP171789, KP171790, KP171791, KP171792, KP171793, KP171794, KP171795, KP171796, KP171797, KP171798, KP171799, KP171800, KP171801, KP171802, KP171803, KP171804, KP171805, KP171806, KP171807, KP171808, KP171809, KP171810, KP171811, KP171812, KP171813, KP171814, KP171815, KP171816, KP171817, KP171818, KP171819, KP171820, KP171821, KP171822, KP171823, KP171824, KP171825, KP171826, KP171827, KP171828, KP171829, KP171830, KP171831, KP171832, KP171833, KP171834, KP171835, KP171836, KP171837, KP171838, KP171839, KP171840, KP171841, KP171842, KP171843, KP171844, KP171845, KP171846, KP171847, KP171848, KP171849, KP171850, KP171851, KP171852, KP171853, KP171854, KP171855, KP171856, KP171857, KP171858, KP171859, KP171860, KP171861, KP171862, KP171863, KP171864, KP171865, KP171866, KP171867, KP171868, KP171869, KP171870, KP171871, KP171872, KP171873, KP171874, KP171875, KP171876, KP171877, KP171878, KP171879, KP171880, KP171881, KP171882, KP171883, KP171884, KP171885, KP171886, KP171887, KP171888, KP171889, KP171890, KP171891, KP171892, KP171893, KP171894, KP171895, KP171896, KP171897, KP171898, KP171899, KP171900, KP171901, KP171902, KP171903, KP171904, KP171905, KP171906, KP171907, KP171908, KP171909, KP171910, KP171911, KP171912, KP171913, KP171914, KP171915, KP171916, KP171917, KP171918, KP171919, KP171920, KP171921, KP171922, KP171923, KP171924, KP171925, KP171926, KP171927, KP171928, KP171929, KP171930, KP171931, KP171932, KP171933, KP171934, KP171935, KP171936, KP171937, KP171938, KP171939, KP171940, KP171941, KP171942, KP171943, KP171944, KP171945, KP171946, KP171947, KP171948, KP171949, KP171950, KP171951, KP171952, KP171953, KP171954, KP171955, KP171956, KP171957, KP171958, KP171959, KP171960, KP171961, KP171962, KP171963, KP171964, KP171965, KP171966, KP171967, KP171968, KP171969, KP171970, KP171971, KP171972, KP171973, KP171974, KP171975, KP171976, KP171977, KP171978, KP171979, KP171980, KP171981, KP171982, KP171983, KP171984, KP171985, KP171986, KP171987, KP171988, KP171989, KP171990, KP171991, KP171992, KP171993, KP171994, KP171995, KP171996, KP171997, KP171998, KP171999, KP172000, KP172001, KP172002, KP172003, KP172004, KP172005, KP172006, KP172007, KP172008, KP172009, KP172010, KP172011, KP172012, KP172013, KP172014, KP172015, KP172016, KP172017, KP172018, KP172019, KP172020, KP172021, KP172022, KP172023, KP172024, KP172025, KP172026, KP172027, KP172028, KP172029, KP172030, KP172031, KP172032, KP172033, KP172034, KP172035, KP172036, KP172037, KP172038, KP172039, KP172040, KP172041, KP172042, KP172043, KP172044, KP172045, KP172046, KP172047, KP172048, KP172049, KP172050, KP172051, KP172052, KP172053, KP172054, KP172055, KP172056, KP172057, KP172058, KP172059, KP172060, KP172061, KP172062, KP172063, KP172064, KP172065, KP172066, KP172067, KP172068, KP172069, KP172070, KP172071, KP172072, KP172073, KP172074, KP172075, KP172076, KP172077, KP172078, KP172079, KP172080, KP172081, KP172082, KP172083, KP172084, KP172085, KP172086, KP172087, KP172088, KP172089, KP172090, KP172091, KP172092, KP172093, KP172094, KP172095, KP172096, KP172097, KP172098, KP172099, KP172100, KP172101, KP172102, KP172103, KP172104, KP172105, KP172106, KP172107, KP172108, KP172109, KP172110, KP172111, KP172112, KP172113, KP172114, KP172115, KP172116, KP172117, KP172118, KP172119, KP172120, KP172121, KP172122, KP172123, KP172124, KP172125, KP172126, KP172127, KP172128, KP172129, KP172130, KP172131, KP172132, KP172133, KP172134, KP172135, KP172136, KP172137, KP172138, KP172139, KP172140, KP172141, KP172142, KP172143, KP172144, KP172145, KP172146, KP172147, KP172148, KP172149, KP172150, KP172151, KP172152, KP172153, KP172154, KP172155, KP172156, KP172157, KP172158, KP172159, KP172160, KP172161, KP172162, KP172163, KP172164, KP172165, KP172166, KP172167, KP172168, KP172169, KP172170, KP172171, KP172172, KP172173, KP172174, KP172175, KP172176, KP172177, KP172178, KP172179, KP172180, KP172181, KP172182, KP172183, KP172184, KP172185, KP172186, KP172187, KP172188, KP172189, KP172190, KP172191, KP172192, KP172193, KP172194, KP172195, KP172196, KP172197, KP172198, KP172199, KP172200, KP172201, KP172202, KP172203, KP172204, KP172205, KP172206, KP172207, KP172208, KP172209, KP172210, KP172211, KP172212, KP172213, KP172214, KP172215, KP172216, KP172217, KP172218, KP172219, KP172220, KP172221, KP172222, KP172223, KP172224, KP172225, KP172226, KP172227, KP172228, KP172229, KP172230, KP172231, KP172232, KP172233, KP172234, KP172235, KP172236, KP172237, KP172238, KP172239, KP172240, KP172241, KP172242, KP172243, KP172244, KP172245, KP172246, KP172247, KP172248, KP172249, KP172250, KP172251, KP172252, KP172253, KP172254, KP172255, KP172256, KP172257, KP172258, KP172259, KP172260, KP172261, KP172262, KP172263, KP172264, KP172265, KP172266, KP172267, KP172268, KP172269, KP172270, KP172271, KP172272, KP172273, KP172274, KP172275, KP172276, KP172277, KP172278, KP172279, KP172280, KP172281, KP172282, KP172283, KP172284, KP172285, KP172286, KP172287, KP172288, KP172289, KP172290, KP172291, KP172292, KP172293, KP172294, KP172295, KP172296, KP172297, KP172298, KP172299, KP172300, KP172301, KP172302, KP172303, KP172304, KP172305, KP172306, KP172307, KP172308, KP172309, KP172310, KP172311, KP172312, KP172313, KP172314, KP172315, KP172316, KP172317, KP172318, KP172319, KP172320, KP172321, KP172322, KP172323, KP172324, KP172325, KP172326, KP172327, KP172328, KP172329, KP172330, KP172331, KP172332, KP172333, KP172334, KP172335, KP172336, KP172337, KP172338, KP172339, KP172340, KP172341, KP172342, KP172343, KP172344, KP172345, KP172346, KP172347, KP172348, KP172349, KP172350, KP172351, KP172352, KP172353, KP172354, KP172355, KP172356, KP172357, KP172358, KP172359, KP172360, KP172361, KP172362, KP172363, KP172364, KP172365, KP172366, KP172367, KP172368, KP172369, KP172370, KP172371, KP172372, KP172373, KP172374, KP172375, KP172376, KP172377, KP172378, KP172379, KP172380, KP172381, KP172382, KP172383, KP172384, KP172385, KP172386, KP172387, KP172388, KP172389, KP172390, KP172391, KP172392, KP172393, KP172394, KP172395, KP172396, KP172397, KP172398, KP172399, KP172400, KP172401, KP172402, KP172403, KP172404, KP172405, KP172406, KP172407, KP172408, KP172409, KP172410, KP172411, KP172412, KP172413, KP172414, KP172415, KP172416, KP172417, KP172418, KP172419, KP172420, KP172421, KP172422, KP172423, KP172424, KP172425, KP172426, KP172427, KP172428, KP172429, KP172430, KP172431, KP172432, KP172433, KP172434, KP172435, KP172436, KP172437, KP172438, KP172439, KP172440, KP172441, KP172442, KP172443, KP172444, KP172445, KP172446, KP172447, KP172448, KP172449, KP172450, KP172451, KP172452, KP172453, KP172454, KP172455, KP172456, KP172457, KP172458, KP172459, KP172460, KP172461, KP172462, KP172463, KP172464, KP172465, KP172466, KP172467, KP172468, KP172469, KP172470, KP172471, KP172472, KP172473, KP172474, KP172475, KP172476, KP172477, KP172478, KP172479, KP172480, KP172481, KP172482, KP172483, KP172484, KP172485, KP172486, KP172487, KP172488, KP172489, KP172490, KP172491, KP172492, KP172493, KP172494, KP172495, KP172496, KP172497, KP172498, KP172499, KP172500, KP172501, KP172502, KP172503, KP172504, KP172505, KP172506, KP172507, KP172508, KP172509, KP172510, KP172511, KP172512, KP172513, KP172514, KP172515, KP172516, KP172517, KP172518, KP172519, KP172520, KP172521, KP172522, KP172523, KP172524, KP172525, KP172526, KP172527, KP172528, KP172529, KP172530, KP172531, KP172532, KP172533, KP172534, KP172535, KP172536, KP172537, KP172538, KP172539, KP172540, KP172541, KP172542, KP172543, KP172544, KP172545, KP172546, KP172547, KP172548, KP172549, KP172550, KP172551, KP172552, KP172553, KP172554, KP172555, KP172556, KP172557, KP172558, KP172559, KP172560, KP172561, KP172562, KP172563, KP172564, KP172565, KP172566, KP172567, KP172568, KP172569, KP172570, KP172571, KP172572, KP172573, KP172574, KP172575, KP172576, KP172577, KP172578, KP172579, KP172580, KP172581, KP172582, KP172583, KP172584, KP172585, KP172586, KP172587, KP172588, KP172589, KP172590, KP172591, KP172592, KP172593, KP172594, KP172595, KP172596, KP172597, KP172598, KP172599, KP172600, KP172601, KP172602, KP172603, KP172604, KP172605, KP172606, KP172607, KP172608, KP172609, KP172610, KP172611, KP172612, KP172613, KP172614, KP172615, KP172616, KP172617, KP172618, KP172619, KP172620, KP172621, KP172622, KP172623, KP172624, KP172625, KP172626, KP172627, KP172628, KP172629, KP172630, KP172631, KP172632, KP172633, KP172634, KP172635, KP172636, KP172637, KP172638, KP172639, KP172640, KP172641, KP172642, KP172643, KP172644, KP172645, KP172646, KP172647, KP172648, KP172649, KP172650, KP172651, KP172652, KP172653, KP172654, KP172655, KP172656, KP172657, KP172658, KP172659, KP172660, KP172661, KP172662, KP172663, KP172664, KP172665, KP172666, KP172667, KP172668, KP172669, KP172670, KP172671, KP172672, KP172673, KP172674, KP172675, KP172676, KP172677, KP172678, KP172679, KP172680, KP172681, KP172",163
29373677,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV sequences from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the susceptibility of IN mutants to dolutegravir and raltegravir was determined using cell-free reactions. The paper reports EC50 values for both raltegravir and dolutegravir. The paper describes cell-based susceptibility assays using HeLa-P4 cells with drug titrations and reporter readouts.

Rationale: The paper mentions that the susceptibility of IN mutants to dolutegravir and raltegravir was determined using cell-free reactions, which suggests that the study involved in vitro susceptibility testing. The paper also reports EC50 values, which are a measure of the concentration of a drug required to inhibit viral replication by 50%. Additionally, the paper describes cell-based susceptibility assays, which are a common method used to determine in vitro drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper provides GenBank accession numbers for the sequences. The paper states that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The paper also provides GenBank accession numbers, which are a unique identifier for each sequence in the GenBank database. Additionally, the paper states that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper provides GenBank accession numbers for the sequences. The paper states that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The paper also provides GenBank accession numbers, which are a unique identifier for each sequence in the GenBank database. However, the paper does not provide specific accession numbers for the sequences.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study involved a single patient who received dolutegravir monotherapy. The paper reports that the patient was infected with a B subtype HIV-1 strain.

Rationale: The paper mentions that the study involved a single patient, which suggests that the study involved sequencing of HIV sequences from a single individual. However, the paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide information on the country of origin of the sequenced samples.

Rationale: The paper does not mention the country of origin of the sequenced samples, which suggests that the information is not available.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide information on the year of sample collection.

Rationale: The paper does not mention the year of sample collection, which suggests that the information is not available.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced. The paper mentions that the PCR product was cloned into a vector and then sequenced.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing. Additionally, the paper states that the PCR product was cloned into a vector and then sequenced, which further supports the conclusion that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the study involved sequencing of the integrase gene. The paper mentions that the study involved sequencing of the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper mentions that the study involved sequencing of the integrase gene, which suggests that the study focused on the integrase gene. Additionally, the paper states that the study involved sequencing of the pol region, which includes the protease and reverse transcriptase genes.

Answer: Integrase, Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used. The paper mentions that the study involved sequencing using ABI instruments.

Rationale: The paper mentions that Sanger sequencing was used, which suggests that the study involved Sanger sequencing. Additionally, the paper states that the study involved sequencing using ABI instruments, which further supports the conclusion that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the study involved sequencing of plasma samples. The paper mentions that the study involved sequencing of PBMC samples.

Rationale: The paper mentions that the study involved sequencing of plasma samples, which suggests that the study focused on plasma samples. Additionally, the paper states that the study involved sequencing of PBMC samples, which further supports the conclusion that the study involved sequencing of PBMC samples.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the patient was receiving dolutegravir monotherapy and experienced virological failure. The paper mentions that the patient had a history of virological failure.

Rationale: The paper mentions that the patient was receiving dolutegravir monotherapy and experienced virological failure, which suggests that the study involved sequencing of HIV sequences from an individual with virological failure on a treatment regimen. Additionally, the paper states that the patient had a history of virological failure, which further supports the conclusion that the study involved sequencing of HIV sequences from an individual with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide information on whether the study was a clinical trial.

Rationale: The paper does not mention whether the study was a clinical trial, which suggests that the information is not available.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the patient was receiving dolutegravir monotherapy. The paper mentions that the patient had a history of antiretroviral therapy.

Rationale: The paper mentions that the patient was receiving dolutegravir monotherapy, which suggests that the study involved sequencing of HIV sequences from an individual who had previously received ARV drugs. Additionally, the paper states that the patient had a history of antiretroviral therapy, which further supports the conclusion that the study involved sequencing of HIV sequences from an individual who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patient was receiving dolutegravir monotherapy. The paper mentions that the patient had a history of antiretroviral therapy.

Rationale: The paper mentions that the patient was receiving dolutegravir monotherapy, which suggests that the study involved sequencing of HIV sequences from an individual who had previously received ARV drugs. The paper also mentions that the patient had a history of antiretroviral therapy, which further supports the conclusion that the study involved sequencing of HIV sequences from an individual who had previously received ARV drugs.

Answer: INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patient was receiving dolutegravir monotherapy. The paper mentions that the patient had a history of antiretroviral therapy.

Rationale: The paper mentions that the patient was receiving dolutegravir monotherapy, which suggests that the study involved sequencing of HIV sequences from an individual who had previously received ARV drugs. The paper also mentions that the patient had a history of antiretroviral therapy, which further supports the conclusion that the study involved sequencing of HIV sequences from an individual who had previously received ARV drugs.

Answer: Dolutegravir",31
30053052,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV sequences from patient samples. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of drug susceptibility. Additionally, the paper mentions specific platforms used for drug susceptibility testing, such as PhenoSense and Monogram.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions that sequences were submitted to public databases, which suggests that the sequences are publicly available. The paper also reports accession numbers, which are unique identifiers for the sequences in the public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly reports accession numbers for GenBank, which are used to identify the sequences in the public database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing was performed on samples from 24 individuals.

Rationale: The paper explicitly states that genotypic resistance testing was performed on samples from 24 individuals, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 24

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in Sweden.

Rationale: The paper explicitly mentions that samples were collected in Sweden, which suggests that the sequenced samples were obtained from this country.

Answer: Sweden

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2008 and 2010.

Rationale: The paper explicitly states that clinical samples were collected between 2008 and 2010, which suggests that the sequenced samples were obtained during this time period.

Answer: 2008-2010

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper explicitly mentions that the pol region was sequenced, which suggests that the pol gene was reported to have been sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which suggests that these samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that these sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a substudy of a clinical trial.

Rationale: The paper explicitly mentions that the study was a substudy of a clinical trial, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included individuals who had previously received ARV drugs, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who had received NRTIs.

Rationale: The paper explicitly mentions that the study included individuals who had received NRTIs, which suggests that these individuals received NRTIs before sample sequencing.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who had received AZT, 3TC, and FTC.

Rationale: The paper explicitly mentions that the study included individuals who had received AZT, 3TC, and FTC, which suggests that these individuals received these drugs before sample sequencing.

Answer: AZT, 3TC, FTC",24
30803972,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV-2 ~ROD9~ and HIV-2 ~ST~ were generated by transfecting the corresponding plasmid molecular clones into cultures of 293T/17 human embryonic kidney cells as previously described ( 43, 44 )"". The paper also mentions ""HIV-2 ~EHO~, HIV-2 ~COU~, and HIV-2 ~BER~ were kindly provided by Jan McClure (University of Washington, Seattle, WA)"".

Rationale: The paper mentions that HIV-2 sequences were generated from plasmid molecular clones, which suggests that the sequences were obtained from patient samples. Additionally, the paper mentions that HIV-2 sequences were provided by a researcher, which further supports the idea that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""Bictegravir showed strong dose-dependent activity against HIV-1 ~NL4~~-3~ in the single-cycle assay, with an EC ~50~ of 1.7 nM, and other group M isolates of HIV-1 were highly susceptible to the drug (EC ~50~, 1.2 to 2.1 nM) ( Table 1 )"". The paper also mentions ""For HIV-2, we performed a total of seven assay runs in which the prototypic strain HIV-2 ~ROD9~ (group A) was tested head to head against HIV-1 ~NL4-3~. Dose-response curves for these two strains were similarly shaped ( Fig. 1A ), and there was no statistically significant difference between the EC ~50~ values for HIV-1 ~NL4-3~ and HIV-2 ~ROD9~ in these experiments ( Fig. 1B )"".

Rationale: The paper reports EC ~50~ values for HIV-1 and HIV-2 isolates, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public repository.

Rationale: The paper does not provide any information about the availability of the sequences, which suggests that the sequences may not have been made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that the accession numbers may not have been reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions ""a total of seven assay runs in which the prototypic strain HIV-2 ~ROD9~ (group A) was tested head to head against HIV-1 ~NL4-3~ "". The paper also mentions ""15 HIV-2 isolates"".

Rationale: The paper mentions that 7 assay runs were performed, which suggests that 7 HIV-2 isolates were sequenced. Additionally, the paper mentions that 15 HIV-2 isolates were tested.

Answer: 15

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions ""HIV-2 ~EHO~, HIV-2 ~COU~, and HIV-2 ~BER~ were kindly provided by Jan McClure (University of Washington, Seattle, WA)"".

Rationale: The paper mentions that the HIV-2 sequences were provided by a researcher at the University of Washington, which suggests that the samples were obtained from the United States.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention any specific years.

Rationale: The paper does not provide any information about the years in which the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""HIV-2 ~ROD9~ and HIV-2 ~ST~ were generated by transfecting the corresponding plasmid molecular clones into cultures of 293T/17 human embryonic kidney cells as previously described ( 43, 44 )"". The paper also mentions ""HIV-2 ~EHO~, HIV-2 ~COU~, and HIV-2 ~BER~ were kindly provided by Jan McClure (University of Washington, Seattle, WA)"".

Rationale: The paper mentions that the HIV-2 sequences were generated from plasmid molecular clones, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper mentions that the pol region, which includes protease and reverse transcriptase, was sequenced.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Bictegravir was purchased from Toronto Research Chemicals, Inc. (North York, ON, Canada)"".

Rationale: The paper does not provide any information about the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"".

Rationale: The paper mentions that viral RNA was extracted from plasma, which suggests that the samples were plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic or virological failure (VF)"".

Rationale: The paper mentions that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""These studies were supported by grants to G.S.G. from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID; 2R01-AI060466 and R01-AI120765)"".

Rationale: The paper mentions that the study was supported by grants from the National Institutes of Health, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"".

Rationale: The paper mentions that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""ART-experienced"".

Rationale: The paper mentions that the sequences were obtained from individuals who had previously received ARV drugs, which suggests that the individuals received NRTIs.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""ART-experienced"".

Rationale: The paper mentions that the sequences were obtained from individuals who had previously received ARV drugs, which suggests that the individuals received specific ARV drugs.

Answer: Not reported",24
31988104,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV sequences from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and single-genome sequencing, which are all methods used to analyze HIV sequences. The mention of GenBank accession numbers also suggests that the sequences were generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure in vitro drug susceptibility. The mention of IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility also suggests that the paper reports in vitro drug susceptibility data. Additionally, the paper refers to specific platforms and assays used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The mention of accession numbers for GenBank also supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank. The accession numbers are provided in the text.

Rationale: The paper explicitly mentions accession numbers for GenBank, which suggests that the sequences are publicly available. The accession numbers are provided in the text, which allows for extraction of the ranges and individual accession numbers.

Answer: Not reported (the paper does not provide specific accession numbers)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing, genotyping, or sequencing was performed on samples from 110 viruses containing TAMs in the presence or absence of M184V.

Rationale: The paper explicitly mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from 110 viruses, which suggests that 110 individuals had samples obtained for HIV sequencing.

Answer: 110

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2008 and 2017.

Rationale: The paper explicitly mentions that clinical samples were collected between 2008 and 2017, which suggests that the sequenced samples were obtained during this time period.

Answer: 2008-2017

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that recombinant mutant HIV-1 viruses were created either by site-directed mutagenesis (SDM) of wild-type HIV-1 DNA, or by direct PCR of ART-experienced patient isolates.

Rationale: The paper explicitly mentions that recombinant mutant HIV-1 viruses were created by site-directed mutagenesis or direct PCR, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper explicitly mentions that the pol region encompassing protease and reverse transcriptase was sequenced, which suggests that the PR and RT genes were reported to have been sequenced.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which suggests that Sanger sequencing was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study investigated the resistance profile of TAF and TDF in viruses containing TAMs in the presence or absence of M184V.

Rationale: The paper explicitly mentions that the study investigated the resistance profile of TAF and TDF in viruses containing TAMs, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention that the study was a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study investigated the resistance profile of TAF and TDF in viruses containing TAMs in the presence or absence of M184V.

Rationale: The paper explicitly mentions that the study investigated the resistance profile of TAF and TDF in viruses containing TAMs, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study investigated the resistance profile of TAF and TDF in viruses containing TAMs in the presence or absence of M184V.

Rationale: The paper explicitly mentions that the study investigated the resistance profile of TAF and TDF in viruses containing TAMs, which suggests that the individuals in the study had previously received NRTI and/or NNRTI drugs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study investigated the resistance profile of TAF and TDF in viruses containing TAMs in the presence or absence of M184V.

Rationale: The paper explicitly mentions that the study investigated the resistance profile of TAF and TDF in viruses containing TAMs, which suggests that the individuals in the study had previously received TAF and/or TDF.

Answer: TAF, TDF",26
32601157,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions sequencing on clinical samples, which is a common source of HIV sequences. The mention of ART-naïve and ART-experienced patients, baseline and virologic failure samples, and transmitted drug resistance surveillance also suggests that the sequences are from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper describes cell-based susceptibility assays with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility and resistance testing, which is a common method for measuring in vitro drug susceptibility. The mention of IC50, EC50, EC90, and fold-change in susceptibility also suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions submitting sequences to public databases, which is a common practice for making sequences publicly available. The mention of accession numbers also suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions accession numbers, which are a unique identifier for sequences in public databases. The accession numbers are likely to be the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported (the paper does not provide specific accession numbers)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a panel of X isolates from the plasma of Y treatment-naïve or experienced individuals. The paper also mentions that sequencing was performed on patients in the study.

Rationale: The paper mentions a panel of isolates from the plasma of treatment-naïve or experienced individuals, which suggests that multiple individuals had samples obtained for HIV sequencing.

Answer: Not reported (the paper does not provide a specific number)

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in the United States.

Rationale: The paper mentions that the study was conducted in the United States, which suggests that the sequenced samples were obtained from this country.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not report specific years for the sequenced samples.

Rationale: The paper does not provide specific years for the sequenced samples, which makes it difficult to determine the exact years.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, which suggests that the samples were not cloned.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing of the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper mentions sequencing of the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing.

Rationale: The paper mentions Sanger sequencing, which is a common method for sequencing DNA.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions sequencing of plasma samples.

Rationale: The paper mentions sequencing of plasma samples, which is a common source of HIV sequences.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions sequencing of samples from individuals with virological failure.

Rationale: The paper mentions sequencing of samples from individuals with virological failure, which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions sequencing of samples from individuals who had previously received ARV drugs.

Rationale: The paper mentions sequencing of samples from individuals who had previously received ARV drugs, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals received NRTIs.

Rationale: The paper mentions that the individuals received NRTIs, which is a common class of antiretroviral drugs.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals received AZT.

Rationale: The paper mentions that the individuals received AZT, which is a specific antiretroviral drug.

Answer: AZT",24
33855437,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions that viral RNA was extracted from plasma and genotypic analyses of all clinical isolates was performed at weeks 8 and 24 of selective drug pressure.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper mentions the extraction of viral RNA from plasma, which further supports the conclusion that patient samples were used for sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that cell-based susceptibility assays were performed with drug titrations and reporter readouts, and that the EC ~50~ was calculated using GraphPad Prism software. The paper also mentions that the assays used named platforms like PhenoSense and Monogram.

Rationale: The paper explicitly mentions the use of cell-based susceptibility assays, which is a clear indication of in vitro drug susceptibility data. The mention of EC ~50~ and GraphPad Prism software further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and provides accession numbers for the sequences. The paper also mentions that the raw reads are in the SRA database.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which is a public database, and provides accession numbers, which is a clear indication that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, including MW484894, MW484895, MW484893, DQ380549, and AF492618.

Rationale: The paper explicitly mentions the accession numbers for the sequences, which are provided in the text.

Answer: MW484894, MW484895, MW484893, DQ380549, AF492618

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that three subtype B and three non-B subtype clinical isolates were used for sequencing.

Rationale: The paper explicitly mentions the number of isolates used for sequencing, which can be used to estimate the number of individuals.

Answer: 6

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the isolates were derived from drug-naive individuals at Clinique Actuel in Canada, and that the subtype C isolate was obtained from Ethiopia.

Rationale: The paper explicitly mentions the countries where the samples were obtained.

Answer: Canada, Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide specific years for the collection of the samples.

Rationale: The paper does not provide specific years for the collection of the samples, so it is not possible to determine the exact years.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, which suggests that direct sequencing was used.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region was sequenced, including the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions the sequencing of the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used, as indicated by the mention of ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly mentions the use of Sanger sequencing, which is a clear indication of the sequencing method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that viral RNA was extracted from plasma, and that genotypic analyses of all clinical isolates was performed.

Rationale: The paper explicitly mentions the extraction of viral RNA from plasma, which suggests that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study was conducted on drug-naive individuals, and that the sequences were obtained from individuals who had not failed treatment.

Rationale: The paper explicitly mentions that the study was conducted on drug-naive individuals, which suggests that the sequences were not obtained from individuals with virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the study was not conducted as part of a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study was conducted on drug-naive individuals, and that the sequences were obtained from individuals who had not received ARV drugs.

Rationale: The paper explicitly mentions that the study was conducted on drug-naive individuals, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted on drug-naive individuals, and that the sequences were obtained from individuals who had not received ARV drugs.

Rationale: The paper explicitly mentions that the study was conducted on drug-naive individuals, which suggests that the individuals had not received any drug classes.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted on drug-naive individuals, and that the sequences were obtained from individuals who had not received ARV drugs.

Rationale: The paper explicitly mentions that the study was conducted on drug-naive individuals, which suggests that the individuals had not received any drugs.

Answer: None",20
34516245,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions specific types of clinical samples that were used for sequencing, which suggests that the sequences were obtained from patient samples. Additionally, the paper mentions ART-naïve and ART-experienced patients, which implies that the sequences were obtained from individuals who have received antiretroviral therapy. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper mentions specific types of in vitro drug susceptibility assays, which suggests that the study measured the susceptibility of HIV to various drugs. The paper also reports specific values, such as IC50 and EC50, which are commonly used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper also reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that the sequences were submitted to a public database, which suggests that the sequences are publicly available. The paper also reports accession numbers, which are used to identify the sequences in the database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as “OK263149 to OK263162”. The accession numbers are provided in the Data Availability statement.

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides the accession numbers, which are used to identify the sequences in the database.

Answer: OK263149 to OK263162

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing, genotyping, or sequencing was performed on samples from 14 individuals. The paper also reports that 14 sequences were reported from 14 individuals.

Rationale: The paper explicitly states that the study included 14 individuals, which suggests that the number of individuals is 14.

Answer: 14

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples, which suggests that the country of origin is not reported.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2004 and 2007.

Rationale: The paper explicitly states that the clinical samples were collected between 2004 and 2007, which suggests that the year range is 2004-2007.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced. The paper also mentions TA cloning/Topo TA cloning and describes use of “single-genome amplification \(SGA\)”, “single-proviral sequencing”, or “limiting dilution for direct sequencing”.

Rationale: The paper explicitly states that the amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the sequencing was done on the “pol region encompassing protease and reverse transcriptase”. The paper also mentions sequencing of the “integrase coding region of pol” and the “reverse transcriptase \(RT\)"".

Rationale: The paper explicitly states that the sequencing was done on specific regions of the HIV genome, which suggests that the genes sequenced are Pol, IN, and RT.

Answer: Pol, IN, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator. The paper also mentions capillary sequencer/capillary electrophoresis with ABI analyzers.

Rationale: The paper explicitly states that the sequencing was done using ABI instruments and BigDye/ABI PRISM Dye Terminator, which suggests that the method used is Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”. The paper also mentions sequencing of “PBMC”, “peripheral blood mononuclear cells”, “proviral DNA”, “cell-associated DNA/RNA”.

Rationale: The paper explicitly states that the sequencing was done on plasma and PBMC samples, which suggests that the type of samples sequenced are plasma and PBMC.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen”. The paper also mentions sequencing of “ART-experienced” patients.

Rationale: The paper explicitly states that the study included individuals with virological failure on a treatment regimen, which suggests that the answer is Yes.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention that the study was a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial, which suggests that the answer is Not Reported.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”. The paper also mentions sequencing of “ART-naïve” patients.

Rationale: The paper explicitly states that the study included individuals who had previously received ARV drugs, which suggests that the answer is Yes.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states “ART-naïve”, “treatment-naïve”, “drug-naive”, “never exposed to antiretrovirals”. The paper also mentions sequencing of “ART-experienced” patients.

Rationale: The paper explicitly states that the study included individuals who had not received any ARV drugs, which suggests that the answer is None.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the drugs received by the individuals in the study.

Rationale: The paper does not provide any information about the drugs received by the individuals in the study, which suggests that the answer is Not Reported.

Answer: Not Reported",28
35730213,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones.

Rationale: The paper does not mention any of the keywords associated with in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, or cell-based susceptibility assays. This suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper does not report accession numbers for GenBank or any of the above databases. The paper does not mention depositing or making sequences available in a sequence database.

Rationale: The paper does not mention submitting sequences to any public database or reporting accession numbers, which suggests that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention submitting sequences to GenBank or reporting accession numbers, which suggests that the paper does not report any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not report the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing, which suggests that the information is not reported.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Lesotho.

Rationale: The paper explicitly mentions that the study was conducted in Lesotho, which suggests that the sequenced samples were obtained from Lesotho.

Answer: Lesotho

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not report the years when the sequenced samples were obtained.

Rationale: The paper does not mention the years when the sequenced samples were obtained, which suggests that the information is not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using single-genome amplification (SGA) or single-proviral sequencing.

Rationale: The paper does not mention cloning amplicons or using SGA or single-proviral sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention sequencing any specific HIV genes.

Rationale: The paper does not mention sequencing any specific HIV genes, which suggests that the information is not reported.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions using Sanger sequencing.

Rationale: The paper explicitly mentions using Sanger sequencing, which suggests that the method used for sequencing was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions sequencing plasma samples.

Rationale: The paper explicitly mentions sequencing plasma samples, which suggests that the type of samples sequenced was plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or treatment regimens.

Rationale: The paper does not mention virological failure or treatment regimens, which suggests that the information is not reported.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was registered at ClinicalTrials.gov.

Rationale: The paper explicitly mentions that the study was registered at ClinicalTrials.gov, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included ART-experienced individuals.

Rationale: The paper explicitly mentions that the study included ART-experienced individuals, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included ART-experienced individuals.

Rationale: The paper explicitly mentions that the study included ART-experienced individuals, which suggests that the individuals in the study had received NRTIs.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs received by the individuals in the study.

Rationale: The paper does not mention any specific drugs received by the individuals in the study, which suggests that the information is not reported.

Answer: Not reported",21
35913500,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not mention any methods or results related to in vitro drug susceptibility testing, which suggests that the study did not report in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper does not report accession numbers for GenBank or any of the above databases. The paper does not mention depositing or making sequences available in a sequence database.

Rationale: The paper does not mention submitting sequences to a public database or reporting accession numbers, which suggests that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention submitting sequences to GenBank or reporting accession numbers, which suggests that the sequences were not submitted to GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 51 patients initiated LAI-ART, with 39 receiving at least 2 follow-up injections by database closure.

Rationale: The paper mentions that 51 patients initiated LAI-ART, but only 39 received at least 2 follow-up injections. This suggests that the study involved 39 individuals who had samples obtained for HIV sequencing.

Answer: 39

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted at Ward 86, a large HIV clinic in San Francisco, which serves publicly insured and underinsured patients.

Rationale: The paper mentions that the study was conducted at a clinic in San Francisco, which suggests that the sequenced samples were obtained from patients in the United States.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between June 2021 and April 2022.

Rationale: The paper mentions the start and end dates of the study, which suggests that the sequenced samples were obtained during this time period.

Answer: 2021-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using TA cloning/Topo TA cloning kits.

Rationale: The paper does not mention any methods related to cloning amplicons or using cloning kits, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention sequencing any specific HIV genes.

Rationale: The paper does not mention sequencing any specific HIV genes, which suggests that the study did not report sequencing any specific genes.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions using Illumina platforms, paired-end, library prep, and target capture.

Rationale: The paper mentions using Illumina platforms, which suggests that the study used next-generation sequencing (NGS).

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper mentions extracting viral RNA from plasma, which suggests that the study involved sequencing plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that 15 patients initiated injections with detectable viremia.

Rationale: The paper mentions that 15 patients initiated injections with detectable viremia, which suggests that the study involved sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention randomization, double-blind, placebo-controlled, open-label, controlled, or multicenter with intervention arms.

Rationale: The paper does not mention any characteristics of a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that 51 patients initiated LAI-ART, with 39 receiving at least 2 follow-up injections by database closure.

Rationale: The paper mentions that 51 patients initiated LAI-ART, which suggests that the study involved individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drug classes.

Rationale: The paper does not mention any specific drug classes, which suggests that the study did not report any specific drug classes.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs.

Rationale: The paper does not mention any specific drugs, which suggests that the study did not report any specific drugs.

Answer: Not reported",21
35945163,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper reports that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not mention any methods or results related to in vitro drug susceptibility testing, which suggests that the study did not report in vitro susceptibility data. The paper focuses on sequencing and genotyping of HIV samples, but does not provide any information on the susceptibility of the viruses to antiretroviral drugs.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive SRA. The paper does not report accession numbers for GenBank or any of the above databases. The paper does not mention depositing or making sequences available in a sequence database.

Rationale: The paper does not provide any information on the availability of the sequences, which suggests that they may not have been made publicly available. The paper does not mention submitting sequences to a public database or providing accession numbers, which are common practices for making sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information on the accession numbers for the sequences, which suggests that they may not have been submitted to GenBank or any other public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 35 people living with HIV-1 had data available for the study.

Rationale: The paper explicitly states that 35 individuals had data available for the study, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 35

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted in multiple countries, including the UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain.

Rationale: The paper explicitly states that the study was conducted in multiple countries, which suggests that the sequenced samples were obtained from these countries.

Answer: UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted from February 2016 through July 2020.

Rationale: The paper explicitly states the time period during which the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2016-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning samples prior to sequencing.

Rationale: The paper does not provide any information on the sequencing process, which suggests that cloning may not have been performed prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not explicitly state which HIV genes were sequenced, but mentions sequencing of the pol region.

Rationale: The paper mentions sequencing of the pol region, which suggests that the study may have sequenced the protease and reverse transcriptase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information on the sequencing method used, which suggests that the method may not have been explicitly stated.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that the study used plasma samples for sequencing.

Rationale: The paper explicitly states that the study used plasma samples for sequencing, which suggests that the sequenced samples were plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that 7 people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response.

Rationale: The paper explicitly states that 7 individuals discontinued therapy due to incomplete virological response, which suggests that these individuals had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper reports that the study was a compassionate use programme, which suggests that the study was not a clinical trial.

Rationale: The paper explicitly states that the study was a compassionate use programme, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study included individuals who had previously received ARV drugs.

Rationale: The paper explicitly states that the study included individuals who had previously received ARV drugs, which suggests that the study reported HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included individuals who had previously received NRTI, NNRTI, and INSTI drugs.

Rationale: The paper explicitly states that the study included individuals who had previously received NRTI, NNRTI, and INSTI drugs, which suggests that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI, and INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included individuals who had previously received cabotegravir, rilpivirine, and other ARV drugs.

Rationale: The paper explicitly states that the study included individuals who had previously received cabotegravir, rilpivirine, and other ARV drugs, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: Cabotegravir, rilpivirine, and other ARV drugs",24
36415058,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to various sequencing methods and genotypic resistance testing, which further supports the conclusion that the study involved sequencing of patient samples. The mention of GenBank accession numbers also suggests that the sequences were generated in this study.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper only discusses genotypic resistance testing and sequencing.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve in vitro susceptibility testing. The focus on genotypic resistance testing and sequencing also supports this conclusion.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention anything about sequences being made publicly available or deposited in a sequence database.

Rationale: The paper does not mention any information about sequences being made publicly available or deposited in a sequence database, which suggests that the sequences may not have been made publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates, which suggests that the accession numbers may not have been provided.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing, which suggests that the information may not have been reported.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any information about the countries where the sequenced samples were obtained.

Rationale: The paper does not mention any information about the countries where the sequenced samples were obtained, which suggests that the information may not have been reported.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention any information about the years when the sequenced samples were obtained.

Rationale: The paper does not mention any information about the years when the sequenced samples were obtained, which suggests that the information may not have been reported.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention anything about samples being cloned prior to sequencing.

Rationale: The paper does not mention anything about samples being cloned prior to sequencing, which suggests that the information may not have been reported.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any specific HIV genes that were sequenced.

Rationale: The paper does not mention any specific HIV genes that were sequenced, which suggests that the information may not have been reported.

Answer: Not reported

**Question: What method was used for sequencing?**

Evidence: The paper does not mention any information about the sequencing method used.

Rationale: The paper does not mention any information about the sequencing method used, which suggests that the information may not have been reported.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper does not mention any information about the type of samples that were sequenced.

Rationale: The paper does not mention any information about the type of samples that were sequenced, which suggests that the information may not have been reported.

Answer: Not reported

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any information about sequences being obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any information about sequences being obtained from individuals with virological failure on a treatment regimen, which suggests that the information may not have been reported.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any information about the study being a clinical trial.

Rationale: The paper does not mention any information about the study being a clinical trial, which suggests that the information may not have been reported.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention any information about the study involving individuals who had previously received ARV drugs.

Rationale: The paper does not mention any information about the study involving individuals who had previously received ARV drugs, which suggests that the information may not have been reported.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any information about the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any information about the drug classes received by individuals in the study before sample sequencing, which suggests that the information may not have been reported.

Answer: Not reported

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any information about the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any information about the specific drugs received by individuals in the study before sample sequencing, which suggests that the information may not have been reported.

Answer: Not reported",19
36454248,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to various sequencing methods, including Sanger, Illumina, and MiSeq, which are commonly used for sequencing patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses.

Rationale: The paper does not mention any of the key terms associated with in vitro drug susceptibility data, such as phenotypic susceptibility or cell-based susceptibility assays. Additionally, the paper does not report any values related to drug susceptibility, which suggests that in vitro drug susceptibility data was not reported.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database. The paper also provides the accession numbers for the sequences, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides the accession numbers for the sequences.

Answer: OM201778 -- OM201846

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that plasma samples were collected from 76 HIV-infected children/adolescents under clinical monitoring at the Hospital del Niño Doctor José Renán Esquivel in Panama.

Rationale: The paper explicitly states that plasma samples were collected from 76 individuals, which suggests that 76 individuals had samples obtained for HIV sequencing.

Answer: 76

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in Panama.

Rationale: The paper explicitly states that samples were collected in Panama, which suggests that the sequenced samples were obtained from Panama.

Answer: Panama

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that plasma samples were collected during 2018--19.

Rationale: The paper explicitly states that plasma samples were collected during 2018--19, which suggests that the sequenced samples were obtained during this time period.

Answer: 2018-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or amplification of samples prior to sequencing.

Rationale: The paper does not mention any cloning or amplification methods, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the HIV-1 pol region was sequenced, including the protease (PR), reverse transcriptase (RT), and integrase (IN) genes.

Rationale: The paper explicitly states that the HIV-1 pol region was sequenced, which includes the PR, RT, and IN genes.

Answer: PR, RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina sequencing.

Rationale: The paper explicitly mentions Sanger sequencing and Illumina sequencing, which are two different sequencing methods.

Answer: Sanger sequencing and Illumina sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were collected from 76 HIV-infected children/adolescents.

Rationale: The paper explicitly states that plasma samples were collected, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs, and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper explicitly states that 71 treated children/adolescents had received NRTIs, NNRTIs, PIs, and INSTIs, which suggests that some individuals were on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention any clinical trial-related terms, such as randomized, double-blind, or placebo-controlled.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs, and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper explicitly states that 71 treated children/adolescents had received NRTIs, NNRTIs, PIs, and INSTIs, which suggests that some individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs, and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper explicitly states that 71 treated children/adolescents had received NRTIs, NNRTIs, PIs, and INSTIs, which suggests that some individuals received these drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs, and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper explicitly states that 71 treated children/adolescents had received NRTIs, NNRTIs, PIs, and INSTIs, which suggests that some individuals received these specific drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, RAL, EVG, DTG, BIC, CAB, LEN, MVC",26
36519389,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" were performed on clinical samples from patients. The paper also reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genotypic resistance testing, genotyping, and sequencing were performed on clinical samples from patients. This indicates that the paper reports HIV sequences from patient samples. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, EC50, or cell-based susceptibility assays.

Rationale: The paper focuses on the clinical and virological outcomes of patients who switched from one antiretroviral regimen to another, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to a public database, such as GenBank, NCBI, or SRA.

Rationale: The paper does not provide any information about the availability of the sequences in a public database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 172 participants were enrolled in the study, but it does not provide the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Johannesburg, South Africa, and that participants were recruited from inner-city Johannesburg.

Rationale: The paper explicitly mentions that the study was conducted in Johannesburg, South Africa.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted from July to November 2022.

Rationale: The paper explicitly mentions the time period during which the study was conducted.

Answer: 2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning or amplification of the samples prior to sequencing.

Rationale: The paper does not provide any information about the preparation of the samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the study focused on the pol region, including the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions that the study focused on the pol region, including the protease and reverse transcriptase genes.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the study used next-generation sequencing (NGS) to sequence the HIV genomes.

Rationale: The paper explicitly mentions that the study used NGS to sequence the HIV genomes.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the study used plasma samples for sequencing.

Rationale: The paper explicitly mentions that the study used plasma samples for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included participants who were experiencing virological failure on their current antiretroviral regimen.

Rationale: The paper explicitly mentions that the study included participants who were experiencing virological failure on their current antiretroviral regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a trial extension of the ADVANCE study, which was a randomized controlled trial.

Rationale: The paper explicitly mentions that the study was a trial extension of the ADVANCE study, which was a randomized controlled trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included participants who were experiencing virological failure on their current antiretroviral regimen, which suggests that they had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included participants who were experiencing virological failure on their current antiretroviral regimen.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included participants who were experiencing virological failure on their current antiretroviral regimen, which suggests that they had previously received NRTIs, NNRTIs, and/or PIs.

Rationale: The paper explicitly mentions that the study included participants who were experiencing virological failure on their current antiretroviral regimen.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included participants who were experiencing virological failure on their current antiretroviral regimen, which suggests that they had previously received a variety of antiretroviral drugs.

Rationale: The paper explicitly mentions that the study included participants who were experiencing virological failure on their current antiretroviral regimen.

Answer: Not reported",18
36571282,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV samples from patient samples. Additionally, the paper mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones.

Rationale: The paper does not mention any of the keywords associated with in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, or cell-based susceptibility assays. The methods and results sections do not report any data related to in vitro drug susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers, which suggests that the sequences were deposited in these databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly mentions accession numbers for GenBank, which suggests that the sequences were deposited in this database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 2705 PWH were included in the study.

Rationale: The paper explicitly mentions the number of participants in the study, which is 2705.

Answer: 2705

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in France, Greece, Italy, Portugal, and Spain.

Rationale: The paper explicitly mentions the countries where samples were collected, which are France, Greece, Italy, Portugal, and Spain.

Answer: France, Greece, Italy, Portugal, Spain

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2018 and 2021.

Rationale: The paper explicitly mentions the years when samples were collected, which are 2018 and 2021.

Answer: 2018-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or amplification of samples prior to sequencing.

Rationale: The paper does not mention any methods related to cloning or amplification of samples prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing of the integrase and RT regions of the HIV genome.

Rationale: The paper explicitly mentions sequencing of the integrase and RT regions, which suggests that these genes were sequenced.

Answer: Integrase, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and next-generation sequencing (NGS).

Rationale: The paper explicitly mentions two sequencing methods, Sanger sequencing and NGS.

Answer: Sanger sequencing, NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions sequencing of plasma and PBMC samples.

Rationale: The paper explicitly mentions sequencing of plasma and PBMC samples.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions sequencing of samples from individuals with virological failure.

Rationale: The paper explicitly mentions sequencing of samples from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention any keywords associated with clinical trials, such as randomized, double-blind, or placebo-controlled.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions sequencing of samples from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions sequencing of samples from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions sequencing of samples from individuals who had previously received NRTI and INSTI drugs.

Rationale: The paper explicitly mentions sequencing of samples from individuals who had previously received NRTI and INSTI drugs.

Answer: NRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions sequencing of samples from individuals who had previously received tenofovir, lamivudine, abacavir, and raltegravir.

Rationale: The paper explicitly mentions sequencing of samples from individuals who had previously received these drugs.

Answer: Tenofovir, Lamivudine, Abacavir, Raltegravir",21
36597160,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not mention any methods or results related to in vitro drug susceptibility testing, which suggests that it does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which suggests that they were made publicly available. Additionally, the paper reports accession numbers for GenBank, which further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank. The accession numbers are not provided in the text, but the paper mentions that sequences were submitted to GenBank.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, but the accession numbers are not provided in the text. However, the paper mentions that the accession numbers are pending, which suggests that they will be available in the future.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 382 patients were included in the study. The paper states that genotypic resistance testing, genotyping, or sequencing was performed on samples from these patients.

Rationale: The paper explicitly mentions that 382 patients were included in the study, which suggests that samples were obtained from these individuals for HIV sequencing.

Answer: 382

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained. However, the paper mentions that the study was conducted in France.

Rationale: The paper does not explicitly mention the countries from which the sequenced samples were obtained, but it mentions that the study was conducted in France, which suggests that the samples were obtained from France.

Answer: France

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between February 2014 and August 2015.

Rationale: The paper explicitly mentions the dates of the study, which suggests that the sequenced samples were obtained during this time period.

Answer: 2014-2015

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or amplification of the samples prior to sequencing.

Rationale: The paper does not mention any methods related to cloning or amplification of the samples prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region was sequenced.

Rationale: The paper explicitly mentions that the pol region was sequenced, which suggests that the protease and reverse transcriptase genes were sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which suggests that these samples were the type of samples that were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that 13 patients experienced virological failure.

Rationale: The paper explicitly mentions that 13 patients experienced virological failure, which suggests that sequences were obtained from these individuals.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patients were ART-experienced.

Rationale: The paper explicitly mentions that the patients were ART-experienced, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were ART-experienced.

Rationale: The paper explicitly mentions that the patients were ART-experienced, which suggests that they had previously received ARV drugs.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were ART-experienced.

Rationale: The paper explicitly mentions that the patients were ART-experienced, which suggests that they had previously received ARV drugs.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, EVG, DTG, BIC, CAB, LEN, MVC",21
36645792,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to various sequencing methods, including genotypic resistance testing, Sanger sequencing, and Illumina sequencing, which further supports the conclusion that the study involved sequencing of patient samples. The mention of GenBank accession numbers also suggests that the sequences were generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility and phenotypic resistance testing, which are methods used to measure the susceptibility of HIV to antiretroviral drugs. The mention of IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility also suggests that the study involved measurement of drug susceptibility. The use of named platforms such as PhenoSense, Monogram, Antivirogram, or Virco further supports the conclusion that the study involved in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA), which suggests that the sequences were made publicly available. The mention of accession numbers also supports this conclusion, as accession numbers are used to identify and access sequences in public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly mentions accession numbers for GenBank, which are used to identify and access sequences in public databases. The accession numbers provided in the paper, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"", can be used to access the corresponding sequences in GenBank.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 130 participants were randomly assigned to receive lead-in supplementary dolutegravir or placebo.

Rationale: The paper explicitly mentions that 130 participants were randomly assigned to receive lead-in supplementary dolutegravir or placebo, which suggests that 130 individuals had samples obtained for HIV sequencing.

Answer: 130

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that participants were recruited from 3 primary care clinics in Khayelitsha, a large, periurban settlement in Cape Town, South Africa.

Rationale: The paper explicitly mentions that participants were recruited from Khayelitsha, South Africa, which suggests that the sequenced samples were obtained from South Africa.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that participants were recruited between 28 August 2020 and 10 November 2021.

Rationale: The paper explicitly mentions the recruitment period, which suggests that the sequenced samples were obtained between 2020 and 2021.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper explicitly mentions that the pol region encompassing protease and reverse transcriptase was sequenced, which suggests that the study involved sequencing of the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions Sanger sequencing, which is a type of sequencing method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that participants were recruited with virologic failure on first-line tenofovir-emtricitabine-efavirenz (TEE).

Rationale: The paper explicitly mentions that participants were recruited with virologic failure on first-line TEE, which suggests that the study involved sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a randomized, double-blind, placebo-controlled, phase 2 trial.

Rationale: The paper explicitly mentions that the study was a randomized, double-blind, placebo-controlled, phase 2 trial, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that participants were recruited with virologic failure on first-line tenofovir-emtricitabine-efavirenz (TEE).

Rationale: The paper explicitly mentions that participants were recruited with virologic failure on first-line TEE, which suggests that the study involved sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that participants were recruited with virologic failure on first-line tenofovir-emtricitabine-efavirenz (TEE).

Rationale: The paper explicitly mentions that participants were recruited with virologic failure on first-line TEE, which suggests that the study involved sequences from individuals who had previously received NRTIs and NNRTIs.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that participants were recruited with virologic failure on first-line tenofovir-emtricitabine-efavirenz (TEE).

Rationale: The paper explicitly mentions that participants were recruited with virologic failure on first-line TEE, which suggests that the study involved sequences from individuals who had previously received tenofovir, emtricitabine, and efavirenz.

Answer: Tenofovir, Emtricitabine, Efavirenz",27
36659824,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility and phenotypic resistance testing, which are methods used to measure the susceptibility of HIV to antiretroviral drugs. Additionally, the paper reports values such as IC50, EC50, and EC90, which are measures of drug susceptibility. The paper also mentions specific platforms used for drug susceptibility testing, such as PhenoSense and Monogram.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. Additionally, the paper reports accession numbers for GenBank, which are unique identifiers for the sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank. The accession numbers are provided in the Data Availability statement.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers for GenBank. The accession numbers are provided in the Data Availability statement, which suggests that they are publicly available.

Answer: Not reported (the paper does not provide specific accession numbers)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 112 participants were included in the ITT population. The paper reports that 90/112 participants achieved pVL < 50 copies/mL at W24.

Rationale: The paper explicitly states that 112 participants were included in the ITT population, which suggests that 112 individuals had samples obtained for HIV sequencing. Additionally, the paper reports that 90/112 participants achieved pVL < 50 copies/mL at W24, which suggests that the sequencing was performed on a subset of the 112 participants.

Answer: 112

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that participants were recruited in, enrolled in, or followed at hospital or clinic in France. The paper mentions nationwide “cohort” or “surveillance” or “registry” in France.

Rationale: The paper explicitly states that participants were recruited in, enrolled in, or followed at hospital or clinic in France, which suggests that the sequenced samples were obtained from France. Additionally, the paper mentions nationwide “cohort” or “surveillance” or “registry” in France, which further supports the conclusion that the samples were obtained from France.

Answer: France

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that participants were enrolled between November 2019 and September 2020. The paper reports that clinical samples were collected between November 2019 and September 2020.

Rationale: The paper explicitly states that participants were enrolled between November 2019 and September 2020, which suggests that the sequenced samples were obtained during this time period. Additionally, the paper reports that clinical samples were collected between November 2019 and September 2020, which further supports the conclusion that the samples were obtained during this time period.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced. The paper describes use of “single-genome amplification (SGA)”, “single-proviral sequencing”, or “limiting dilution for direct sequencing”.

Rationale: The paper explicitly states that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing. Additionally, the paper describes use of single-genome amplification (SGA), single-proviral sequencing, or limiting dilution for direct sequencing, which are all methods that involve cloning of the samples prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that pol genotyping/sequencing was performed. The paper mentions sequencing of the pol region encompassing protease and reverse transcriptase.

Rationale: The paper explicitly states that pol genotyping/sequencing was performed, which suggests that the pol gene was sequenced. Additionally, the paper mentions sequencing of the pol region encompassing protease and reverse transcriptase, which further supports the conclusion that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was performed. The paper mentions use of ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly states that Sanger sequencing was performed, which suggests that the sequencing method used was Sanger sequencing. Additionally, the paper mentions use of ABI instruments and BigDye/ABI PRISM Dye Terminator, which are both associated with Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma. The paper mentions sequencing of plasma HIV-1 RNA.

Rationale: The paper explicitly states that viral RNA was extracted from plasma, which suggests that plasma samples were used for sequencing. Additionally, the paper mentions sequencing of plasma HIV-1 RNA, which further supports the conclusion that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that participants with virologic or virological failure (VF) were included in the study. The paper mentions sequencing of participants with VL > 50 copies/mL while on ART.

Rationale: The paper explicitly states that participants with virologic or virological failure (VF) were included in the study, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen. Additionally, the paper mentions sequencing of participants with VL > 50 copies/mL while on ART, which further supports the conclusion that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a national, multicenter, prospective, open-label single-arm study. The paper mentions enrollment of participants in the study.

Rationale: The paper explicitly states that the study was a national, multicenter, prospective, open-label single-arm study, which suggests that the study was a clinical trial. Additionally, the paper mentions enrollment of participants in the study, which further supports the conclusion that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that participants were ART-experienced. The paper mentions sequencing of participants who had received ARV drugs.

Rationale: The paper explicitly states that participants were ART-experienced, which suggests that the participants had previously received ARV drugs. Additionally, the paper mentions sequencing of participants who had received ARV drugs, which further supports the conclusion that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that participants were ART-experienced. The paper mentions sequencing of participants who had received NRTIs, PIs, and INSTIs.

Rationale: The paper explicitly states that participants were ART-experienced, which suggests that the participants had previously received ARV drugs. Additionally, the paper mentions sequencing of participants who had received NRTIs, PIs, and INSTIs, which further supports the conclusion that the participants had received these drug classes before sample sequencing.

Answer: NRTIs, PIs, and INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that participants were ART-experienced. The paper mentions sequencing of participants who had received AZT, 3TC, FTC, TDF, ABC, EFV, NVP, and RAL.

Rationale: The paper explicitly states that participants were ART-experienced, which suggests that the participants had previously received ARV drugs. Additionally, the paper mentions sequencing of participants who had received AZT, 3TC, FTC, TDF, ABC, EFV, NVP, and RAL, which further supports the conclusion that the participants had received these drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, and RAL",33
36660819,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of drug susceptibility. Furthermore, the paper mentions specific platforms used for drug susceptibility testing, such as PhenoSense and Monogram.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which suggests that the sequences are publicly available. Additionally, the paper reports accession numbers for GenBank, which are unique identifiers for the sequences. However, the paper also mentions that the accession numbers are pending, which suggests that the sequences may not be immediately available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including KP170487.

Rationale: The paper explicitly mentions accession numbers for GenBank, which are unique identifiers for the sequences. The accession number KP170487 is reported in the paper, which suggests that this is one of the accession numbers for the sequenced HIV isolates.

Answer: KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1045 participants received CAB+RPV LA (Q8W, n = 522; Q4W, n = 523).

Rationale: The paper explicitly mentions the number of participants who received CAB+RPV LA, which suggests that this is the number of individuals who had samples obtained for HIV sequencing.

Answer: 1045

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in multiple countries, including the USA, Botswana, Uganda, and Zimbabwe.

Rationale: The paper explicitly mentions that the study was conducted in multiple countries, which suggests that the sequenced samples were obtained from these countries.

Answer: USA, Botswana, Uganda, Zimbabwe

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2008 and 2017.

Rationale: The paper explicitly mentions the year range in which the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2008-2017

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper explicitly mentions that the pol region was sequenced, which suggests that this region was the focus of the sequencing analysis.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions Sanger sequencing, which is a specific method of DNA sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which suggests that these were the type of samples that were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that these individuals were included in the study.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a randomized, multicenter study.

Rationale: The paper explicitly mentions that the study was a randomized, multicenter study, which suggests that it was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included individuals who had previously received ARV drugs, which suggests that these individuals were included in the study.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who had received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions that the study included individuals who had received NRTIs, NNRTIs, and PIs, which suggests that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who had received AZT, 3TC, FTC, TDF, ABC, EFV, RPV, and DRV.

Rationale: The paper explicitly mentions that the study included individuals who had received AZT, 3TC, FTC, TDF, ABC, EFV, RPV, and DRV, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, RPV, DRV",25
36694270,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that HIV genotyping and drug resistance was evaluated using the Stanford v8.7 algorithm.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which is a clear indication that HIV sequences were obtained from patient samples. Additionally, the paper mentions the use of the Stanford v8.7 algorithm, which is a tool used for HIV genotyping and drug resistance analysis.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only reports on genotypic resistance, mutation prevalence, or algorithmic/predicted susceptibility.

Rationale: The paper does not mention any in vitro drug susceptibility data, which is a key indicator of whether the paper reports in vitro drug susceptibility data. The paper only focuses on genotypic resistance, mutation prevalence, or algorithmic/predicted susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public repository. However, the paper does mention that the sequences were evaluated using the Stanford v8.7 algorithm, which is a publicly available tool.

Rationale: The paper does not explicitly mention that sequences were submitted to a public repository, which is a key indicator of whether the sequences were made publicly available. However, the paper does mention the use of a publicly available tool, which suggests that the sequences may be available for public access.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers, which is a key piece of information for identifying the sequences.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 62 HIV-1 patients were included in the study.

Rationale: The paper explicitly mentions the number of patients included in the study, which is a clear indication of the number of individuals who had samples obtained for HIV sequencing.

Answer: 62

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Chongqing, China.

Rationale: The paper explicitly mentions the location where the study was conducted, which is a clear indication of the country where the sequenced samples were obtained.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from June 2020 to June 2022.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which is a clear indication of the years when the sequenced samples were obtained.

Answer: 2020-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that the viral nucleic acid extraction kit (Jiangsu Shuoshi Company, China) was used to extract RNA from 00 μL plasma and CFS, and that the first round of PCR was performed using the HiScript II One-Step RT-PCR Kit (Vazyme, Nanjing, China).

Rationale: The paper explicitly mentions the use of PCR, which is a technique that requires cloning prior to sequencing. However, the paper does not mention the use of cloning kits or other cloning techniques.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the nucleotide sequences of HIV-1 protease, reverse transcriptase, and integrase were amplified.

Rationale: The paper explicitly mentions the specific HIV genes that were sequenced, which is a clear indication of the genes that were reported.

Answer: Protease, Reverse Transcriptase, Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the first round of PCR was performed using the HiScript II One-Step RT-PCR Kit (Vazyme, Nanjing, China), and that the second round of nested PCR was performed using Ace Taq kit (Vazyme, Nanjing China).

Rationale: The paper explicitly mentions the use of PCR, which is a technique that is commonly used for sequencing. However, the paper does not mention the use of Sanger sequencing or NGS.

Answer: PCR

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma and CFS.

Rationale: The paper explicitly mentions the type of samples that were sequenced, which is a clear indication of the type of samples that were used.

Answer: Plasma, CFS

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that 13 patients (21.0%) were detected with drug-resistant mutations, and that the mutation subtypes were mainly nonnucleoside reverse transcriptase inhibitor (NNRTI), nucleotide reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI).

Rationale: The paper explicitly mentions the presence of drug-resistant mutations in some patients, which is a clear indication that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was conducted at Chongqing Public Health Medical Center, and that the study was approved by the Medical Ethics Committee of Chongqing Public Health Medical Center.

Rationale: The paper explicitly mentions the study site and the approval process, which suggests that the study was conducted in a clinical setting. However, the paper does not mention the use of a clinical trial protocol or the registration of the study on ClinicalTrials.gov.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that 11 patients were receiving ARV treatment, and that the most common regimen was NRTIs.

Rationale: The paper explicitly mentions the use of ARV treatment in some patients, which is a clear indication that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the most common regimen was NRTIs.

Rationale: The paper explicitly mentions the most common regimen used in the study, which is a clear indication of the drug classes that were received by individuals in the study.

Answer: NRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the most common regimen was NRTIs, and that the specific drugs used were not mentioned.

Rationale: The paper explicitly mentions the most common regimen used in the study, but does not mention the specific drugs used.

Answer: Not reported",23
36706364,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are commonly used to express the results of in vitro drug susceptibility assays. Additionally, the paper mentions specific platforms used for in vitro drug susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA), which suggests that the sequences were made publicly available. The paper also reports accession numbers, which are unique identifiers assigned to sequences in public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly reports accession numbers for GenBank, which are unique identifiers assigned to sequences in public databases.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 62 adults with two viral loads (VL) >1000 copies/mL were enrolled in the study and switched to TLD.

Rationale: The paper explicitly states that 62 adults were enrolled in the study, which suggests that 62 individuals had samples obtained for HIV sequencing.

Answer: 62

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in South Africa.

Rationale: The paper explicitly mentions that the study was conducted in South Africa, which suggests that the sequenced samples were obtained from this country.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between August 2019 and July 2020.

Rationale: The paper explicitly states that the study was conducted between August 2019 and July 2020, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper explicitly mentions that the pol region was sequenced, which suggests that the study involved sequencing of the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing.

Rationale: The paper explicitly mentions Sanger sequencing, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included participants with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the study included participants with virological failure on a treatment regimen, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a single-arm, prospective, interventional study.

Rationale: The paper explicitly mentions that the study was a single-arm, prospective, interventional study, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included participants who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included participants who had previously received ARV drugs, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included participants who had previously received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions that the study included participants who had previously received NRTIs and NNRTIs, which suggests that the individuals in the study received these drug classes before sample sequencing.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included participants who had previously received tenofovir, lamivudine, and efavirenz.

Rationale: The paper explicitly mentions that the study included participants who had previously received tenofovir, lamivudine, and efavirenz, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: Tenofovir, Lamivudine, Efavirenz",24
36738248,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any of the keywords associated with in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. Additionally, the paper does not report any values related to in vitro susceptibility, such as IC50, EC50, EC90, or fold-change in susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which suggests that the sequences were made publicly available. Additionally, the paper reports accession numbers for GenBank, which further supports the idea that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank. The accession numbers are not provided in the text, but they are mentioned in the Data Availability statement.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, and the accession numbers are mentioned in the Data Availability statement. However, the accession numbers are not provided in the text.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 594 sample pairs were obtained from 527 PLHIV. The paper reports that the majority of PLHIV included in the study were male, and at sample collection, 20.4% of PLHIV were on ART and 76.3% were ART naive.

Rationale: The paper explicitly mentions that 594 sample pairs were obtained from 527 PLHIV, which suggests that the number of individuals with samples obtained for HIV sequencing is 527.

Answer: 527

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Switzerland and that the samples were collected from patients enrolled in the Swiss HIV Cohort Study (SHCS) and the Zurich Primary HIV Cohort Study (ZPHI).

Rationale: The paper explicitly mentions that the study was conducted in Switzerland and that the samples were collected from patients enrolled in the SHCS and ZPHI, which suggests that the sequenced samples were obtained from Switzerland.

Answer: Switzerland

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the samples were collected between 2002 and 2021. The paper mentions that the SHCS has a cumulative total of 21,529 patients as of August 2021.

Rationale: The paper explicitly mentions that the samples were collected between 2002 and 2021, which suggests that the sequenced samples were obtained over a period of 19 years.

Answer: 2002-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or amplification of the samples prior to sequencing. The paper mentions that the sequences were generated using Illumina MiSeq or HiSeq platforms.

Rationale: The paper does not mention any cloning or amplification steps prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequences were generated for the pol region of HIV. The paper reports that the PR region was covered by 584 (98.3%) NGS sequences, and the RT region was covered by 559 (94.1%) NGS sequences.

Rationale: The paper explicitly mentions that the sequences were generated for the pol region of HIV, which suggests that the genes sequenced were PR and RT.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the sequences were generated using Illumina MiSeq or HiSeq platforms. The paper reports that the sequences were generated using next-generation sequencing (NGS).

Rationale: The paper explicitly mentions that the sequences were generated using Illumina MiSeq or HiSeq platforms, which suggests that the method used for sequencing was NGS.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the sequences were generated from plasma samples. The paper reports that the sequences were generated from viral RNA extracted from plasma.

Rationale: The paper explicitly mentions that the sequences were generated from plasma samples, which suggests that the type of sample sequenced was plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included participants who were on ART and had virological failure. The paper reports that the sequences were generated from participants who were on ART and had virological failure.

Rationale: The paper explicitly mentions that the study included participants who were on ART and had virological failure, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial. The paper mentions that the study was a prospective multicenter study.

Rationale: The paper does not mention any keywords associated with clinical trials, such as randomized, double-blind, or placebo-controlled. Additionally, the paper mentions that the study was a prospective multicenter study, which suggests that it was an observational study.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included participants who were on ART and had virological failure. The paper reports that the sequences were generated from participants who were on ART and had virological failure.

Rationale: The paper explicitly mentions that the study included participants who were on ART and had virological failure, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included participants who were on ART and had virological failure. The paper reports that the sequences were generated from participants who were on ART and had virological failure.

Rationale: The paper explicitly mentions that the study included participants who were on ART and had virological failure, which suggests that the participants had received ART before sample sequencing.

Answer: NRTI, PI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included participants who were on ART and had virological failure. The paper reports that the sequences were generated from participants who were on ART and had virological failure.

Rationale: The paper explicitly mentions that the study included participants who were on ART and had virological failure, which suggests that the participants had received ART before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, CAB, LEN",28
36751650,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV sequences from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results sections focus on genotypic resistance testing and sequencing, but do not report any in vitro susceptibility data.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve testing the susceptibility of HIV isolates to antiretroviral drugs in vitro. The focus of the paper is on genotypic resistance testing and sequencing, which is a different approach to analyzing HIV resistance.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and provides accession numbers for the sequences. The paper also mentions that the raw reads are in the SRA database.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The provision of accession numbers also supports this, as accession numbers are used to identify sequences in public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, including FJ800379–FJ800386, GQ477441-GQ477451, and KP170487.

Rationale: The paper explicitly provides accession numbers for the sequences, which allows us to identify the sequences in public databases.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 1653 samples were successfully sequenced, including 716 MSM and 827 HES.

Rationale: The paper explicitly states the number of samples that were sequenced, which allows us to determine the number of individuals who had samples obtained for HIV sequencing.

Answer: 1653

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Guangxi, China, and that samples were collected from patients in Guangxi.

Rationale: The paper explicitly mentions that the study was conducted in Guangxi, China, which suggests that the sequenced samples were obtained from patients in Guangxi.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2016 and 2020.

Rationale: The paper explicitly states the time period during which the samples were collected, which allows us to determine the years in which the sequenced samples were obtained.

Answer: 2016-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced, and that the PCR products were sent to a company for Sanger sequencing.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region was sequenced, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions that the pol region was sequenced, which suggests that the protease and reverse transcriptase genes were sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used, and that the PCR products were sent to a company for sequencing.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which suggests that the sequencing method was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma, and that the PCR products were amplified from patient plasma.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that the samples were plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included patients who were on ART and had virological failure.

Rationale: The paper explicitly mentions that the study included patients who were on ART and had virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial, and does not mention any clinical trial registration numbers.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included patients who were on ART and had virological failure.

Rationale: The paper explicitly mentions that the study included patients who were on ART and had virological failure, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drug classes that were received by the individuals in the study.

Rationale: The paper does not mention any specific drug classes that were received by the individuals in the study, which suggests that the study did not report any specific drug classes.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs that were received by the individuals in the study.

Rationale: The paper does not mention any specific drugs that were received by the individuals in the study, which suggests that the study did not report any specific drugs.

Answer: Not reported",23
36779485,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any of the keywords associated with in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. Additionally, the paper does not report any values related to in vitro susceptibility, such as IC50, EC50, EC90, or fold-change in susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive SRA. The paper does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not mention submitting sequences to any public database, and it does not report any accession numbers. This suggests that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers.

Rationale: The paper does not mention submitting sequences to GenBank or reporting any accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that genotypic resistance testing was performed on samples from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure.

Rationale: The paper explicitly mentions the number of patients from whom samples were obtained for HIV sequencing.

Answer: 277 (for ART-naive patients) and 1372 (for patients experiencing NNRTI-treatment failure)

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples. However, it mentions that the study was conducted in South Africa.

Rationale: The paper does not provide explicit information about the country of origin for the sequenced samples. However, it mentions that the study was conducted in South Africa, which suggests that the samples were obtained from that country.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not report the exact years when the samples were collected. However, it mentions that the study was conducted in the past, and it references previous studies that were conducted in 2019.

Rationale: The paper does not provide explicit information about the years when the samples were collected. However, it mentions that the study was conducted in the past, and it references previous studies that were conducted in 2019.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using single-genome amplification (SGA) or single-proviral sequencing.

Rationale: The paper does not mention any of the keywords associated with cloning or SGA, such as amplicons, cloning, or SGA.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that pol sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs.

Rationale: The paper explicitly mentions that pol sequences were submitted to Stanford HIVdb v9.0, which suggests that the study involved sequencing of the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention Sanger sequencing or NGS. However, it mentions that the sequences were submitted to Stanford HIVdb v9.0, which suggests that the study involved Sanger sequencing.

Rationale: The paper does not explicitly mention Sanger sequencing or NGS. However, it mentions that the sequences were submitted to Stanford HIVdb v9.0, which is a tool used for Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included patients who were experiencing NNRTI-treatment failure.

Rationale: The paper explicitly mentions that the study included patients who were experiencing NNRTI-treatment failure, which suggests that the study involved sequencing of samples from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention any keywords associated with clinical trials, such as randomized, double-blind, placebo-controlled, or multicenter.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included patients who were experiencing NNRTI-treatment failure.

Rationale: The paper explicitly mentions that the study included patients who were experiencing NNRTI-treatment failure, which suggests that the study involved sequencing of samples from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included patients who were experiencing NNRTI-treatment failure.

Rationale: The paper explicitly mentions that the study included patients who were experiencing NNRTI-treatment failure, which suggests that the study involved patients who had previously received NNRTI-based treatment.

Answer: NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs that were received by the individuals in the study.

Rationale: The paper does not mention any specific drugs that were received by the individuals in the study.

Answer: Not reported",22
36795586,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any of the keywords associated with in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, or cell-based susceptibility assays. This suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not mention submitting sequences to any public database, and it does not report accession numbers, which suggests that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers.

Rationale: The paper does not mention submitting sequences to GenBank or reporting accession numbers, which suggests that the GenBank accession numbers are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 9419 CALHIV received DTG across the BIPAI COEs during the study period.

Rationale: The paper explicitly mentions the number of individuals who received DTG, which suggests that this number represents the number of individuals who had samples obtained for HIV sequencing.

Answer: 9419

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in 6 countries in eastern and southern Africa, including Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda.

Rationale: The paper explicitly mentions the countries where the study was conducted, which suggests that the sequenced samples were obtained from these countries.

Answer: Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2017 and 2020.

Rationale: The paper explicitly mentions the years when the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using single-genome amplification (SGA).

Rationale: The paper does not mention any cloning methods or techniques, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the study sequenced the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions the pol region, which suggests that the study sequenced the protease and reverse transcriptase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Illumina platforms, including MiSeq and HiSeq.

Rationale: The paper explicitly mentions Illumina platforms, which suggests that the study used next-generation sequencing (NGS) methods.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the study used plasma samples.

Rationale: The paper explicitly mentions plasma samples, which suggests that the study sequenced plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included individuals who were experiencing virological failure on a treatment regimen.

Rationale: The paper explicitly mentions virological failure, which suggests that the study included individuals who were experiencing treatment failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention any keywords associated with clinical trials, such as randomized, double-blind, or placebo-controlled.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included individuals who were ART-experienced.

Rationale: The paper explicitly mentions ART-experienced individuals, which suggests that the study included individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who were ART-experienced, which implies that they received NRTIs.

Rationale: The paper explicitly mentions ART-experienced individuals, which suggests that they received NRTIs.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who were receiving DTG.

Rationale: The paper explicitly mentions DTG, which suggests that the study included individuals who received DTG.

Answer: DTG",21
36851704,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper reports that sequences were submitted to GenBank, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that phenotypic susceptibility was tested using the PhenoSense platform. The paper reports values such as IC50 and EC50 for certain antiretroviral drugs.

Rationale: The paper mentions the use of the PhenoSense platform, which is a type of phenotypic susceptibility assay. Additionally, the paper reports specific values for IC50 and EC50, which are measures of drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"" and ""GQ477441-GQ477451"".

Rationale: The paper provides specific accession numbers for GenBank, which can be used to retrieve the sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 206 adults who initiated or reinitiated ART in Uruguay were enrolled in the survey.

Rationale: The paper provides a specific number of individuals who were enrolled in the survey.

Answer: 206

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Uruguay.

Rationale: The paper explicitly mentions the country where the study was conducted.

Answer: Uruguay

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between October 2018 and October 2019.

Rationale: The paper provides a specific date range for the study.

Answer: 2018-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned before sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region, including protease and reverse transcriptase, was sequenced.

Rationale: The paper provides specific information about the genes that were sequenced.

Answer: Pol, including protease and reverse transcriptase

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma was used for sequencing.

Rationale: The paper provides specific information about the type of samples used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that sequences were obtained from individuals with virological failure.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a nationally representative cross-sectional survey.

Rationale: The paper explicitly mentions that the study was a survey, which suggests that it was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that 35.6% of the participants reported previous exposure to ARV drugs.

Rationale: The paper provides specific information about the proportion of participants who reported previous exposure to ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that 35.6% of the participants reported previous exposure to ARV drugs, including NRTIs and NNRTIs.

Rationale: The paper provides specific information about the drug classes that were received by individuals in the study.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that 35.6% of the participants reported previous exposure to ARV drugs, including specific drugs such as efavirenz and tenofovir.

Rationale: The paper provides specific information about the drugs that were received by individuals in the study.

Answer: Efavirenz, tenofovir",17
36851760,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali. The paper mentions that HIV-1 RNA was extracted from the 107 DBSs using EasyMag technology as per the manufacturer's instructions. The paper reports that the sequences were successfully analyzed from 75 DBS samples.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which is a key criterion for answering this question. Additionally, the paper mentions the extraction of HIV-1 RNA from DBSs, which is a common method for obtaining viral sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility or cell-based susceptibility assays. The paper focuses on genotypic resistance testing and sequencing of HIV-1 integrase.

Rationale: The paper does not mention any in vitro drug susceptibility data or assays, which is a key criterion for answering this question. The paper's focus on genotypic resistance testing and sequencing of HIV-1 integrase suggests that it does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that the sequences were submitted to GenBank and registered under accession numbers OQ435656-OQ435729.

Rationale: The paper explicitly states that the sequences were submitted to GenBank, which is a public database for genetic sequences. The paper also provides the accession numbers for the sequences, which is a key criterion for answering this question.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that the sequences were submitted to GenBank and registered under accession numbers OQ435656-OQ435729.

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides the accession numbers for the sequences. This information can be used to extract the accession numbers for the sequenced HIV isolates.

Answer: OQ435656-OQ435729

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 107 DBSs were obtained from HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali. The paper reports that the sequences were successfully analyzed from 75 DBS samples.

Rationale: The paper explicitly states that 107 DBSs were obtained from patients, which is a key criterion for answering this question. The paper also reports that the sequences were successfully analyzed from 75 DBS samples, which suggests that 75 individuals had samples obtained for HIV sequencing.

Answer: 75

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali.

Rationale: The paper explicitly states that the samples were obtained from patients in Benin and Mali, which is a key criterion for answering this question.

Answer: Benin, Mali

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide specific information on the years when the samples were obtained. However, it mentions that the samples were collected between 2015 and 2016 in Benin and between 2018 and 2020 in Mali.

Rationale: The paper does not provide specific information on the years when the samples were obtained, which is a key criterion for answering this question. However, it mentions the time periods when the samples were collected, which can be used to infer the years when the samples were obtained.

Answer: 2015-2016 (Benin), 2018-2020 (Mali)

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning or amplification of the samples prior to sequencing. The paper mentions that HIV-1 RNA was extracted from the 107 DBSs using EasyMag technology as per the manufacturer's instructions.

Rationale: The paper does not mention any cloning or amplification of the samples prior to sequencing, which is a key criterion for answering this question. The paper's focus on direct sequencing suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequences were analyzed from the HIV-1 integrase gene.

Rationale: The paper explicitly states that the sequences were analyzed from the HIV-1 integrase gene, which is a key criterion for answering this question.

Answer: Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the sequences were analyzed using Sanger sequencing.

Rationale: The paper explicitly states that the sequences were analyzed using Sanger sequencing, which is a key criterion for answering this question.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the samples were obtained from DBSs.

Rationale: The paper explicitly states that the samples were obtained from DBSs, which is a key criterion for answering this question.

Answer: DBSs

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the samples were obtained from HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali, who were either ART-naive or ART-experienced.

Rationale: The paper explicitly states that the samples were obtained from HIV-1-infected children who were either ART-naive or ART-experienced, which is a key criterion for answering this question. However, the paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial or study registration.

Rationale: The paper does not mention any clinical trial or study registration, which is a key criterion for answering this question. The paper's focus on observational data suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the samples were obtained from HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali, who were either ART-naive or ART-experienced.

Rationale: The paper explicitly states that the samples were obtained from HIV-1-infected children who were either ART-naive or ART-experienced, which is a key criterion for answering this question.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the samples were obtained from HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali, who were either ART-naive or ART-experienced.

Rationale: The paper explicitly states that the samples were obtained from HIV-1-infected children who were either ART-naive or ART-experienced, which is a key criterion for answering this question. However, the paper does not mention any specific drug classes received by the individuals.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs received by the individuals.

Rationale: The paper does not mention any specific drugs received by the individuals, which is a key criterion for answering this question.

Answer: Not reported",25
36920025,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". Additionally, the paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"".

Rationale: The paper explicitly mentions the use of clinical samples such as plasma, serum, PBMC, and proviral DNA for genetic sequencing, which indicates that the sequences were obtained from patient samples. The paper also mentions the use of genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the study uses recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones and tests antiviral activity in vitro against drugs. The paper also mentions that in vitro enzymatic inhibition assays or resistance passage/selection experiments with subsequent phenotypic susceptibility measures are reported.

Rationale: The paper explicitly mentions the use of in vitro assays to test the antiviral activity of drugs against HIV, which indicates that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper also mentions that accession numbers for GenBank or any of the above databases are provided.

Rationale: The paper explicitly mentions the submission of sequences to public databases such as GenBank, NCBI, and SRA, which indicates that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly provides accession numbers for GenBank, which can be used to retrieve the sequences from the database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a panel of 10 DRV analogs were chosen with enzymatic inhibition constants (K ~i~ ) in the single or double-digit picomolar range to wild-type NL4-3 protease and the I84V and I50V drug-resistant variants, respectively. The paper also mentions that the EC ~50~ values for the selected virus pools were determined by a TZM infection assay.

Rationale: The paper explicitly mentions the use of a panel of 10 DRV analogs, which suggests that the study involved a large number of individuals or samples.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the samples were obtained.

Rationale: The paper does not provide any information about the countries from which the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the years from which the samples were obtained.

Rationale: The paper does not provide any information about the years from which the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that the PCR conditions are available upon request, and that the PCR products were purified by using QIAquick PCR purification kit (QIAGEN) and directly sequenced or cloned into the pT7Blue vector (Novagen).

Rationale: The paper explicitly mentions the use of PCR and cloning to prepare the samples for sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequencing was done on the protease-coding domain of viral DNA.

Rationale: The paper explicitly mentions the sequencing of the protease-coding domain of viral DNA.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the sequencing was done using the Illumina MiSeq platform.

Rationale: The paper explicitly mentions the use of the Illumina MiSeq platform for sequencing.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the sequencing was done on plasma samples.

Rationale: The paper explicitly mentions the use of plasma samples for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study was conducted on individuals who were on ART and had virological failure.

Rationale: The paper explicitly mentions the use of individuals who were on ART and had virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was conducted on a panel of 10 DRV analogs, which suggests that the study was a clinical trial.

Rationale: The paper explicitly mentions the use of a panel of 10 DRV analogs, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study was conducted on individuals who were on ART and had virological failure.

Rationale: The paper explicitly mentions the use of individuals who were on ART and had virological failure.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted on individuals who were on ART and had virological failure.

Rationale: The paper explicitly mentions the use of individuals who were on ART and had virological failure.

Answer: NRTI, PI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted on individuals who were on ART and had virological failure.

Rationale: The paper explicitly mentions the use of individuals who were on ART and had virological failure.

Answer: AZT, 3TC, FTC, TDF, ATV, DRV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",26
36931676,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper also reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for question 1. Additionally, the paper mentions GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters.

Rationale: The paper does not mention any in vitro drug susceptibility data, which meets the criteria for question 2. The paper's focus on sequencing and epidemiology suggests that it does not report in vitro susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database. However, the paper does mention that data are available upon reasonable request.

Rationale: The paper does not explicitly state that sequences were submitted to a public database, which meets the criteria for question 3. However, the paper does mention that data are available upon reasonable request, which suggests that the sequences may be available upon request.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which meets the criteria for question 4.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention any specific numbers or estimates of individuals who had samples obtained for HIV sequencing, which meets the criteria for question 5.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Sweden and that the cohort includes data on all diagnosed PLHIV in Sweden.

Rationale: The paper explicitly states that the study was conducted in Sweden, which meets the criteria for question 6.

Answer: Sweden

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the years when the sequenced samples were obtained.

Rationale: The paper does not mention any specific years or time periods when the sequenced samples were obtained, which meets the criteria for question 7.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning or amplification of samples prior to sequencing.

Rationale: The paper does not mention any cloning or amplification of samples, which meets the criteria for question 8.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the study focused on the pol region, including protease and reverse transcriptase.

Rationale: The paper explicitly states that the study focused on the pol region, which includes protease and reverse transcriptase, which meets the criteria for question 9.

Answer: Pol, PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper mentions that the study used Sanger sequencing.

Rationale: The paper explicitly states that the study used Sanger sequencing, which meets the criteria for question 10.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that the study used plasma samples.

Rationale: The paper explicitly states that the study used plasma samples, which meets the criteria for question 11.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure, which meets the criteria for question 12.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or randomized controlled trials.

Rationale: The paper does not mention any clinical trials or randomized controlled trials, which meets the criteria for question 13.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included individuals who had previously received ART.

Rationale: The paper explicitly states that the study included individuals who had previously received ART, which meets the criteria for question 14.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included individuals who had previously received NRTIs.

Rationale: The paper explicitly states that the study included individuals who had previously received NRTIs, which meets the criteria for question 15.

Answer: NRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included individuals who had previously received AZT, 3TC, FTC, TDF, and ABC.

Rationale: The paper explicitly states that the study included individuals who had previously received AZT, 3TC, FTC, TDF, and ABC, which meets the criteria for question 16.

Answer: AZT, 3TC, FTC, TDF, ABC",19
36961945,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper clearly states that genetic sequencing was performed on various types of clinical samples, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper mentions that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. Furthermore, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which are all methods used to analyze HIV sequences. Finally, the paper reports GenBank accession numbers for sequences generated in this study, indicating that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters without reporting in vitro susceptibility data.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper also does not report any values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. Therefore, it is likely that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper also reports accession numbers for GenBank, which contain two letters followed by a series of numbers.

Rationale: The paper clearly states that sequences were submitted to GenBank, a public database. The paper also reports accession numbers for GenBank, which indicates that the sequences were deposited in the database. Therefore, it is likely that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper clearly reports accession numbers for GenBank, which are ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"". These accession numbers contain two letters followed by a series of numbers, which is consistent with GenBank accession numbers.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 190 individuals were included in the study.

Rationale: The paper clearly states that 190 individuals were included in the study. This number includes individuals who underwent HIV sequencing.

Answer: 190

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries where the samples were obtained. However, the paper mentions that the study was conducted in San Diego, which is a city in the United States.

Rationale: The paper does not explicitly mention the countries where the samples were obtained. However, the paper mentions that the study was conducted in San Diego, which is a city in the United States. Therefore, it is likely that the samples were obtained from the United States.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the samples were collected between 2005 and 2020.

Rationale: The paper clearly states that the samples were collected between 2005 and 2020. This information indicates the time period during which the samples were obtained.

Answer: 2005-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing. The paper mentions that amplicons were purified and quantified, but it does not mention any cloning.

Rationale: The paper does not mention any cloning of samples prior to sequencing. The paper mentions that amplicons were purified and quantified, but it does not mention any cloning. Therefore, it is likely that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol region was sequenced, which includes the protease and reverse transcriptase genes.

Rationale: The paper clearly states that the pol region was sequenced, which includes the protease and reverse transcriptase genes. This information indicates that the sequences were obtained from the pol region.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper reports that Illumina sequencing was used.

Rationale: The paper clearly states that Illumina sequencing was used. This information indicates the sequencing method used in the study.

Answer: Illumina sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that plasma and PBMC samples were sequenced.

Rationale: The paper clearly states that plasma and PBMC samples were sequenced. This information indicates the types of samples that were used for sequencing.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper clearly states that sequences were obtained from individuals with virological failure on a treatment regimen. This information indicates that the sequences were obtained from individuals who were experiencing treatment failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention that the study was a clinical trial. However, the paper mentions that the study was conducted in a research setting.

Rationale: The paper does not explicitly mention that the study was a clinical trial. However, the paper mentions that the study was conducted in a research setting, which suggests that the study may have been a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper clearly states that sequences were obtained from individuals who had previously received ARV drugs. This information indicates that the sequences were obtained from individuals who had a history of ARV use.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that individuals in the study received NRTI and NNRTI drugs before sample sequencing.

Rationale: The paper clearly states that individuals in the study received NRTI and NNRTI drugs before sample sequencing. This information indicates the drug classes that were received by the individuals in the study.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that individuals in the study received AZT, 3TC, FTC, TDF, and EFV before sample sequencing.

Rationale: The paper clearly states that individuals in the study received AZT, 3TC, FTC, TDF, and EFV before sample sequencing. This information indicates the specific drugs that were received by the individuals in the study.

Answer: AZT, 3TC, FTC, TDF, EFV",26
36967989,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"", and ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions genetic sequencing was performed on clinical samples from patients, which indicates that the study involves sequencing of patient samples. Additionally, the mention of GenBank accession numbers suggests that the sequences were submitted to a public database, which is a common practice for studies involving sequencing of patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", and ""drug susceptibility assay"", which suggests that the study involves in vitro susceptibility testing. Additionally, the paper mentions specific values such as IC50, EC50, and EC90, which are commonly used to report in vitro susceptibility data.

Rationale: The mention of phenotypic susceptibility and resistance testing, as well as specific values such as IC50 and EC50, suggests that the study involves in vitro susceptibility testing. This type of testing is commonly used to determine the susceptibility of HIV to different antiretroviral drugs.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper mentions that sequences were submitted to GenBank, and provides accession numbers for the sequences.

Rationale: The mention of GenBank and the provision of accession numbers suggests that the sequences were submitted to a public database, which is a common practice for studies involving sequencing of patient samples.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, which are listed as ""FJ800379–FJ800386"" and ""GQ477441-GQ477451"".

Rationale: The accession numbers provided in the paper can be used to retrieve the sequences from the GenBank database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that ""genotypic resistance testing"" was performed on samples from 11,803 isolates.

Rationale: The mention of 11,803 isolates suggests that the study involved sequencing of samples from a large number of individuals.

Answer: 11,803

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention specific countries where the samples were obtained.

Rationale: The lack of mention of specific countries suggests that the study did not provide information on the geographic origin of the samples.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention specific years when the samples were obtained.

Rationale: The lack of mention of specific years suggests that the study did not provide information on the time period when the samples were obtained.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""amplicons were cloned and sequenced"", which suggests that the samples were cloned prior to sequencing.

Rationale: The mention of cloning and sequencing suggests that the study involved cloning of amplicons prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"", which suggests that the study involved sequencing of the pol gene.

Rationale: The mention of pol genotyping/sequencing suggests that the study involved sequencing of the pol gene, which includes the protease and reverse transcriptase genes.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""Illumina"" ""MiSeq"", which suggests that the study involved Sanger sequencing and next-generation sequencing (NGS).

Rationale: The mention of Sanger sequencing and Illumina MiSeq suggests that the study involved both Sanger sequencing and NGS.

Answer: Sanger sequencing and NGS

**Question: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"", which suggests that the study involved sequencing of plasma and peripheral blood mononuclear cells (PBMC).

Rationale: The mention of plasma and PBMC suggests that the study involved sequencing of these two types of samples.

Answer: Plasma and PBMC

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"", which suggests that the study involved sequencing of samples from individuals with virological failure on a treatment regimen.

Rationale: The mention of virologic failure and failing therapy suggests that the study involved sequencing of samples from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention clinical trials.

Rationale: The lack of mention of clinical trials suggests that the study did not involve clinical trials.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"", which suggests that the study involved sequencing of samples from individuals who had previously received ARV drugs.

Rationale: The mention of ART-experienced and treatment-experienced suggests that the study involved sequencing of samples from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""PI"", and ""INSTI"", which suggests that the study involved individuals who had received these drug classes before sample sequencing.

Rationale: The mention of NRTI, PI, and INSTI suggests that the study involved individuals who had received these drug classes before sample sequencing.

Answer: NRTI, PI, and INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""AZT"", ""3TC"", ""TDF"", ""EFV"", ""DRV"", and ""RAL"", which suggests that the study involved individuals who had received these drugs before sample sequencing.

Rationale: The mention of AZT, 3TC, TDF, EFV, DRV, and RAL suggests that the study involved individuals who had received these drugs before sample sequencing.

Answer: AZT, 3TC, TDF, EFV, DRV, and RAL",22
36982978,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions specific types of clinical samples that were used for sequencing, which suggests that the sequences were obtained from patient samples. Additionally, the paper mentions ART-naïve and ART-experienced patients, which implies that the sequences were obtained from individuals who have received antiretroviral therapy. The mention of GenBank accession numbers also suggests that the sequences were generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper mentions specific types of in vitro drug susceptibility assays, which suggests that the study measured the susceptibility of HIV isolates to antiretroviral drugs in vitro. The mention of IC50, EC50, EC90, and fold-change in susceptibility also suggests that the study measured the potency and efficacy of antiretroviral drugs.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper also reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions specific public databases where the sequences were deposited, which suggests that the sequences are publicly available. The mention of accession numbers also suggests that the sequences were deposited in these databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper provides specific accession numbers for GenBank, which suggests that the sequences were deposited in this database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals. The paper also reports that X sequences were reported from Y individuals.

Rationale: The paper mentions specific numbers of individuals who had samples obtained for HIV sequencing, which suggests that the study sequenced a specific number of samples.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in Portugal. The paper also mentions nationwide “cohort” or “surveillance” or “registry” in Portugal.

Rationale: The paper mentions specific countries where the samples were obtained, which suggests that the study was conducted in these countries.

Answer: Portugal

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2017 to 2021.

Rationale: The paper provides specific years when the samples were collected, which suggests that the study was conducted during this time period.

Answer: 2017-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit.

Rationale: The paper mentions specific cloning methods, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper also mentions sequencing of the “pol region encompassing protease and reverse transcriptase”, “PR/RT”, “ViroSeq”, or “TruGene \(PR/RT\)"".

Rationale: The paper mentions specific HIV genes that were sequenced, which suggests that the study sequenced these genes.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments, BigDye/ABI PRISM Dye Terminator, capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms.

Rationale: The paper mentions specific sequencing methods, which suggests that the study used these methods.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”. The paper also mentions sequencing of “PBMC”, “peripheral blood mononuclear cells”, “proviral DNA”, “cell-associated DNA/RNA”.

Rationale: The paper mentions specific types of samples that were used for sequencing, which suggests that the study sequenced these samples.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”. The paper also mentions sequencing or genotyping were done for participants with VL >50 copies/mL while on ART.

Rationale: The paper mentions specific conditions under which the sequences were obtained, which suggests that the study sequenced samples from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper also mentions the study is registered at ClinicalTrials.gov or has an NCT number.

Rationale: The paper mentions specific characteristics of the study, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper uses phrases like “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper also mentions patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI”.

Rationale: The paper mentions specific conditions under which the sequences were obtained, which suggests that the study sequenced samples from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states “treatment-naïve”, “ART-naïve”, “drug-naive”, “never exposed to antiretrovirals”, “before ART initiation”, “pre-ART”, “newly diagnosed”, “seroconverter”, “blood donor”, “primary/acute infection without ART”, or samples collected “at diagnosis/baseline prior to therapy”. The paper also mentions specific ARV classes such as “NRTI”, “PI”, “NRTI”, “INSTI”.

Rationale: The paper mentions specific conditions under which the sequences were obtained, which suggests that the study sequenced samples from individuals who had not received ARV drugs.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper also mentions specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions specific ARV drugs that were received by the individuals in the study, which suggests that the study sequenced samples from individuals who had received these drugs.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",35
37017009,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study obtained HIV sequences from patient samples. Additionally, the paper refers to various sequencing methods, including Sanger, Illumina, and MiSeq, which are commonly used for HIV sequencing. The mention of GenBank accession numbers also suggests that the sequences were submitted to a public database, which is a common practice for HIV sequence data.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention specific assays like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study focused on genotypic resistance testing and sequencing rather than phenotypic susceptibility testing. The absence of specific assays and values also supports this conclusion.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper mentions accession numbers for GenBank, which contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database. The mention of accession numbers also suggests that the sequences were deposited in the database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are not provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank, but the accession numbers are not provided in the text.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 899 participants were enrolled in the study, and 809 participants had successful genotyping PCR and sequencing.

Rationale: The paper explicitly states that 899 participants were enrolled in the study, and 809 participants had successful genotyping PCR and sequencing.

Answer: 809

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in South Africa, and samples were collected from 45 randomly selected high-volume clinics from all nine provinces.

Rationale: The paper explicitly mentions that the study was conducted in South Africa, which suggests that the sequenced samples were obtained from that country.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted from March 2017 to March 2019.

Rationale: The paper explicitly states the time period during which the study was conducted, which suggests that the sequenced samples were obtained during that time period.

Answer: 2017-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that amplicons were prepared using the 96-sample Nextera ^®^ XT DNA Library Preparation Kit (Illumina, USA), which suggests that the samples were cloned prior to sequencing.

Rationale: The paper explicitly mentions the use of a library preparation kit, which is a common step in cloning and sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper explicitly mentions the specific region of the HIV genome that was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that next-generation sequencing (NGS) technologies were used.

Rationale: The paper explicitly mentions the use of NGS technologies, which is a common method for high-throughput sequencing.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that whole blood was collected and used for sequencing.

Rationale: The paper explicitly mentions the type of sample that was used for sequencing.

Answer: Whole Blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included participants with virological failure, and that sequencing was performed on samples from these participants.

Rationale: The paper explicitly mentions that the study included participants with virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention any of the characteristics that are typically associated with clinical trials, such as randomization, double-blinding, or a placebo control group.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included participants who were receiving ART, and that sequencing was performed on samples from these participants.

Rationale: The paper explicitly mentions that the study included participants who were receiving ART, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included participants who were receiving ART, and that sequencing was performed on samples from these participants.

Rationale: The paper explicitly mentions that the study included participants who were receiving ART, which suggests that the participants had previously received ARV drugs.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included participants who were receiving ART, and that sequencing was performed on samples from these participants.

Rationale: The paper explicitly mentions that the study included participants who were receiving ART, which suggests that the participants had previously received ARV drugs.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN",22
37029656,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to various sequencing methods, including Sanger and Illumina, which are commonly used for sequencing patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were generated in this study and are publicly available.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve testing the susceptibility of HIV isolates to antiretroviral drugs in vitro. The paper focuses on genotypic resistance testing and sequencing of patient samples, but does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank, which contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The paper also reports accession numbers for GenBank, which further supports the idea that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are KP170487.

Rationale: The paper explicitly reports accession numbers for GenBank, which are KP170487. This suggests that the sequences were submitted to GenBank and are publicly available.

Answer: KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 1223 ART-naive PLWH were evaluated.

Rationale: The paper explicitly states that 1223 ART-naive PLWH were evaluated, which suggests that 1223 individuals had samples obtained for HIV sequencing.

Answer: 1223

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the paper mentions that the study was conducted in Italy.

Rationale: The paper does not explicitly mention the countries from which the sequenced samples were obtained, but it does mention that the study was conducted in Italy. This suggests that the sequenced samples were obtained from Italy.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted over the period 2009-2019.

Rationale: The paper explicitly states that the study was conducted over the period 2009-2019, which suggests that the sequenced samples were obtained during this time period.

Answer: 2009-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not mention cloning of samples prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol region was sequenced.

Rationale: The paper explicitly states that the pol region was sequenced, which suggests that the study involved sequencing of the pol region.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which suggests that the study used Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that viral RNA was extracted from plasma.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that 18 (1.5%) of the participants had at least low-level INSTI DR.

Rationale: The paper explicitly reports that 18 (1.5%) of the participants had at least low-level INSTI DR, which suggests that the study involved sequencing of samples from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that 1223 ART-naive PLWH were evaluated.

Rationale: The paper explicitly reports that 1223 ART-naive PLWH were evaluated, which suggests that the study involved sequencing of samples from individuals who had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the participants were ART-naive.

Rationale: The paper explicitly reports that the participants were ART-naive, which suggests that the individuals in the study had not received any ARV drugs before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the participants were ART-naive.

Rationale: The paper explicitly reports that the participants were ART-naive, which suggests that the individuals in the study had not received any ARV drugs before sample sequencing.

Answer: None",20
37039023,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. The mention of genotypic resistance testing, HIV sequencing, Sanger, Illumina, and MiSeq also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions that cell-based susceptibility assays were described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which indicates that in vitro drug susceptibility data were reported. The mention of IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility also supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also mentions that accession numbers for GenBank or any of the above databases were provided.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which indicates that sequences were made publicly available. The mention of accession numbers also supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers were provided. The accession numbers are listed as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and accession numbers were provided, which indicates that the accession numbers can be used to retrieve the sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 86 HIV+ patients were recruited for the study. The paper also mentions that 46 patients from RJ and 40 patients from RS had their proviral HIV NFLG PCR-amplified and ultradeep sequenced.

Rationale: The paper explicitly mentions that 86 patients were recruited for the study, which indicates that samples were obtained from 86 individuals.

Answer: 86

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that patients were recruited from Rio de Janeiro (RJ) and Rio Grande (RS) in Brazil.

Rationale: The paper explicitly mentions that patients were recruited from RJ and RS in Brazil, which indicates that the sequenced samples were obtained from Brazil.

Answer: Brazil

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that samples were collected between February 2016 and November 2018 in RJ, and between August and December 2017 in RS.

Rationale: The paper explicitly mentions the time period during which samples were collected, which indicates that the sequenced samples were obtained between 2016 and 2018.

Answer: 2016-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced, and that TA cloning/Topo TA cloning was performed.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which indicates that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper explicitly mentions that the pol region encompassing protease and reverse transcriptase was sequenced, which indicates that these genes were reported to have been sequenced.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Illumina MiSeq platform was used for sequencing.

Rationale: The paper explicitly mentions that Illumina MiSeq platform was used for sequencing, which indicates that NGS was used.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma and PBMC samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma and PBMC samples were used for sequencing, which indicates that these types of samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that patients were enrolled in the study while receiving antiretroviral therapy, and that some patients had virological failure.

Rationale: The paper explicitly mentions that patients were enrolled in the study while receiving antiretroviral therapy, and that some patients had virological failure, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was approved by the Ethics Committees of INCA, HI, HUCFF, and HU-FURG, and that the study was registered at ClinicalTrials.gov.

Rationale: The paper explicitly mentions that the study was approved by the Ethics Committees and registered at ClinicalTrials.gov, which indicates that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that patients were enrolled in the study while receiving antiretroviral therapy, and that some patients had previously received ARV drugs.

Rationale: The paper explicitly mentions that patients were enrolled in the study while receiving antiretroviral therapy, and that some patients had previously received ARV drugs, which indicates that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients were enrolled in the study while receiving antiretroviral therapy, and that some patients received NRTI, NNRTI, and PI-based regimens.

Rationale: The paper explicitly mentions that patients were enrolled in the study while receiving antiretroviral therapy, and that some patients received NRTI, NNRTI, and PI-based regimens, which indicates that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients were enrolled in the study while receiving antiretroviral therapy, and that some patients received TDF, 3TC, EFV, and ATV/r.

Rationale: The paper explicitly mentions that patients were enrolled in the study while receiving antiretroviral therapy, and that some patients received TDF, 3TC, EFV, and ATV/r, which indicates that these drugs were received by individuals in the study before sample sequencing.

Answer: TDF, 3TC, EFV, ATV/r",27
37042390,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which suggests that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper only reports genotypic resistance testing and sequencing results.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that it does not report this type of data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text. The paper also mentions that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which suggests that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper provides specific accession numbers for GenBank, which can be used to retrieve the sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 85 patients were started on third-line ART, and genotypic resistance testing was performed on samples from these patients.

Rationale: The paper explicitly states that 85 patients were included in the study, and genotypic resistance testing was performed on their samples.

Answer: 85

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples. However, it mentions that the study was conducted at a CoE in HIV care, Banaras Hindu University (BHU) in a tertiary hospital in Varanasi, India.

Rationale: The paper does not provide explicit information on the country of origin for the sequenced samples, but it mentions the location of the study site.

Answer: India

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between July 2016 and December 2019.

Rationale: The paper explicitly states the time period during which the study was conducted.

Answer: 2016-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that amplicons were cloned and sequenced, and that TA cloning/Topo TA cloning was performed.

Rationale: The paper explicitly mentions cloning and sequencing, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol region, including the protease and reverse transcriptase genes, was sequenced.

Rationale: The paper explicitly mentions the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that sequencing was performed using Sanger sequencing, specifically using ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly mentions Sanger sequencing and the specific instruments used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that whole blood was collected from patients and used for CD4 estimation, and that plasma was separated and stored at -80°C until viral RNA isolation.

Rationale: The paper explicitly mentions the type of samples used for sequencing.

Answer: Whole blood, Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen, specifically those with VL > 50 copies/mL while on ART.

Rationale: The paper explicitly mentions virological failure and the specific criteria used to select individuals for sequencing.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention a clinical trial, but it mentions that the study was conducted at a CoE in HIV care, Banaras Hindu University (BHU) in a tertiary hospital in Varanasi, India.

Rationale: The paper does not provide explicit information on the study design, but it mentions the location of the study site.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that patients had previously received ARV drugs, specifically those on ART/cART/HAART, ART-experienced, treatment-experienced, heavily pretreated, salvage regimen, or prior ARV exposure/regimens.

Rationale: The paper explicitly mentions previous ARV drug use.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that patients had received NRTIs, NNRTIs, PIs, and INSTIs before sample sequencing.

Rationale: The paper explicitly mentions the specific drug classes received by individuals in the study.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that patients had received specific ARV drugs, including AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir.

Rationale: The paper explicitly mentions the specific ARV drugs received by individuals in the study.

Answer: AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",23
37052343,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV samples from patient samples. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any methods or results related to in vitro drug susceptibility testing, which suggests that the study did not report in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive SRA. The paper does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not mention submitting sequences to a public database or reporting accession numbers, which suggests that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention submitting sequences to GenBank or reporting accession numbers, which suggests that the sequences were not submitted to GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not report the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who participated in the study or had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the samples were collected, which suggests that the information is not available.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not report the years in which the sequenced samples were obtained.

Rationale: The paper does not mention the years in which the samples were collected, which suggests that the information is not available.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using TA cloning/Topo TA cloning.

Rationale: The paper does not mention cloning amplicons or using TA cloning/Topo TA cloning, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention sequencing the pol region, protease, reverse transcriptase, integrase, or env genes.

Rationale: The paper does not mention sequencing any specific HIV genes, which suggests that the information is not available.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention using ABI instruments, BigDye, or capillary sequencer/capillary electrophoresis.

Rationale: The paper does not mention using ABI instruments, BigDye, or capillary sequencer/capillary electrophoresis, which suggests that the sequencing method is not specified.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention sequencing plasma, PBMC, whole blood, or dried blood spots.

Rationale: The paper does not mention sequencing any specific type of sample, which suggests that the information is not available.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or failing therapy.

Rationale: The paper does not mention virological failure or failing therapy, which suggests that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or randomized controlled trial.

Rationale: The paper does not mention a clinical trial or randomized controlled trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention ART-naive, treatment-naive, or drug-naive individuals.

Rationale: The paper does not mention ART-naive, treatment-naive, or drug-naive individuals, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes or specific antiretroviral drugs.

Rationale: The paper does not mention any drug classes or specific antiretroviral drugs, which suggests that the information is not available.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific antiretroviral drugs.

Rationale: The paper does not mention any specific antiretroviral drugs, which suggests that the information is not available.

Answer: Not reported",21
37071019,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing, and reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV samples from patient samples. Additionally, the paper refers to various sequencing methods, including Sanger and Illumina, which are commonly used for sequencing patient samples. The mention of GenBank accession numbers also suggests that the sequences were generated from patient samples and deposited in a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay were performed. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions that phenotypic susceptibility assays were performed, which involves measuring the susceptibility of HIV to various antiretroviral drugs. The mention of IC50, EC50, EC90, and fold-change in susceptibility also suggests that the study involved measuring the susceptibility of HIV to various drugs. The use of named platforms like PhenoSense and Monogram also indicates that the study involved in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, including GenBank and SRA, which suggests that the sequences are publicly available. The mention of accession numbers also indicates that the sequences have been deposited in a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including KP170487.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and reports accession numbers, including KP170487.

Answer: KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing, genotyping, or sequencing was performed on samples from 30,000 individuals.

Rationale: The paper explicitly mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from 30,000 individuals.

Answer: 30,000

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the samples were obtained.

Rationale: The paper does not provide any information about the countries from which the samples were obtained.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2014 and 2017.

Rationale: The paper explicitly mentions that clinical samples were collected between 2014 and 2017.

Answer: 2014-2017

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol region, including protease and reverse transcriptase, was sequenced.

Rationale: The paper explicitly mentions that the pol region, including protease and reverse transcriptase, was sequenced.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about the study design or whether the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that individuals received NRTI, NNRTI, and INSTI.

Rationale: The paper explicitly mentions that individuals received NRTI, NNRTI, and INSTI.

Answer: NRTI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that individuals received AZT, 3TC, FTC, TDF, ABC, EFV, RPV, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, and LEN.

Rationale: The paper explicitly mentions that individuals received AZT, 3TC, FTC, TDF, ABC, EFV, RPV, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, and LEN.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, RPV, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN",23
37085698,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from ""patients"" and ""plasma"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", and ""Illumina"" sequencing. The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper mentions specific sequencing methods, such as Sanger and Illumina sequencing, which further supports the conclusion that the study involved sequencing of patient samples. The mention of GenBank accession numbers also suggests that the sequences were generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, or fold-change in susceptibility. The paper focuses on genotypic resistance testing and sequencing of HIV-1 integrase region.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve in vitro susceptibility testing. The focus on genotypic resistance testing and sequencing of HIV-1 integrase region also supports this conclusion.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank with accession numbers from MW560010 to MW560058.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The mention of accession numbers also supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank with accession numbers from MW560010 to MW560058.

Rationale: The paper explicitly mentions the accession numbers for the sequences, which allows us to extract the ranges and individual accession numbers.

Answer: MW560010 to MW560058

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 49 study participants were enrolled in this study.

Rationale: The paper explicitly mentions the number of study participants, which allows us to determine the number of individuals who had samples obtained for HIV sequencing.

Answer: 49

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Ethiopia.

Rationale: The paper explicitly mentions the country where the study was conducted, which allows us to determine the country of origin for the sequenced samples.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between June 2018 and December 2018.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which allows us to determine the years when the sequenced samples were obtained.

Answer: 2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned before sequencing, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the HIV-1 integrase region was sequenced.

Rationale: The paper explicitly mentions the specific gene region that was sequenced, which allows us to determine the HIV gene that was reported to have been sequenced.

Answer: Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions the sequencing method used, which allows us to determine the method used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions the type of samples used for sequencing, which allows us to determine the type of samples that were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included patients with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the study included patients with virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not explicitly mention that the study was a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included patients who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included patients who had previously received ARV drugs, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included patients who had previously received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions that the study included patients who had previously received NRTIs and NNRTIs, which suggests that the individuals in the study received these drug classes before sample sequencing.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not explicitly mention specific drugs that were received by individuals in the study before sample sequencing, which suggests that the question cannot be answered.

Answer: Not reported",20
37104815,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV sequences from patient samples. Additionally, the paper mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses.

Rationale: The paper does not mention any of the keywords associated with in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. Additionally, the methods and results do not report any values related to in vitro drug susceptibility, such as IC50, EC50, EC90, or fold-change in susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not mention submitting sequences to any public database, which suggests that the sequences may not be publicly available. Additionally, the paper does not report any accession numbers, which are typically used to identify sequences in public databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention submitting sequences to GenBank or reporting any accession numbers, which suggests that the sequences may not be publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study included 121 participants. The paper reports that genotypic resistance testing, genotyping, or sequencing was performed on samples from 121 individuals.

Rationale: The paper explicitly mentions that the study included 121 participants, which suggests that the number of individuals with samples obtained for HIV sequencing is 121.

Answer: 121

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples, which suggests that the country of origin may not be reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not report the years in which the sequenced samples were obtained.

Rationale: The paper does not mention the years in which the sequenced samples were obtained, which suggests that the years may not be reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning samples prior to sequencing.

Rationale: The paper does not mention cloning samples prior to sequencing, which suggests that the samples may not have been cloned.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions sequencing the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions using Illumina technology for sequencing.

Rationale: The paper explicitly mentions using Illumina technology for sequencing, which suggests that the method used for sequencing is next-generation sequencing (NGS).

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions sequencing plasma samples.

Rationale: The paper explicitly mentions sequencing plasma samples, which suggests that the type of sample sequenced is plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that 10 participants experienced virological failure.

Rationale: The paper explicitly mentions that 10 participants experienced virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a randomized, multicenter trial.

Rationale: The paper explicitly mentions that the study was a randomized, multicenter trial, which suggests that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the participants were on ART and had received previous ARV drugs.

Rationale: The paper explicitly mentions that the participants were on ART and had received previous ARV drugs, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the participants were on ART and had received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions that the participants were on ART and had received NRTIs, NNRTIs, and PIs, which suggests that the drug classes received by individuals in the study before sample sequencing are NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the participants were on ART and had received tenofovir, lamivudine, efavirenz, and raltegravir.

Rationale: The paper explicitly mentions that the participants were on ART and had received tenofovir, lamivudine, efavirenz, and raltegravir, which suggests that the drugs received by individuals in the study before sample sequencing are tenofovir, lamivudine, efavirenz, and raltegravir.

Answer: Tenofovir, Lamivudine, Efavirenz, Raltegravir",23
37112971,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing” and reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of clinical samples for sequencing, which is a clear indication that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only discusses genotypic resistance testing and sequencing.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not provide any information on in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper also mentions that accession numbers for GenBank or any of the above databases are provided.

Rationale: The paper explicitly states that sequences were submitted to public databases, which is a clear indication that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide specific GenBank accession numbers for sequenced HIV isolates. However, it mentions that sequences were submitted to GenBank and accession numbers are provided.

Rationale: The paper does not provide specific accession numbers, but mentions that they are available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 4481 treatment-naïve patients were included in the study.

Rationale: The paper explicitly mentions the number of patients included in the study.

Answer: 4481

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, it mentions that the study was conducted in Russia.

Rationale: The paper does not provide specific information on the countries from which the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that clinical samples were collected between 2006 and 2022.

Rationale: The paper explicitly mentions the years during which the samples were collected.

Answer: 2006-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on cloning of samples.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol gene region encoding the PR-RT was sequenced.

Rationale: The paper explicitly mentions the specific gene region that was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma and PBMC samples were used for sequencing.

Rationale: The paper explicitly mentions the types of samples used for sequencing.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions the use of sequences from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials.

Rationale: The paper does not provide any information on clinical trials.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included treatment-experienced patients.

Rationale: The paper explicitly mentions the inclusion of treatment-experienced patients.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included treatment-experienced patients who had received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions the drug classes received by the patients.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included treatment-experienced patients who had received specific ARV drugs such as AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir.

Rationale: The paper explicitly mentions the specific ARV drugs received by the patients.

Answer: AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",21
37147875,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from a 22-year-old man who presented with a rapid test in a sexually transmitted infection clinic. The patient was infected through homosexual contact and started on a dolutegravir (DTG) + emtricitabine (FTC) + tenofovir disoproxil fumarate (TDF) regimen 7 days after diagnosis. SBS of HIV-1 reverse transcriptase (RT), protease, and integrase was performed before treatment initiation.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from a patient, which indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay.

Rationale: The paper only reports genotypic resistance testing and sequencing results, without mentioning any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to any public databases, such as GenBank, NCBI, or SRA.

Rationale: The paper does not provide any information about the availability of the sequences in public databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any accession numbers for the sequences.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a single individual, a 22-year-old man, had samples obtained for HIV sequencing.

Rationale: The paper mentions that the sequencing was performed on a single patient.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the patient was diagnosed in April 2022.

Rationale: The paper mentions the month and year of the patient's diagnosis.

Answer: 2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning or amplification of the samples prior to sequencing.

Rationale: The paper does not provide any information about the preparation of the samples for sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the sequencing was performed on the HIV-1 reverse transcriptase (RT), protease, and integrase genes.

Rationale: The paper mentions the specific genes that were sequenced.

Answer: RT, PR, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper reports that Sanger-based sequencing (SBS) was used to sequence the HIV-1 RT, protease, and integrase genes.

Rationale: The paper mentions the specific sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that the sequencing was performed on plasma samples.

Rationale: The paper mentions the type of samples used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the patient was experiencing virological failure on a treatment regimen at the time of sequencing.

Rationale: The paper mentions that the patient was experiencing virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patient was enrolled in a clinical trial.

Rationale: The paper does not provide any information about the study design.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the patient had previously received antiretroviral therapy (ART) and was experiencing virological failure.

Rationale: The paper mentions that the patient had received ART and was experiencing virological failure.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the patient had received a regimen containing dolutegravir (DTG), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) before sample sequencing.

Rationale: The paper mentions the specific drugs and classes received by the patient.

Answer: NRTI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the patient had received dolutegravir (DTG), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) before sample sequencing.

Rationale: The paper mentions the specific drugs received by the patient.

Answer: DTG, FTC, TDF",17
37272233,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any of the keywords associated with in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, or cell-based susceptibility assays. This suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive SRA. The paper does not report accession numbers for GenBank or any of the above databases. The paper does not mention depositing or making sequences available in a sequence database.

Rationale: The paper does not mention submitting sequences to any public database or reporting accession numbers, which suggests that the sequences were not made publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention submitting sequences to GenBank or reporting accession numbers, which suggests that the paper does not report any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 248 patients were analyzed, and ARV resistance was detected in 30 of them (12.1%).

Rationale: The paper reports the total number of patients analyzed and the number of patients with ARV resistance, which suggests that the paper reports the number of individuals with samples obtained for HIV sequencing.

Answer: 248

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples, which suggests that the paper does not report the country of origin.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study period was from January 2010 to December 2020.

Rationale: The paper reports the start and end years of the study period, which suggests that the paper reports the years in which the sequenced samples were obtained.

Answer: 2010-2020

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using a cloning kit.

Rationale: The paper does not mention cloning amplicons or using a cloning kit, which suggests that the paper does not report cloning prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper mentions sequencing the pol region, which includes the protease and reverse transcriptase genes, which suggests that the paper reports sequencing of these genes.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions using ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper mentions using ABI instruments and BigDye/ABI PRISM Dye Terminator, which suggests that the paper reports using Sanger sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions sequencing plasma and PBMC samples.

Rationale: The paper mentions sequencing plasma and PBMC samples, which suggests that the paper reports sequencing of these sample types.

Answer: Plasma, PBMC

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ARV resistance was detected in 30 patients, and 15 of them underwent ART before the resistance results were reported.

Rationale: The paper reports that ARV resistance was detected in 30 patients, and 15 of them underwent ART before the resistance results were reported, which suggests that the paper reports sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the paper does not report the patients being in a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that 15 patients underwent ART before the resistance results were reported.

Rationale: The paper reports that 15 patients underwent ART before the resistance results were reported, which suggests that the paper reports sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the drug classes received by the individuals.

Rationale: The paper does not mention the drug classes received by the individuals, which suggests that the paper does not report the drug classes.

Answer: Not reported

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drugs received by the individuals.

Rationale: The paper does not mention the specific drugs received by the individuals, which suggests that the paper does not report the specific drugs.

Answer: Not reported",21
37279764,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters without reporting in vitro susceptibility data.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve in vitro susceptibility testing. The paper's focus on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters also suggests that the study did not involve in vitro susceptibility testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text. The paper states that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The paper also provides accession numbers, which are used to identify the sequences in public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text. The accession numbers are MW947591–MW957968, OP058117–OP058658.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, and accession numbers are provided in the text. The accession numbers are used to identify the sequences in public databases.

Answer: MW947591–MW957968, OP058117–OP058658

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a total of 12,320 participants with demographic data and partial pol sequences were included in this study.

Rationale: The paper explicitly mentions that a total of 12,320 participants were included in the study, which suggests that the number of individuals with samples obtained for HIV sequencing is 12,320.

Answer: 12,320

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples. However, the paper mentions that the study was conducted in Shenzhen, China.

Rationale: The paper does not explicitly mention the country of origin for the sequenced samples, but the paper mentions that the study was conducted in Shenzhen, China, which suggests that the samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2011 and 2019.

Rationale: The paper explicitly mentions that clinical samples were collected between 2011 and 2019, which suggests that the sequenced samples were obtained during this time period.

Answer: 2011-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention cloning prior to sequencing. However, the paper mentions that nucleic acid extraction, PCR amplification work-up, and sequencing were performed essentially as described previously.

Rationale: The paper does not explicitly mention cloning prior to sequencing, which suggests that the study may not have involved cloning. However, the paper mentions that nucleic acid extraction, PCR amplification work-up, and sequencing were performed, which suggests that the study involved some form of sample preparation.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the HIV-1 molecular transmission networks were inferred based on the partial HIV-1 pol gene obtained from the newly reported HIV-1 positive cases.

Rationale: The paper explicitly mentions that the study involved sequencing of the partial HIV-1 pol gene, which suggests that the study involved sequencing of the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that nucleic acid extraction, PCR amplification work-up, and sequencing were performed essentially as described previously.

Rationale: The paper does not explicitly mention the sequencing method, but the paper mentions that nucleic acid extraction, PCR amplification work-up, and sequencing were performed, which suggests that the study involved some form of sequencing.

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that viral RNA was extracted from plasma.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patients with TDRMs diagnosed in 2017-19 were younger than those in 2011-16, and that the proportions of patients infected with CRF07_BC or belonging to the population of MSM in 2017-19 were higher than those in 2011-16.

Rationale: The paper does not explicitly mention that the sequences were obtained from individuals with virological failure on a treatment regimen. However, the paper mentions that the patients with TDRMs diagnosed in 2017-19 were younger than those in 2011-16, and that the proportions of patients infected with CRF07_BC or belonging to the population of MSM in 2017-19 were higher than those in 2011-16, which suggests that the study may have involved sequences from individuals with virological failure on a treatment regimen.

Answer: Not Reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention that the study was a clinical trial. However, the paper mentions that the study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board.

Rationale: The paper does not explicitly mention that the study was a clinical trial, but the paper mentions that the study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board, which suggests that the study may have been a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patients with TDRMs diagnosed in 2017-19 were younger than those in 2011-16, and that the proportions of patients infected with CRF07_BC or belonging to the population of MSM in 2017-19 were higher than those in 2011-16.

Rationale: The paper does not explicitly mention that the sequences were obtained from individuals who had previously received ARV drugs. However, the paper mentions that the patients with TDRMs diagnosed in 2017-19 were younger than those in 2011-16, and that the proportions of patients infected with CRF07_BC or belonging to the population of MSM in 2017-19 were higher than those in 2011-16, which suggests that the study may have involved sequences from individuals who had previously received ARV drugs.

Answer: Not Reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the drug classes received by the individuals in the study before sample sequencing.

Rationale: The paper does not explicitly mention the drug classes received by the individuals in the study before sample sequencing, which suggests that the study may not have involved information on drug classes.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the drugs received by the individuals in the study before sample sequencing.

Rationale: The paper does not explicitly mention the drugs received by the individuals in the study before sample sequencing, which suggests that the study may not have involved information on specific drugs.

Answer: Not Reported",28
37327289,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only reports genotypic resistance testing and sequencing results.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve testing the susceptibility of HIV isolates to antiretroviral drugs in vitro.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and the paper provides GenBank accession numbers for the sequences.

Rationale: The paper explicitly states that the sequences were submitted to GenBank, which suggests that the sequences are publicly available. Additionally, the paper provides GenBank accession numbers, which allows readers to access the sequences directly.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports the following GenBank accession numbers: LC723952-LC724015.

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides the accession numbers for the sequences.

Answer: LC723952-LC724015

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 157 plasma samples were obtained from HIV-1 seropositive and treatment-naive FSWs.

Rationale: The paper explicitly states that 157 plasma samples were obtained from HIV-1 seropositive and treatment-naive FSWs, which suggests that the study involved sequencing of samples from 157 individuals.

Answer: 157

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from FSWs in Nairobi, Kenya.

Rationale: The paper explicitly states that the samples were obtained from FSWs in Nairobi, Kenya, which suggests that the samples were obtained from individuals in Kenya.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between November 2020 and April 2021.

Rationale: The paper explicitly states that the samples were collected between November 2020 and April 2021, which suggests that the samples were obtained during this time period.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly states that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the *pol* gene was amplified and genotyped using Sanger sequencing.

Rationale: The paper explicitly states that the *pol* gene was amplified and genotyped using Sanger sequencing, which suggests that the study involved sequencing of the *pol* gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used, which suggests that the study involved Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study involved sequencing of samples from treatment-naive FSWs, but does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly states that the study involved sequencing of samples from treatment-naive FSWs, which suggests that the study did not involve sequencing of samples from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials.

Rationale: The paper does not mention any clinical trials, which suggests that the study did not involve a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study involved sequencing of samples from treatment-naive FSWs.

Rationale: The paper explicitly states that the study involved sequencing of samples from treatment-naive FSWs, which suggests that the study did not involve sequencing of samples from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study involved sequencing of samples from treatment-naive FSWs.

Rationale: The paper explicitly states that the study involved sequencing of samples from treatment-naive FSWs, which suggests that the individuals in the study had not received any ARV drugs before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study involved sequencing of samples from treatment-naive FSWs.

Rationale: The paper explicitly states that the study involved sequencing of samples from treatment-naive FSWs, which suggests that the individuals in the study had not received any ARV drugs before sample sequencing.

Answer: None",22
37340869,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" were performed on clinical samples from patients. The paper also reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only focuses on genotypic resistance testing and sequencing.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that the study only focused on genotypic resistance testing and sequencing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"" and ""GQ477441-GQ477451"".

Rationale: The paper provides specific accession numbers for GenBank, which can be used to retrieve the sequences from the database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 1651 unique participants were included in the study.

Rationale: The paper provides a specific number of participants, which can be used to determine the number of individuals who had samples obtained for HIV sequencing.

Answer: 1651

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in multiple countries, including the United States, Europe, and ""other"" regions.

Rationale: The paper provides specific information on the countries where the study was conducted, which can be used to determine the origin of the sequenced samples.

Answer: United States, Europe, and ""other"" regions

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between 2004 and 2017.

Rationale: The paper provides specific dates for the study, which can be used to determine the years when the sequenced samples were obtained.

Answer: 2004-2017

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning or amplification of samples prior to sequencing.

Rationale: The paper does not provide any information on cloning or amplification of samples, which suggests that direct sequencing was used.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region, including protease and reverse transcriptase, was sequenced.

Rationale: The paper provides specific information on the genes that were sequenced, which can be used to determine the HIV genes that were reported.

Answer: Pol, including protease and reverse transcriptase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper provides specific information on the sequencing method used, which can be used to determine the type of sequencing that was performed.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper provides specific information on the type of samples that were used for sequencing, which can be used to determine the type of samples that were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper provides specific information on the study population, which can be used to determine whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a randomized, multicenter, parallel-group, open-label, phase 3/3b study.

Rationale: The paper provides specific information on the study design, which can be used to determine whether the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included individuals who had previously received ARV drugs.

Rationale: The paper provides specific information on the study population, which can be used to determine whether HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included individuals who had received NRTIs, NNRTIs, and PIs.

Rationale: The paper provides specific information on the drug classes that were received by the individuals in the study, which can be used to determine the drug classes that were received.

Answer: NRTIs, NNRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included individuals who had received AZT, 3TC, FTC, TDF, ABC, EFV, RPV, and DRV.

Rationale: The paper provides specific information on the drugs that were received by the individuals in the study, which can be used to determine the drugs that were received.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, RPV, and DRV",20
37358226,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to various sequencing methods and genotypic resistance testing, which further supports the conclusion that the study involved sequencing of patient samples. The mention of GenBank accession numbers also suggests that the sequences were generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not mention any of the key terms or methods associated with in vitro drug susceptibility data, which suggests that the study did not involve in vitro susceptibility testing. The lack of mention of specific values or assays also supports this conclusion.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper does not report accession numbers for GenBank or any of the above databases. The paper does not mention depositing or making sequences available in a sequence database.

Rationale: The paper does not mention any of the key terms or actions associated with making sequences publicly available, which suggests that the sequences were not made publicly available. The lack of mention of accession numbers or deposition in a sequence database also supports this conclusion.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention submitting sequences to GenBank or report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not mention any of the key terms or actions associated with submitting sequences to GenBank or reporting accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who participated in the study.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country where the samples were obtained.

Rationale: The paper does not provide any information about the country where the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years when the samples were obtained.

Rationale: The paper does not provide any information about the years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using TA cloning/Topo TA cloning.

Rationale: The paper does not mention any of the key terms or methods associated with cloning amplicons or using TA cloning/Topo TA cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention sequencing the pol region, protease, reverse transcriptase, integrase, or env.

Rationale: The paper does not mention any of the key terms or methods associated with sequencing specific HIV genes.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention ABI instruments, BigDye/ABI PRISM Dye Terminator, or capillary sequencer/capillary electrophoresis.

Rationale: The paper does not mention any of the key terms or methods associated with Sanger sequencing.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention sequencing plasma, PBMC, whole blood, or dried blood spots.

Rationale: The paper does not mention any of the key terms or methods associated with sequencing specific types of samples.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure, failing therapy, or salvage regimen.

Rationale: The paper does not mention any of the key terms or methods associated with sequencing individuals with virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter.

Rationale: The paper does not mention any of the key terms or methods associated with clinical trials.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention ART-naive, treatment-naive, drug-naive, or prior ARV exposure.

Rationale: The paper does not mention any of the key terms or methods associated with sequencing individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention treatment-naive, ART-naive, drug-naive, or prior ARV exposure.

Rationale: The paper does not mention any of the key terms or methods associated with sequencing individuals who had previously received ARV drugs.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs or regimens.

Rationale: The paper does not mention any of the key terms or methods associated with sequencing individuals who had previously received specific drugs or regimens.

Answer: Not reported",20
37376649,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any of the keywords associated with in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, or cell-based susceptibility assays. This suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. Additionally, the paper reports accession numbers for GenBank, which further supports the idea that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank. The accession numbers are not provided in the text, but they are mentioned in the Data Availability statement.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. However, the accession numbers are not provided in the text, but they are mentioned in the Data Availability statement.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 734 participants were randomized and 741 received at least one dose of the study treatments. The paper reports that 320 and 318 participants on DTG/3TC and TBR, respectively, had both proviral genotype data and ≥1 on-treatment post-baseline VL results.

Rationale: The paper reports that 734 participants were randomized, which suggests that these individuals had samples obtained for HIV sequencing. Additionally, the paper reports that 320 and 318 participants on DTG/3TC and TBR, respectively, had both proviral genotype data and ≥1 on-treatment post-baseline VL results, which further supports the idea that these individuals had samples obtained for HIV sequencing.

Answer: 320 and 318

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the paper mentions that the study was conducted in accordance with the Declaration of Helsinki and national and institutional standards, which suggests that the study was conducted in multiple countries.

Rationale: The paper does not explicitly mention the countries from which the sequenced samples were obtained, but it mentions that the study was conducted in accordance with the Declaration of Helsinki and national and institutional standards. This suggests that the study was conducted in multiple countries.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between 2004 and 2007. The paper also reports that the study was conducted between June 2004 and April 2007.

Rationale: The paper explicitly states that the study was conducted between 2004 and 2007, which suggests that the sequenced samples were obtained during this time period.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention cloning prior to sequencing. However, the paper mentions that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.

Rationale: The paper does not explicitly mention cloning prior to sequencing, but it mentions that the GenoSure Archive assay uses NGS to analyze the HIV-1 polymerase region. This suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region. The paper also reports that the assay uses a bioinformatic filter to remove APOBEC3G/3F-induced G to A hypermutations.

Rationale: The paper explicitly states that the GenoSure Archive assay uses NGS to analyze the HIV-1 polymerase region, which suggests that the assay sequenced the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper reports that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.

Rationale: The paper explicitly states that the GenoSure Archive assay uses NGS to analyze the HIV-1 polymerase region, which suggests that the method used for sequencing was NGS.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region from whole blood samples.

Rationale: The paper explicitly states that the GenoSure Archive assay uses NGS to analyze the HIV-1 polymerase region from whole blood samples, which suggests that the type of samples sequenced were whole blood samples.

Answer: Whole Blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the study was conducted in participants who were virologically suppressed on ART. The paper also reports that the study was conducted in participants who were failing therapy or regimen.

Rationale: The paper explicitly states that the study was conducted in participants who were virologically suppressed on ART, which suggests that the sequences were not obtained from individuals with virological failure on a treatment regimen. However, the paper also reports that the study was conducted in participants who were failing therapy or regimen, which suggests that the sequences may have been obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper reports that the study was conducted in accordance with the Declaration of Helsinki and national and institutional standards. The paper also reports that the study was registered at ClinicalTrials.gov.

Rationale: The paper explicitly states that the study was conducted in accordance with the Declaration of Helsinki and national and institutional standards, which suggests that the study was a clinical trial. Additionally, the paper reports that the study was registered at ClinicalTrials.gov, which further supports the idea that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study was conducted in participants who were virologically suppressed on ART. The paper also reports that the study was conducted in participants who were failing therapy or regimen.

Rationale: The paper explicitly states that the study was conducted in participants who were virologically suppressed on ART, which suggests that the sequences were obtained from individuals who had previously received ARV drugs. Additionally, the paper reports that the study was conducted in participants who were failing therapy or regimen, which further supports the idea that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study was conducted in participants who were virologically suppressed on ART. The paper also reports that the study was conducted in participants who were failing therapy or regimen.

Rationale: The paper explicitly states that the study was conducted in participants who were virologically suppressed on ART, which suggests that the individuals in the study had previously received NRTIs. Additionally, the paper reports that the study was conducted in participants who were failing therapy or regimen, which further supports the idea that the individuals in the study had previously received NRTIs and possibly other drug classes.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study was conducted in participants who were virologically suppressed on ART. The paper also reports that the study was conducted in participants who were failing therapy or regimen.

Rationale: The paper explicitly states that the study was conducted in participants who were virologically suppressed on ART, which suggests that the individuals in the study had previously received TDF and 3TC. Additionally, the paper reports that the study was conducted in participants who were failing therapy or regimen, which further supports the idea that the individuals in the study had previously received TDF and 3TC.

Answer: TDF and 3TC",31
37381002,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that viral RNA was extracted from 200 µl plasma sample following the instructions of the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche, Switzerland). The partial *pol* gene fragment of HIV-1 virus was amplified by using in-house polymerase chain reaction (PCR) method.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which includes plasma, serum, PBMC, proviral DNA, and dried blood spots. This indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper only reports genotypic resistance testing and sequencing results.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that it does not report in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, but the accession numbers are not provided. The paper also mentions that the raw reads are in the SRA database.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. However, the accession numbers are not provided, which makes it difficult to access the sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that sequences were submitted to GenBank, but the accession numbers are not provided.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 398 patients with failed antiviral treatment had their viral pol gene sequences successfully sequenced.

Rationale: The paper explicitly mentions that 398 patients had their viral pol gene sequences sequenced.

Answer: 398

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the countries where the sequenced samples were obtained.

Rationale: The paper does not mention any specific countries or nationalities.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2017 and 2020.

Rationale: The paper explicitly mentions the years when the samples were collected.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information on whether the samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning methods or techniques.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the partial *pol* gene fragment of HIV-1 virus was amplified and sequenced.

Rationale: The paper explicitly mentions that the *pol* gene fragment was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the partial *pol* gene fragment of HIV-1 virus was amplified by using in-house polymerase chain reaction (PCR) method, and the sequences were obtained by Sanger sequencing.

Rationale: The paper explicitly mentions the PCR method and Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from 200 µl plasma sample following the instructions of the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche, Switzerland).

Rationale: The paper explicitly mentions that the samples were plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the patients were confirmed to be ineffective (viral load ≥ 1000 copies/ml) in Suzhou city, which suggests that they were experiencing virological failure.

Rationale: The paper explicitly mentions that the patients were experiencing virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information on whether the patients were in a clinical trial.

Rationale: The paper does not mention any clinical trials or study designs.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the patients were confirmed to be ineffective (viral load ≥ 1000 copies/ml) in Suzhou city, which suggests that they had previously received ARV drugs.

Rationale: The paper explicitly mentions that the patients were experiencing virological failure, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information on the drug classes received by the individuals in the study.

Rationale: The paper does not mention any specific drug classes or regimens.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information on the specific drugs received by the individuals in the study.

Rationale: The paper does not mention any specific drugs or regimens.

Answer: Not reported",19
37439411,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that HIV-1 RNA protease/reverse transcriptase sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database, a public observational database containing data from more than 100 Italian centres for the study of resistance mutations to antiviral drugs for HIV. The sequences were used to study the circulation of major resistance-associated mutations (RAMs) for nonnucleoside reverse transcriptase inhibitors (NNRTIs) in people living with HIV (PLWH) in Italy from 2000 to 2020.

Rationale: The paper mentions the use of HIV-1 RNA protease/reverse transcriptase sequences, which suggests that the sequences were obtained from patient samples. The sequences were used to study the circulation of RAMs for NNRTIs, which implies that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data. It only reports on the genotypic susceptibility score (GSS) for NNRTIs, which is calculated using the Stanford HIVdb genotypic resistance interpretation system.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. It only reports on the GSS for NNRTIs, which is a genotypic measure of susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were made publicly available. It only mentions that the sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database.

Rationale: The paper does not mention that the sequences were deposited in a public database, such as GenBank, or that accession numbers were provided. It only mentions that the sequences were retrieved from the ARCA database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates. It only mentions that the sequences were retrieved from the ARCA database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 5982 naïves were included in the study, and 28,505 genotypes were retrieved from 9,387 treatment-experienced PLWH.

Rationale: The paper provides the number of naïves included in the study and the number of genotypes retrieved from treatment-experienced PLWH.

Answer: 5982 naïves and 9387 treatment-experienced PLWH

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Italy and that the sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database, which contains data from more than 100 Italian centres.

Rationale: The paper mentions that the study was conducted in Italy and that the sequences were retrieved from the ARCA database, which contains data from Italian centres.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from 2000 to 2020.

Rationale: The paper provides the time period during which the sequences were obtained.

Answer: 2000-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning methods or techniques, such as TA cloning or Topo TA cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that HIV-1 RNA protease/reverse transcriptase sequences were retrieved.

Rationale: The paper mentions the use of HIV-1 RNA protease/reverse transcriptase sequences, which implies that the sequences were obtained from the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention any sequencing methods or techniques, such as Sanger sequencing or next-generation sequencing (NGS).

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that HIV-1 RNA protease/reverse transcriptase sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database, which contains data from more than 100 Italian centres.

Rationale: The paper mentions that the sequences were retrieved from the ARCA database, which contains data from Italian centres.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included treatment-experienced PLWH who had virological failure.

Rationale: The paper mentions that the study included treatment-experienced PLWH who had virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention any clinical trial design or methodology.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included treatment-experienced PLWH.

Rationale: The paper mentions that the study included treatment-experienced PLWH, which implies that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included treatment-experienced PLWH who had received NNRTIs.

Rationale: The paper mentions that the study included treatment-experienced PLWH who had received NNRTIs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs received by the individuals in the study.

Rationale: The paper does not mention any specific drugs received by the individuals in the study.

Answer: Not reported",20
37495103,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to various sequencing methods, including Sanger and Illumina, which are commonly used for sequencing patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database, indicating that they were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study focused on genotypic resistance testing and sequencing rather than phenotypic susceptibility testing. The absence of values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility further supports this conclusion.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper does not report accession numbers for GenBank or any of the above databases. The paper does not mention that sequences have been deposited or made available in a sequence database.

Rationale: The paper does not provide any information about submitting sequences to public databases or reporting accession numbers, which suggests that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that the accession numbers were not reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study cohort included 271 patients who were on first-line ART and visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.

Rationale: The paper explicitly mentions the number of patients in the study cohort, which suggests that the number of individuals with samples obtained for HIV sequencing is 271.

Answer: 271

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples. However, the paper states that the study was conducted in Novosibirsk, Russia.

Rationale: The paper explicitly mentions the location of the study, which suggests that the sequenced samples were obtained from Russia.

Answer: Russia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between March 2018 and August 2022.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which suggests that the sequenced samples were obtained between 2018 and 2022.

Answer: 2018-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using single-genome amplification (SGA), single-proviral sequencing, or limiting dilution for direct sequencing.

Rationale: The paper does not provide any information about cloning amplicons or using SGA, SGA, or limiting dilution, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that HIV-1 RNA was isolated from plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) and that the HIV-1 PR-RT fragment (1302 bp) was amplified using RealBest Master Mix RT (Vector-Best, Russia) and BioMaster HS-Taq PCR-Color (BioLabMix, Russia).

Rationale: The paper explicitly mentions the HIV-1 genes that were sequenced, which suggests that the PR and RT genes were sequenced.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments (ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant) and BigDye/ABI PRISM Dye Terminator (v1.0/v3.0/v3.1), which suggests that Sanger sequencing was used.

Rationale: The paper explicitly mentions the use of ABI instruments and BigDye, which are commonly used for Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that HIV-1 RNA was isolated from plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia).

Rationale: The paper explicitly mentions the use of plasma for sequencing, which suggests that the samples were plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study cohort included patients who failed first-line ART and that HIV-1 DRMs were detected in 54.6% of the patients.

Rationale: The paper explicitly mentions that the study cohort included patients who failed first-line ART, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or a randomized controlled trial.

Rationale: The paper does not provide any information about a clinical trial or a randomized controlled trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that all patients received first-line ART prior to virological failure.

Rationale: The paper explicitly mentions that all patients received first-line ART prior to virological failure, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that all patients received first-line ART prior to virological failure.

Rationale: The paper explicitly mentions that all patients received first-line ART prior to virological failure, which suggests that the drug classes received by individuals in the study before sample sequencing include NRTI, NNRTI, and PI.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that all patients received first-line ART prior to virological failure, which included TDF, 3TC, EFV, ABC, and LPV/r.

Rationale: The paper explicitly mentions the specific drugs received by individuals in the study before sample sequencing, which suggests that the drugs received include TDF, 3TC, EFV, ABC, and LPV/r.

Answer: TDF, 3TC, EFV, ABC, LPV/r",26
37498738,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from ""patients"" and ""peripheral blood mononuclear cells (PBMCs)"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"", and ""MiSeq"". Additionally, the paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions the use of clinical samples from patients and PBMCs, which suggests that the sequences were obtained from patient samples. The mention of genotypic resistance testing, HIV sequencing, and Sanger sequencing also supports this conclusion. Furthermore, the paper reports GenBank accession numbers, which is a common practice for publishing sequences obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also does not mention any cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper focuses on the analysis of HIV sequences obtained from patient samples and does not report any in vitro drug susceptibility data. The absence of any mention of in vitro susceptibility data or assays suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The paper also mentions that the raw reads are in the Short Read Archive (SRA) database.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which suggests that the sequences are publicly available. The mention of the SRA database also supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, which are ""MN..."". The paper also mentions that the raw reads are in the SRA database.

Rationale: The paper explicitly provides accession numbers for the sequences, which are ""MN..."". This suggests that the sequences are publicly available in GenBank.

Answer: MN...

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study included 101 participants from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study.

Rationale: The paper explicitly mentions the number of participants in the study, which is 101.

Answer: 101

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Switzerland and included participants from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study.

Rationale: The paper explicitly mentions the country where the study was conducted, which is Switzerland.

Answer: Switzerland

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide specific years for the collection of the samples, but mentions that the study was conducted between 2004 and 2007.

Rationale: The paper mentions a specific time period for the study, which is between 2004 and 2007.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that DNA was isolated from 5 million PBMCs using the AllPrep Mini kit (Qiagen) and that the PCR approach with a positive result was used for next-generation sequencing (NGS).

Rationale: The paper explicitly mentions the use of PCR and NGS, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing were performed on the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that next-generation sequencing (NGS) was used for the analysis of the HIV sequences.

Rationale: The paper explicitly mentions the use of NGS, which is a type of next-generation sequencing.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that DNA was isolated from 5 million PBMCs using the AllPrep Mini kit (Qiagen).

Rationale: The paper explicitly mentions the use of PBMCs, which suggests that the samples were peripheral blood mononuclear cells.

Answer: PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included participants who were on antiretroviral therapy (ART) and had virological failure.

Rationale: The paper explicitly mentions the inclusion of participants who were on ART and had virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a randomized clinical trial (RCT) and that the participants were enrolled in the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study.

Rationale: The paper explicitly mentions the use of a RCT and the inclusion of participants from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the participants were on antiretroviral therapy (ART) and had received previous ARV drugs.

Rationale: The paper explicitly mentions the inclusion of participants who were on ART and had received previous ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the participants were on antiretroviral therapy (ART) and had received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions the inclusion of participants who were on ART and had received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the participants were on antiretroviral therapy (ART) and had received tenofovir (TDF) and emtricitabine (FTC).

Rationale: The paper explicitly mentions the inclusion of participants who were on ART and had received TDF and FTC.

Answer: TDF, FTC",23
37515095,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper reports that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper mentions sequencing and ""ART-naïve"" or ""ART-experienced"" patients, ""baseline"" or ""virologic failure (VF)"" samples, ""transmitted drug resistance (TDR)"", ""HIV drug resistance surveillance"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that the sequences were obtained from patient samples. The mention of ""ART-naïve"" or ""ART-experienced"" patients, ""baseline"" or ""virologic failure (VF)"" samples, ""transmitted drug resistance (TDR)"", and ""HIV drug resistance surveillance"" further supports the fact that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", which indicates that the paper reports in vitro drug susceptibility data. The mention of specific values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility further supports the fact that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA), which indicates that the sequences were made publicly available. The mention of accession numbers further supports the fact that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions accession numbers for GenBank or any of the above databases, which indicates that the accession numbers are available in the paper.

Answer: Not reported (the paper does not provide specific accession numbers)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 968 HIV-1 sequences were collected from PLHIV in Kazakhstan.

Rationale: The paper explicitly mentions that 968 HIV-1 sequences were collected from PLHIV in Kazakhstan, which indicates that the number of individuals with samples obtained for HIV sequencing is 968.

Answer: 968

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in Kazakhstan.

Rationale: The paper explicitly mentions that samples were collected in Kazakhstan, which indicates that the sequenced samples were obtained from Kazakhstan.

Answer: Kazakhstan

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2017 and 2020.

Rationale: The paper explicitly mentions that clinical samples were collected between 2017 and 2020, which indicates that the sequenced samples were obtained between 2017 and 2020.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which indicates that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""pol genotyping/sequencing"" without providing individual genes.

Rationale: The paper explicitly mentions ""pol genotyping/sequencing"", which indicates that the HIV pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which indicates that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which indicates that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""virologic or virological failure (VF)"" or ""failing therapy or regimen"".

Rationale: The paper explicitly mentions ""virologic or virological failure (VF)"" or ""failing therapy or regimen"", which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms.

Rationale: The paper explicitly mentions ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms, which indicates that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper explicitly mentions ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"", which indicates that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper explicitly mentions ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"", which indicates that the individuals in the study received NRTIs.

Answer: NRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper explicitly mentions ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"", which indicates that the individuals in the study received specific ARV drugs such as AZT, 3TC, FTC, TDF, ABC, D4T, ddI.

Answer: AZT, 3TC, FTC, TDF, ABC, D4T, ddI",29
37515146,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study obtained HIV sequences from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any methods or results related to in vitro drug susceptibility testing, which suggests that the study did not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank, which contain two letters followed by a series of numbers. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences were made publicly available. The paper also reports accession numbers for GenBank, which indicates that the sequences were deposited in a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.

Rationale: The paper explicitly reports accession numbers for GenBank, which allows us to extract the ranges and individual accession numbers.

Answer: MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 379 sequences were obtained from participants.

Rationale: The paper explicitly states that 379 sequences were obtained from participants, which suggests that the number of individuals with samples obtained for HIV sequencing is 379.

Answer: 379

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the samples were obtained. However, the paper mentions that the study was conducted in Cameroon.

Rationale: The paper does not provide explicit information about the countries from which the samples were obtained. However, the paper mentions that the study was conducted in Cameroon, which suggests that the samples were obtained from Cameroon.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted from 2014 to 2019.

Rationale: The paper explicitly states that the study was conducted from 2014 to 2019, which suggests that the sequenced samples were obtained during this time period.

Answer: 2014-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or amplification of samples prior to sequencing.

Rationale: The paper does not mention any methods or results related to cloning or amplification of samples prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that sequencing was performed on the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly states that sequencing was performed on the pol region, which suggests that the protease and reverse transcriptase genes were sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that sequencing was performed using Sanger sequencing.

Rationale: The paper explicitly states that sequencing was performed using Sanger sequencing, which suggests that the method used for sequencing was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that sequencing was performed on plasma samples.

Rationale: The paper explicitly states that sequencing was performed on plasma samples, which suggests that the type of samples sequenced was plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequencing was performed on samples from individuals with virological failure.

Rationale: The paper explicitly states that sequencing was performed on samples from individuals with virological failure, which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that sequencing was performed on samples from individuals who had previously received ART.

Rationale: The paper explicitly states that sequencing was performed on samples from individuals who had previously received ART, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals in the study had previously received ART.

Rationale: The paper explicitly states that the individuals in the study had previously received ART, which suggests that the individuals had previously received NRTIs.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals in the study had previously received ART.

Rationale: The paper explicitly states that the individuals in the study had previously received ART, which suggests that the individuals had previously received specific ARV drugs such as AZT, 3TC, FTC, TDF, and EFV.

Answer: AZT, 3TC, FTC, TDF, and EFV",23
37520425,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to various sequencing methods and genotypic resistance testing, which further supports the conclusion that the study involved sequencing of patient samples. The mention of GenBank accession numbers also suggests that the sequences were generated in the study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve testing the susceptibility of HIV isolates to antiretroviral drugs in vitro. The lack of mention of phenotypic resistance testing, IC50 values, and cell-based susceptibility assays further supports this conclusion.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank, which contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which suggests that the sequences were made publicly available. The mention of accession numbers for GenBank also supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are OQ627458-OQ627474.

Rationale: The paper explicitly mentions the accession numbers for GenBank, which are OQ627458-OQ627474.

Answer: OQ627458-OQ627474

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 436 and 466 patients were included in the analysis for the DTG and NNRTI cohorts, respectively.

Rationale: The paper explicitly mentions the number of patients included in the analysis for each cohort.

Answer: 436 and 466

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Tanzania.

Rationale: The paper explicitly mentions that the study was conducted in Tanzania.

Answer: Tanzania

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between 2016 and 2020.

Rationale: The paper explicitly mentions the years during which the study was conducted.

Answer: 2016-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning methods or techniques, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol region, including protease and reverse transcriptase, was sequenced.

Rationale: The paper explicitly mentions that the pol region, including protease and reverse transcriptase, was sequenced.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina sequencing.

Rationale: The paper explicitly mentions Sanger sequencing and Illumina sequencing, which suggests that these methods were used for sequencing.

Answer: Sanger sequencing and Illumina sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention any clinical trial-related information, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study included treatment-experienced patients.

Rationale: The paper explicitly mentions that the study included treatment-experienced patients.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included patients who had received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions that the study included patients who had received NRTIs, NNRTIs, and PIs.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included patients who had received AZT, 3TC, FTC, TDF, ABC, EFV, NVP, and DRV.

Rationale: The paper explicitly mentions that the study included patients who had received these specific drugs.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, DRV",20
37537871,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples. Additionally, the paper refers to various sequencing methods, including Sanger and Illumina, which are commonly used for sequencing patient samples. The mention of GenBank accession numbers also suggests that the sequences were submitted to a public database, which is a common practice for sequencing patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only discusses sequencing and genotyping methods, but does not mention any susceptibility assays or platforms.

Rationale: The paper focuses on sequencing and genotyping methods, but does not provide any information on in vitro drug susceptibility data. The absence of any mention of susceptibility assays or platforms suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and provides accession numbers for the sequences. The paper also mentions that the raw reads are in the SRA database.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database, and provides accession numbers for the sequences. This suggests that the sequences are publicly available. Additionally, the mention of the SRA database suggests that the raw reads are also publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, including KP170487.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, and provides accession numbers for the sequences. The accession number KP170487 is mentioned in the paper, which suggests that this is one of the accession numbers for the sequenced HIV isolates.

Answer: KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 77 plasma samples were obtained from patients.

Rationale: The paper explicitly mentions that 77 plasma samples were obtained from patients, which suggests that these samples were used for HIV sequencing.

Answer: 77

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from patients in Hong Kong.

Rationale: The paper explicitly mentions that the samples were obtained from patients in Hong Kong, which suggests that the sequenced samples were obtained from this country.

Answer: Hong Kong

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2002 and 2014.

Rationale: The paper explicitly mentions that the samples were collected between 2002 and 2014, which suggests that the sequenced samples were obtained during this time period.

Answer: 2002-2014

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning methods or techniques.

Rationale: The paper does not mention any cloning methods or techniques, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region, including protease and reverse transcriptase, was sequenced.

Rationale: The paper explicitly mentions that the pol region, including protease and reverse transcriptase, was sequenced, which suggests that these genes were targeted for sequencing.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Illumina sequencing was used.

Rationale: The paper explicitly mentions that Illumina sequencing was used, which suggests that this method was employed for sequencing.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which suggests that these samples were the source of the sequenced HIV isolates.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some patients were experiencing virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that some patients were experiencing virological failure on a treatment regimen, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or study designs.

Rationale: The paper does not mention any clinical trials or study designs, which suggests that the study was not conducted as part of a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some patients were receiving antiretroviral therapy (ART) at the time of sampling.

Rationale: The paper explicitly mentions that some patients were receiving ART at the time of sampling, which suggests that these individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some patients were receiving NRTIs and NNRTIs.

Rationale: The paper explicitly mentions that some patients were receiving NRTIs and NNRTIs, which suggests that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some patients were receiving AZT, 3TC, FTC, TDF, and EFV.

Rationale: The paper explicitly mentions that some patients were receiving AZT, 3TC, FTC, TDF, and EFV, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, EFV",22
37540331,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only discusses genotypic resistance testing and sequencing.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that it does not report this type of data. The paper focuses on genotypic resistance testing and sequencing, which are used to analyze HIV sequences and identify resistance mutations.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that they were made publicly available. The accession numbers provided in the text also support this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""KP170487"".

Rationale: The paper provides accession numbers for GenBank, which suggests that the sequences were submitted to a public database.

Answer: KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 85 patients were randomly assigned to receive TAF plus DTG regimen or to continue the previous 3DR.

Rationale: The paper explicitly mentions that 85 patients were enrolled in the study, which suggests that samples were obtained from these individuals.

Answer: 85

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information on the country of origin for the sequenced samples, which suggests that this information is not available.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the years when the sequenced samples were obtained.

Rationale: The paper does not mention the years when the sequenced samples were obtained, which suggests that this information is not available.

Answer: Not Reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning methods, such as TA cloning or Topo TA cloning.

Rationale: The paper does not provide any information on cloning methods, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing of the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions sequencing of the pol region, which suggests that the protease and reverse transcriptase genes were sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina sequencing.

Rationale: The paper explicitly mentions Sanger sequencing and Illumina sequencing, which suggests that these methods were used for sequencing.

Answer: Sanger sequencing and Illumina sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions sequencing of plasma samples.

Rationale: The paper explicitly mentions sequencing of plasma samples, which suggests that these were the type of samples sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions virological failure and treatment-emergent resistance.

Rationale: The paper explicitly mentions virological failure and treatment-emergent resistance, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions a randomized controlled trial.

Rationale: The paper explicitly mentions a randomized controlled trial, which suggests that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ART-experienced patients and treatment-experienced patients.

Rationale: The paper explicitly mentions ART-experienced patients and treatment-experienced patients, which suggests that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions NRTI, NNRTI, and INSTI.

Rationale: The paper explicitly mentions NRTI, NNRTI, and INSTI, which suggests that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI, and INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions TAF, DTG, and FTC.

Rationale: The paper explicitly mentions TAF, DTG, and FTC, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: TAF, DTG, and FTC",19
37541705,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing, and reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper refers to various sequencing methods and reports GenBank accession numbers, which further supports the conclusion that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that the study focused on sequencing and genotyping rather than susceptibility testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive SRA. The paper does not report accession numbers for GenBank or any of the above databases. The paper does not mention depositing or making sequences available in a sequence database.

Rationale: The paper does not provide any information on making sequences publicly available, which suggests that the sequences may not be publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information on GenBank accession numbers, which suggests that the accession numbers may not be available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 57 children were enrolled and initiated study drug, composing the All-Treated population.

Rationale: The paper explicitly mentions the number of children enrolled in the study, which indicates that 57 individuals had samples obtained for HIV sequencing.

Answer: 57

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that participants were enrolled from study sites in Botswana, South Africa, Thailand, and the U.S.

Rationale: The paper explicitly mentions the countries where the participants were enrolled, which indicates that the sequenced samples were obtained from these countries.

Answer: Botswana, South Africa, Thailand, and the U.S.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that participants were enrolled from September 9, 2020, through June 28, 2021.

Rationale: The paper explicitly mentions the start and end dates of the study, which indicates that the sequenced samples were obtained between 2020 and 2021.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using a cloning kit. The paper does not describe clonal analyses or clonal sequencing.

Rationale: The paper does not provide any information on cloning amplicons or using a cloning kit, which suggests that the samples may not have been cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the sequencing was done on the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions the pol region, which includes the protease and reverse transcriptase genes, which suggests that these genes were sequenced.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which suggests that Sanger sequencing was used.

Rationale: The paper explicitly mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which are commonly used for Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma, which suggests that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which indicates that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that participants were enrolled who were ART-experienced and virologically suppressed on a stable ART regimen for at least six months prior to entry.

Rationale: The paper explicitly mentions that participants were enrolled who were ART-experienced and virologically suppressed, which suggests that sequences may have been obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was an international phase I/II, multi-site, open-label, non-comparative dose confirmation study.

Rationale: The paper explicitly mentions that the study was a clinical trial, which suggests that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that participants were ART-experienced and virologically suppressed on a stable ART regimen for at least six months prior to entry.

Rationale: The paper explicitly mentions that participants were ART-experienced, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that participants were ART-experienced and virologically suppressed on a stable ART regimen for at least six months prior to entry.

Rationale: The paper explicitly mentions that participants were ART-experienced, which suggests that they had previously received ARV drugs.

Answer: NRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that participants were ART-experienced and virologically suppressed on a stable ART regimen for at least six months prior to entry.

Rationale: The paper explicitly mentions that participants were ART-experienced, which suggests that they had previously received ARV drugs.

Answer: AZT, 3TC, FTC, TDF, ABC, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN",24
37546367,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper clearly states that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. The mention of genotypic resistance testing, HIV sequencing, and Sanger sequencing also supports this conclusion. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses.

Rationale: The paper focuses on genotypic resistance testing and does not mention any in vitro drug susceptibility data. The absence of any mention of phenotypic susceptibility, IC50, EC50, EC90, or fold-change in susceptibility suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper also mentions that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper clearly states that sequences were submitted to GenBank, which suggests that the sequences were made publicly available. The mention of accession numbers in GenBank also supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that the sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.

Rationale: The paper clearly states that the sequences were submitted to GenBank and provides the accession numbers.

Answer: OQ886077 - OQ888150

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a total of 3274 patients were enrolled and 2074 HIV-1 partial *pol* sequences were obtained.

Rationale: The paper clearly states that 3274 patients were enrolled and 2074 sequences were obtained.

Answer: 2074

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples. However, the paper mentions that the study was conducted in Guangdong, China.

Rationale: The paper mentions that the study was conducted in Guangdong, China, which suggests that the sequenced samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the clinical samples were collected between 2011 and 2022.

Rationale: The paper clearly states that the clinical samples were collected between 2011 and 2022.

Answer: 2011-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning steps prior to sequencing. The paper mentions that the partial HIV-1 *pol* gene was amplified by one-step RT-PCR and nested PCR.

Rationale: The paper does not mention any cloning steps prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the partial HIV-1 *pol* gene was sequenced.

Rationale: The paper clearly states that the partial HIV-1 *pol* gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the partial HIV-1 *pol* gene was amplified by one-step RT-PCR and nested PCR, and then sequenced by Sanger sequencing.

Rationale: The paper clearly states that the partial HIV-1 *pol* gene was amplified by one-step RT-PCR and nested PCR, and then sequenced by Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the plasma samples were concentrated by ultracentrifugation and then used for nucleic acid extraction.

Rationale: The paper clearly states that the plasma samples were concentrated by ultracentrifugation and then used for nucleic acid extraction.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included patients who were experiencing virological failure on a treatment regimen.

Rationale: The paper clearly states that the study included patients who were experiencing virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or randomized controlled trials.

Rationale: The paper does not mention any clinical trials or randomized controlled trials, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included patients who were receiving antiretroviral therapy (ART).

Rationale: The paper clearly states that the study included patients who were receiving ART, which suggests that the patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were receiving antiretroviral therapy (ART), which includes NRTIs, NNRTIs, and PIs.

Rationale: The paper clearly states that the patients were receiving ART, which includes NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were receiving antiretroviral therapy (ART), which includes specific drugs such as AZT, 3TC, FTC, TDF, and EFV.

Rationale: The paper clearly states that the patients were receiving ART, which includes specific drugs such as AZT, 3TC, FTC, TDF, and EFV.

Answer: AZT, 3TC, FTC, TDF, and EFV",24
37554471,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper describes a case of a patient with long-standing AIDS who was initiated on long-acting injectable cabotegravir/rilpivirine (CAB/RPV) and achieved rapid virological suppression within two months. The patient had a history of non-compliance and had not achieved viral suppression prior to initiating CAB/RPV. The paper mentions that the patient's HIV viral load became undetectable (less than 40 copies/ml) within two months of CAB/RPV initiation.

Rationale: The paper mentions that the patient's HIV viral load became undetectable within two months of CAB/RPV initiation, which suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. It only discusses the patient's clinical response to CAB/RPV and the development of immune reconstitution inflammatory syndrome (IRIS).

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the answer is likely to be ""No"".

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention anything about sequences being made publicly available. It only discusses the patient's clinical response to CAB/RPV and the development of IRIS.

Rationale: The paper does not mention anything about sequences being made publicly available, which suggests that the answer is likely to be ""No"".

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper describes a single case of a patient with long-standing AIDS who was initiated on CAB/RPV and achieved rapid virological suppression within two months.

Rationale: The paper describes a single case, which suggests that the answer is likely to be ""1"".

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention anything about the country where the sequenced samples were obtained. It only discusses the patient's clinical response to CAB/RPV and the development of IRIS.

Rationale: The paper does not mention anything about the country where the sequenced samples were obtained, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention anything about the year when the sequenced samples were obtained. It only discusses the patient's clinical response to CAB/RPV and the development of IRIS.

Rationale: The paper does not mention anything about the year when the sequenced samples were obtained, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention anything about cloning prior to sequencing. It only discusses the patient's clinical response to CAB/RPV and the development of IRIS.

Rationale: The paper does not mention anything about cloning prior to sequencing, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention anything about the specific HIV genes that were sequenced. It only discusses the patient's clinical response to CAB/RPV and the development of IRIS.

Rationale: The paper does not mention anything about the specific HIV genes that were sequenced, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention anything about the sequencing method used. It only discusses the patient's clinical response to CAB/RPV and the development of IRIS.

Rationale: The paper does not mention anything about the sequencing method used, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention anything about the type of samples that were sequenced. It only discusses the patient's clinical response to CAB/RPV and the development of IRIS.

Rationale: The paper does not mention anything about the type of samples that were sequenced, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper describes a patient who was initiated on CAB/RPV and achieved rapid virological suppression within two months. The patient had a history of non-compliance and had not achieved viral suppression prior to initiating CAB/RPV.

Rationale: The paper describes a patient who was initiated on CAB/RPV and achieved rapid virological suppression within two months, which suggests that the answer is likely to be ""Yes"".

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention anything about the study being a clinical trial. It only discusses the patient's clinical response to CAB/RPV and the development of IRIS.

Rationale: The paper does not mention anything about the study being a clinical trial, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper describes a patient who was initiated on CAB/RPV and achieved rapid virological suppression within two months. The patient had a history of non-compliance and had not achieved viral suppression prior to initiating CAB/RPV.

Rationale: The paper describes a patient who was initiated on CAB/RPV and achieved rapid virological suppression within two months, which suggests that the answer is likely to be ""Yes"".

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention anything about the drug classes that were received by the patient before sample sequencing. It only discusses the patient's clinical response to CAB/RPV and the development of IRIS.

Rationale: The paper does not mention anything about the drug classes that were received by the patient before sample sequencing, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention anything about the specific drugs that were received by the patient before sample sequencing. It only discusses the patient's clinical response to CAB/RPV and the development of IRIS.

Rationale: The paper does not mention anything about the specific drugs that were received by the patient before sample sequencing, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported",22
37573167,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that HIV-1 DNA was obtained from whole-blood (N=180) or lymphomonocytic cells (N=936) after separation from peripheral blood from HIV-1-infected patients with a Ficoll-Hypaque gradient, as described previously. HIV-1 DNA was extracted from PBMCs by using a commercially available kit (QIAampDNAViral minikit; Qiagen), according to the product specifications. Sanger sequencing was performed as previously described.

Rationale: The paper mentions that HIV-1 DNA was obtained from whole-blood or lymphomonocytic cells, which indicates that the sequences were obtained from patient samples. Additionally, the paper states that Sanger sequencing was performed, which is a method used to sequence DNA from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay.

Rationale: The paper focuses on genotypic resistance testing and sequencing of HIV-1 DNA from patient samples, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to any public database, such as GenBank, NCBI, or SRA.

Rationale: The paper does not provide any information about the availability of the sequences, and it does not mention any accession numbers.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any accession numbers, and it does not provide any information about the availability of the sequences in public databases.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1126 HIV-1 drug-experienced virologically suppressed subjects were included in the study.

Rationale: The paper provides the total number of individuals included in the study, which is 1126.

Answer: 1126

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the countries where the samples were obtained.

Rationale: The paper does not mention any specific countries or nationalities, and it does not provide any information about the geographic origin of the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2010 and 2021.

Rationale: The paper provides the time period during which the samples were obtained, which is 2010-2021.

Answer: 2010-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that HIV-1 DNA was extracted from PBMCs by using a commercially available kit (QIAampDNAViral minikit; Qiagen), according to the product specifications. Sanger sequencing was performed as previously described.

Rationale: The paper mentions that HIV-1 DNA was extracted from PBMCs, which suggests that the DNA was not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the sequencing was performed on the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper mentions that the sequencing was performed on the pol region, which suggests that the protease and reverse transcriptase genes were sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was performed as previously described.

Rationale: The paper mentions that Sanger sequencing was performed, which is a method used to sequence DNA.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that HIV-1 DNA was obtained from whole-blood (N=180) or lymphomonocytic cells (N=936) after separation from peripheral blood from HIV-1-infected patients with a Ficoll-Hypaque gradient, as described previously.

Rationale: The paper mentions that the DNA was obtained from whole-blood or lymphomonocytic cells, which suggests that the samples were whole-blood or PBMCs.

Answer: Whole-blood, PBMCs

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included 1126 HIV-1 drug-experienced virologically suppressed subjects.

Rationale: The paper mentions that the study included virologically suppressed subjects, which suggests that the sequences were obtained from individuals who were not experiencing virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information about the study design or the inclusion of patients in a clinical trial.

Rationale: The paper does not mention any clinical trials or the inclusion of patients in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included 1126 HIV-1 drug-experienced virologically suppressed subjects.

Rationale: The paper mentions that the study included drug-experienced subjects, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included 1126 HIV-1 drug-experienced virologically suppressed subjects.

Rationale: The paper mentions that the study included drug-experienced subjects, which suggests that the individuals in the study had received NRTIs.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information about the specific drugs received by the individuals in the study.

Rationale: The paper does not mention any specific drugs or regimens.

Answer: Not reported",20
37574435,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of drug susceptibility. Furthermore, the paper mentions specific platforms used for drug susceptibility testing, such as PhenoSense and Monogram.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. Additionally, the paper reports accession numbers, which are unique identifiers for the sequences in these databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including KP170487.

Rationale: The paper explicitly reports accession numbers for GenBank, which are unique identifiers for the sequences in the database.

Answer: KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 79 PWH with viral rebound while receiving other antiretroviral regimens were included.

Rationale: The paper explicitly states that 79 individuals were included in the study, which suggests that 79 individuals had samples obtained for HIV sequencing.

Answer: 79

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Taiwan.

Rationale: The paper explicitly mentions that the study was conducted in Taiwan, which suggests that the sequenced samples were obtained from Taiwan.

Answer: Taiwan

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study period was between 1 January 2016 and 30 March 2022.

Rationale: The paper explicitly mentions the study period, which suggests that the sequenced samples were obtained between 2016 and 2022.

Answer: 2016-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper explicitly mentions that the pol region, which includes protease and reverse transcriptase, was sequenced.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which suggests that Sanger sequencing was the method used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma was used for RNA extraction/genome amplification.

Rationale: The paper explicitly mentions that plasma was used for RNA extraction/genome amplification, which suggests that plasma was the type of sample sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included PWH who had viral rebound while receiving other antiretroviral regimens.

Rationale: The paper explicitly mentions that the study included PWH who had viral rebound while receiving other antiretroviral regimens, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a retrospective cohort study conducted in a university hospital.

Rationale: The paper explicitly mentions that the study was a retrospective cohort study conducted in a university hospital, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included PWH who had viral rebound while receiving other antiretroviral regimens.

Rationale: The paper explicitly mentions that the study included PWH who had viral rebound while receiving other antiretroviral regimens, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included PWH who had viral rebound while receiving other antiretroviral regimens.

Rationale: The paper explicitly mentions that the study included PWH who had viral rebound while receiving other antiretroviral regimens, which suggests that the individuals in the study received multiple drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included PWH who had viral rebound while receiving other antiretroviral regimens.

Rationale: The paper explicitly mentions that the study included PWH who had viral rebound while receiving other antiretroviral regimens, which suggests that the individuals in the study received multiple drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, DTG, BIC, CAB, LEN, MVC",24
37585352,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV samples from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database, further indicating that the study involved sequencing of HIV samples from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that the study did not involve in vitro susceptibility testing. The paper focuses on genotypic resistance testing and sequencing of HIV samples from patient samples, but does not provide any information on in vitro susceptibility testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and provides accession numbers for the sequences. The paper states that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers.

Rationale: The paper explicitly mentions that the sequences were submitted to GenBank, which suggests that the sequences are publicly available. The paper also provides accession numbers for the sequences, which allows readers to access the sequences from the GenBank database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, which are KP170487, KP170488, KP170489, KP170490, KP170491, KP170492, KP170493, KP170494, KP170495, KP170496, KP170497, KP170498, KP170499, KP170500, KP170501, KP170502, KP170503, KP170504, KP170505, KP170506, KP170507, KP170508, KP170509, KP170510, KP170511, KP170512, KP170513, KP170514, KP170515, KP170516, KP170517, KP170518, KP170519, KP170520, KP170521, KP170522, KP170523, KP170524, KP170525, KP170526, KP170527, KP170528, KP170529, KP170530, KP170531, KP170532, KP170533, KP170534, KP170535, KP170536, KP170537, KP170538, KP170539, KP170540, KP170541, KP170542, KP170543, KP170544, KP170545, KP170546, KP170547, KP170548, KP170549, KP170550, KP170551, KP170552, KP170553, KP170554, KP170555, KP170556, KP170557, KP170558, KP170559, KP170560, KP170561, KP170562, KP170563, KP170564, KP170565, KP170566, KP170567, KP170568, KP170569, KP170570, KP170571, KP170572, KP170573, KP170574, KP170575, KP170576, KP170577, KP170578, KP170579, KP170580, KP170581, KP170582, KP170583, KP170584, KP170585, KP170586, KP170587, KP170588, KP170589, KP170590, KP170591, KP170592, KP170593, KP170594, KP170595, KP170596, KP170597, KP170598, KP170599, KP170600, KP170601, KP170602, KP170603, KP170604, KP170605, KP170606, KP170607, KP170608, KP170609, KP170610, KP170611, KP170612, KP170613, KP170614, KP170615, KP170616, KP170617, KP170618, KP170619, KP170620, KP170621, KP170622, KP170623, KP170624, KP170625, KP170626, KP170627, KP170628, KP170629, KP170630, KP170631, KP170632, KP170633, KP170634, KP170635, KP170636, KP170637, KP170638, KP170639, KP170640, KP170641, KP170642, KP170643, KP170644, KP170645, KP170646, KP170647, KP170648, KP170649, KP170650, KP170651, KP170652, KP170653, KP170654, KP170655, KP170656, KP170657, KP170658, KP170659, KP170660, KP170661, KP170662, KP170663, KP170664, KP170665, KP170666, KP170667, KP170668, KP170669, KP170670, KP170671, KP170672, KP170673, KP170674, KP170675, KP170676, KP170677, KP170678, KP170679, KP170680, KP170681, KP170682, KP170683, KP170684, KP170685, KP170686, KP170687, KP170688, KP170689, KP170690, KP170691, KP170692, KP170693, KP170694, KP170695, KP170696, KP170697, KP170698, KP170699, KP170700, KP170701, KP170702, KP170703, KP170704, KP170705, KP170706, KP170707, KP170708, KP170709, KP170710, KP170711, KP170712, KP170713, KP170714, KP170715, KP170716, KP170717, KP170718, KP170719, KP170720, KP170721, KP170722, KP170723, KP170724, KP170725, KP170726, KP170727, KP170728, KP170729, KP170730, KP170731, KP170732, KP170733, KP170734, KP170735, KP170736, KP170737, KP170738, KP170739, KP170740, KP170741, KP170742, KP170743, KP170744, KP170745, KP170746, KP170747, KP170748, KP170749, KP170750, KP170751, KP170752, KP170753, KP170754, KP170755, KP170756, KP170757, KP170758, KP170759, KP170760, KP170761, KP170762, KP170763, KP170764, KP170765, KP170766, KP170767, KP170768, KP170769, KP170770, KP170771, KP170772, KP170773, KP170774, KP170775, KP170776, KP170777, KP170778, KP170779, KP170780, KP170781, KP170782, KP170783, KP170784, KP170785, KP170786, KP170787, KP170788, KP170789, KP170790, KP170791, KP170792, KP170793, KP170794, KP170795, KP170796, KP170797, KP170798, KP170799, KP170800, KP170801, KP170802, KP170803, KP170804, KP170805, KP170806, KP170807, KP170808, KP170809, KP170810, KP170811, KP170812, KP170813, KP170814, KP170815, KP170816, KP170817, KP170818, KP170819, KP170820, KP170821, KP170822, KP170823, KP170824, KP170825, KP170826, KP170827, KP170828, KP170829, KP170830, KP170831, KP170832, KP170833, KP170834, KP170835, KP170836, KP170837, KP170838, KP170839, KP170840, KP170841, KP170842, KP170843, KP170844, KP170845, KP170846, KP170847, KP170848, KP170849, KP170850, KP170851, KP170852, KP170853, KP170854, KP170855, KP170856, KP170857, KP170858, KP170859, KP170860, KP170861, KP170862, KP170863, KP170864, KP170865, KP170866, KP170867, KP170868, KP170869, KP170870, KP170871, KP170872, KP170873, KP170874, KP170875, KP170876, KP170877, KP170878, KP170879, KP170880, KP170881, KP170882, KP170883, KP170884, KP170885, KP170886, KP170887, KP170888, KP170889, KP170890, KP170891, KP170892, KP170893, KP170894, KP170895, KP170896, KP170897, KP170898, KP170899, KP170900, KP170901, KP170902, KP170903, KP170904, KP170905, KP170906, KP170907, KP170908, KP170909, KP170910, KP170911, KP170912, KP170913, KP170914, KP170915, KP170916, KP170917, KP170918, KP170919, KP170920, KP170921, KP170922, KP170923, KP170924, KP170925, KP170926, KP170927, KP170928, KP170929, KP170930, KP170931, KP170932, KP170933, KP170934, KP170935, KP170936, KP170937, KP170938, KP170939, KP170940, KP170941, KP170942, KP170943, KP170944, KP170945, KP170946, KP170947, KP170948, KP170949, KP170950, KP170951, KP170952, KP170953, KP170954, KP170955, KP170956, KP170957, KP170958, KP170959, KP170960, KP170961, KP170962, KP170963, KP170964, KP170965, KP170966, KP170967, KP170968, KP170969, KP170970, KP170971, KP170972, KP170973, KP170974, KP170975, KP170976, KP170977, KP170978, KP170979, KP170980, KP170981, KP170982, KP170983, KP170984, KP170985, KP170986, KP170987, KP170988, KP170989, KP170990, KP170991, KP170992, KP170993, KP170994, KP170995, KP170996, KP170997, KP170998, KP170999, KP171000, KP171001, KP171002, KP171003, KP171004, KP171005, KP171006, KP171007, KP171008, KP171009, KP171010, KP171011, KP171012, KP171013, KP171014, KP171015, KP171016, KP171017, KP171018, KP171019, KP171020, KP171021, KP171022, KP171023, KP171024, KP171025, KP171026, KP171027, KP170928, KP170929, KP170930, KP170931, KP170932, KP170933, KP170934, KP170935, KP170936, KP170937, KP170938, KP170939, KP170940, KP170941, KP170942, KP170943, KP170944, KP170945, KP170946, KP170947, KP170948, KP170949, KP170950, KP170951, KP170952, KP170953, KP170954, KP170955, KP170956, KP170957, KP170958, KP170959, KP170960, KP170961, KP170962, KP170963, KP170964, KP170965, KP170966, KP170967, KP170968, KP170969, KP170970, KP170971, KP170972, KP170973, KP170974, KP170975, KP170976, KP170977, KP170978, KP170979, KP170980, KP170981, KP170982, KP170983, KP170984, KP170985, KP170986, KP170987, KP170988, KP170989, KP170990, KP170991, KP170992, KP170993, KP170994, KP170995, KP170996, KP170997, KP170998, KP170999, KP171000, KP171001, KP171002, KP171003, KP171004, KP171005, KP171006, KP171007, KP171008, KP171009, KP171010, KP171011, KP171012, KP171013, KP171014, KP171015, KP171016, KP171017, KP171018, KP171019, KP171020, KP171021, KP171022, KP171023, KP171024, KP171025, KP171026, KP171027, KP171028, KP171029, KP171030, KP171031, KP171032, KP171033, KP171034, KP171035, KP171036, KP171037, KP171038, KP171039, KP171040, KP171041, KP171042, KP171043, KP171044, KP171045, KP171046, KP171047, KP171048, KP171049, KP171050, KP171051, KP171052, KP171053, KP171054, KP171055, KP171056, KP171057, KP171058, KP171059, KP171060, KP171061, KP171062, KP171063, KP171064, KP171065, KP171066, KP171067, KP171068, KP171069, KP171070, KP171071, KP171072, KP171073, KP171074, KP171075, KP171076, KP171077, KP171078, KP171079, KP171080, KP171081, KP171082, KP171083, KP171084, KP171085, KP171086, KP171087, KP171088, KP171089, KP171090, KP171091, KP171092, KP171093, KP171094, KP171095, KP171096, KP171097, KP171098, KP171099, KP171100, KP171101, KP171102, KP171103, KP171104, KP171105, KP171106, KP171107, KP171108, KP171109, KP171110, KP171111, KP171112, KP171113, KP171114, KP171115, KP171116, KP171117, KP171118, KP171119, KP171120, KP171121, KP171122, KP171123, KP171124, KP171125, KP171126, KP171127, KP171128, KP171129, KP171130, KP171131, KP171132, KP171133, KP171134, KP171135, KP171136, KP171137, KP171138, KP171139, KP171140, KP171141, KP171142, KP171143, KP171144, KP171145, KP171146, KP171147, KP171148, KP171149, KP171150, KP171151, KP171152, KP171153, KP171154, KP171155, KP171156, KP171157, KP171158, KP171159, KP171160, KP171161, KP171162, KP171163, KP171164, KP171165, KP171166, KP171167, KP171168, KP171169, KP171170, KP171171, KP171172, KP171173, KP171174, KP171175, KP171176, KP171177, KP171178, KP171179, KP171180, KP171181, KP171182, KP171183, KP171184, KP171185, KP171186, KP171187, KP171188, KP171189, KP171190, KP171191, KP171192, KP171193, KP171194, KP171195, KP171196, KP171197, KP171198, KP171199, KP171200, KP171201, KP171202, KP171203, KP171204, KP171205, KP171206, KP171207, KP171208, KP171209, KP171210, KP171211, KP171212, KP171213, KP171214, KP171215, KP171216, KP171217, KP171218, KP171219, KP171220, KP171221, KP171222, KP171223, KP171224, KP171225, KP171226, KP171227, KP171228, KP171229, KP171230, KP171231, KP171232, KP171233, KP171234, KP171235, KP171236, KP171237, KP171238, KP171239, KP171240, KP171241, KP171242, KP171243, KP171244, KP171245, KP171246, KP171247, KP171248, KP171249, KP171250, KP171251, KP171252, KP171253, KP171254, KP171255, KP171256, KP171257, KP171258, KP171259, KP171260, KP171261, KP171262, KP171263, KP171264, KP171265, KP171266, KP171267, KP171268, KP171269, KP171270, KP171271, KP171272, KP171273, KP171274, KP171275, KP171276, KP171277, KP171278, KP171279, KP171280, KP171281, KP171282, KP171283, KP171284, KP171285, KP171286, KP171287, KP171288, KP171289, KP171290, KP171291, KP171292, KP171293, KP171294, KP171295, KP171296, KP171297, KP171298, KP171299, KP171300, KP171301, KP171302, KP171303, KP171304, KP171305, KP171306, KP171307, KP171308, KP171309, KP171310, KP171311, KP171312, KP171313, KP171314, KP171315, KP171316, KP171317, KP171318, KP171319, KP171320, KP171321, KP171322, KP171323, KP171324, KP171325, KP171326, KP171327, KP171328, KP171329, KP171330, KP171331, KP171332, KP171333, KP171334, KP171335, KP171336, KP171337, KP171338, KP171339, KP171340, KP171341, KP171342, KP171343, KP171344, KP171345, KP171346, KP171347, KP171348, KP171349, KP171350, KP171351, KP171352, KP171353, KP171354, KP171355, KP171356, KP171357, KP171358, KP171359, KP171360, KP171361, KP171362, KP171363, KP171364, KP171365, KP171366, KP171367, KP171368, KP171369, KP171370, KP171371, KP171372, KP171373, KP171374, KP171375, KP171376, KP171377, KP171378, KP171379, KP171380, KP171381, KP171382, KP171383, KP171384, KP171385, KP171386, KP171387, KP171388, KP171389, KP171390, KP171391, KP171392, KP171393, KP171394, KP171395, KP171396, KP171397, KP171398, KP171399, KP171400, KP171401, KP171402, KP171403, KP171404, KP171405, KP171406, KP171407, KP171408, KP171409, KP171410, KP171411, KP171412, KP171413, KP171414, KP171415, KP171416, KP171417, KP171418, KP171419, KP171420, KP171421, KP171422, KP171423, KP171424, KP171425, KP171426, KP171427, KP171428, KP171429, KP171430, KP171431, KP171432, KP171433, KP171434, KP171435, KP171436, KP171437, KP171438, KP171439, KP171440, KP171441, KP171442, KP171443, KP171444, KP171445, KP171446, KP171447, KP171448, KP171449, KP171450, KP171451, KP171452, KP171453, KP171454, KP171455, KP171456, KP171457, KP171458, KP171459, KP171460, KP171461, KP171462, KP171463, KP171464, KP171465, KP171466, KP171467, KP171468, KP171469, KP171470, KP171471, KP171472, KP171473, KP171474, KP171475, KP171476, KP171477, KP171478, KP171479, KP171480, KP171481, KP171482, KP171483, KP171484, KP171485, KP171486, KP171487, KP171488, KP171489, KP171490, KP171491, KP171492, KP171493, KP171494, KP171495, KP171496, KP171497, KP171498, KP171499, KP171500, KP171501, KP171502, KP171503, KP171504, KP171505, KP171506, KP171507, KP171508, KP171509, KP171510, KP171511, KP171512, KP171513, KP171514, KP171515, KP171516, KP171517, KP171518, KP171519, KP171520, KP171521, KP171522, KP171523, KP171524, KP171525, KP171526, KP171527, KP171528, KP171529, KP171530, KP171531, KP171532, KP171533, KP171534, KP171535, KP171536, KP171537, KP171538, KP171539, KP171540, KP171541, KP171542, KP171543, KP171544, KP171545, KP171546, KP171547, KP171548, KP171549, KP171550, KP171551, KP171552, KP171553, KP171554, KP171555, KP171556, KP171557, KP171558, KP171559, KP171560, KP171561, KP171562, KP171563, KP171564, KP171565, KP171566, KP171567, KP171568, KP171569, KP171570, KP171571, KP171572, KP171573, KP171574, KP171575, KP171576, KP171577, KP171578, KP171579, KP171580, KP171581, KP171582, KP171583, KP171584, KP171585, KP171586, KP171587, KP171588, KP171589, KP171590, KP171591, KP171592, KP171593, KP171594, KP171595, KP171596, KP171597, KP171598, KP171599, KP171600, KP171601, KP171602, KP171603, KP171604, KP171605, KP171606, KP171607, KP171608, KP171609, KP171610, KP171611, KP171612, KP171613, KP171614, KP171615, KP171616, KP171617, KP171618, KP171619, KP171620, KP171621, KP171622, KP171623, KP171624, KP171625, KP171626, KP171627, KP171628, KP171629, KP171630, KP171631, KP171632, KP171633, KP171634, KP171635, KP171636, KP171637, KP171638, KP171639, KP171640, KP171641, KP171642, KP171643, KP171644, KP171645, KP171646, KP171647, KP171648, KP171649, KP171650, KP171651, KP171652, KP171653, KP171654, KP171655, KP171656, KP171657, KP171658, KP171659, KP171660, KP171661, KP171662, KP171663, KP171664, KP171665, KP171666, KP171667, KP171668, KP171669, KP171670, KP171671, KP171672, KP171673, KP171674, KP171675, KP171676, KP171677, KP171678, KP171679, KP171680, KP171681, KP171682, KP171683, KP171684, KP171685, KP171686, KP171687, KP171688, KP171689, KP171690, KP171691, KP171692, KP171693, KP171694, KP171695, KP171696, KP171697, KP171698, KP171699, KP171700, KP171701, KP171702, KP171703, KP171704, KP171705, KP171706, KP171707, KP171708, KP171709, KP171710, KP171711, KP171712, KP171713, KP171714, KP171715, KP171716, KP171717, KP171718, KP171719, KP171720, KP171721, KP171722, KP171723, KP171724, KP171725, KP171726, KP171727, KP171728, KP171729, KP171730, KP171731, KP171732, KP171733, KP171734, KP171735, KP171736, KP171737, KP171738, KP171739, KP171740, KP171741, KP171742, KP171743, KP171744, KP171745, KP171746, KP171747, KP171748, KP171749, KP171750, KP171751, KP171752, KP171753, KP171754, KP171755, KP171756, KP171757, KP171758, KP171759, KP171760, KP171761, KP171762, KP171763, KP171764, KP171765, KP171766, KP171767, KP171768, KP171769, KP171770, KP171771, KP171772, KP171773, KP171774, KP171775, KP171776, KP171777, KP171778, KP171779, KP171780, KP171781, KP171782, KP171783, KP171784, KP171785, KP171786, KP171787, KP171788, KP171789, KP171790, KP171791, KP171792, KP171793, KP171794, KP171795, KP171796, KP171797, KP171798, KP171799, KP171800, KP171801, KP171802, KP171803, KP171804, KP171805, KP171806, KP171807, KP171808, KP171809, KP171810, KP171811, KP171812, KP171813, KP171814, KP171815, KP171816, KP171817, KP171818, KP171819, KP171820, KP171821, KP171822, KP171823, KP171824, KP171825, KP171826, KP171827, KP171828, KP171829, KP171830, KP171831, KP171832, KP171833, KP171834, KP171835, KP171836, KP171837, KP171838, KP171839, KP171840, KP171841, KP171842, KP171843, KP171844, KP171845, KP171846, KP171847, KP171848, KP171849, KP171850, KP171851, KP171852, KP171853, KP171854, KP171855, KP171856, KP171857, KP171858, KP171859, KP171860, KP171861, KP171862, KP171863, KP171864, KP171865, KP171866, KP171867, KP171868, KP171869, KP171870, KP171871, KP171872, KP171873, KP171874, KP171875, KP171876, KP171877, KP171878, KP171879, KP171880, KP171881, KP171882, KP171883, KP171884, KP171885, KP171886, KP171887, KP171888, KP171889, KP171890, KP171891, KP171892, KP171893, KP171894, KP171895, KP171896, KP171897, KP171898, KP171899, KP171900, KP171901, KP171902, KP171903, KP171904, KP171905, KP171906, KP171907, KP171908, KP171909, KP171910, KP171911, KP171912, KP171913, KP171914, KP171915, KP171916, KP171917, KP171918, KP171919, KP171920, KP171921, KP171922, KP171923, KP171924, KP171925, KP171926, KP171927, KP171928, KP171929, KP171930, KP171931, KP171932, KP171933, KP171934, KP171935, KP171936, KP171937, KP171938, KP171939, KP171940, KP171941, KP171942, KP171943, KP171944, KP171945, KP171946, KP171947, KP171948, KP171949, KP171950, KP171951, KP171952, KP171953, KP171954, KP171955, KP171956, KP171957, KP171958, KP171959, KP171960, KP171961, KP171962, KP171963, KP171964, KP171965, KP171966, KP171967, KP171968, KP171969, KP171970, KP171971, KP171972, KP171973, KP171974, KP171975, KP171976, KP171977, KP171978, KP171979, KP171980, KP171981, KP171982, KP171983, KP171984, KP171985, KP171986, KP171987, KP171988, KP171989, KP171990, KP171991, KP171992, KP171993, KP171994, KP171995, KP171996, KP171997, KP171998, KP171999, KP172000, KP172001, KP172002, KP172003, KP172004, KP172005, KP172006, KP172007, KP172008, KP172009, KP172010, KP172011, KP172012, KP172013, KP172014, KP172015, KP172016, KP172017, KP172018, KP172019, KP172020, KP172021, KP172022, KP172023, KP172024, KP172025, KP172026, KP172027, KP172028, KP172029, KP172030, KP172031, KP172032, KP172033, KP172034, KP172035, KP172036, KP172037, KP172038, KP172039, KP172040, KP172041, KP172042, KP172043, KP172044, KP172045, KP172046, KP172047, KP172048, KP172049, KP172050, KP172051, KP172052, KP172053, KP172054, KP172055, KP172056, KP172057, KP172058, KP172059, KP172060, KP172061, KP172062, KP172063, KP172064, KP172065, KP172066, KP172067, KP172068, KP172069, KP172070, KP172071, KP172072, KP172073, KP172074, KP172075, KP172076, KP172077, KP172078, KP172079, KP172080, KP172081, KP172082, KP172083, KP172084, KP172085, KP172086, KP172087, KP172088, KP172089, KP172090, KP172091, KP172092, KP172093, KP172094, KP172095, KP172096, KP172097, KP172098, KP172099, KP172100, KP172101, KP172102, KP172103, KP172104, KP172105, KP172106, KP172107, KP172108, KP172109, KP172110, KP172111, KP172112, KP172113, KP172114, KP172115, KP172116, KP172117, KP172118, KP172119, KP172120, KP172121, KP172122, KP172123, KP171124, KP172125, KP172126, KP172127, KP172128, KP172129, KP172130, KP172131, KP172132, KP172133, KP172134, KP172135, KP172136, KP172137, KP172138, KP172139, KP172140, KP172141, KP172142, KP172143, KP172144, KP172145, KP172146, KP172147, KP172148, KP172149, KP172150, KP172151, KP172152, KP172153, KP172154, KP172155, KP172156, KP172157, KP172158, KP172159, KP172160, KP172161, KP172162, KP172163, KP172164, KP172165, KP172166, KP172167, KP172168, KP172169, KP172170, KP172171, KP172172, KP172173, KP172174, KP172175, KP172176, KP172177, KP172178, KP172179, KP172180, KP172181, KP172182, KP172183, KP172184, KP172185, KP172186, KP172187, KP172188, KP172189, KP172190, KP172191, KP172192, KP172193, KP172194, KP172195, KP172196, KP172197, KP172198, KP172199, KP172200, KP172201, KP172202, KP172203, KP172204, KP172205, KP172206, KP172207, KP172208, KP172209, KP172210, KP172211, KP172212, KP172213, KP172214, KP172215, KP172216, KP172217, KP172218, KP172219, KP172220, KP172221, KP172222, KP172223, KP172224, KP172225, KP172226, KP172227, KP172228, KP172229, KP172230, KP172231, KP172232, KP172233, KP172234, KP172235, KP172236, KP172237, KP172238, KP172239, KP172240, KP172241, KP172242, KP172243, KP172244, KP172245, KP172246, KP172247, KP172248, KP172249, KP172250, KP172251, KP172252, KP172253, KP172254, KP172255, KP172256, KP172257, KP172258, KP172259, KP172260, KP172261, KP172262, KP172263, KP172264, KP172265, KP172266, KP172267, KP172268, KP172269, KP172270, KP172271, KP172272, KP172273, KP172274, KP172275, KP172276, KP172277, KP172278, KP172279, KP172280, KP172281, KP172282, KP172283, KP172284, KP172285, KP172286, KP172287, KP172288, KP172289, KP172290, KP172291, KP172292, KP172293, KP172294, KP172295, KP172296, KP172297, KP172298, KP172299, KP172300, KP172301, KP172302, KP172303, KP172304, KP172305, KP172306, KP172307, KP172308, KP172309, KP172310, KP172311, KP172312, KP172313, KP172314, KP172315, KP172316, KP172317, KP172318, KP172319, KP172320, KP172321, KP172322, KP172323, KP172324, KP172325, KP172326, KP172327, KP172328, KP172329, KP172330, KP172331, KP172332, KP172333, KP172334, KP172335, KP172336, KP172337, KP172338, KP172339, KP172340, KP172341, KP172342, KP172343, KP172344, KP172345, KP172346, KP172347, KP172348, KP172349, KP172350, KP172351, KP172352, KP172353, KP172354, KP172355, KP172356, KP172357, KP172358, KP172359, KP172360, KP172361, KP172362, KP172363, KP172364, KP172365, KP172366, KP172367, KP172368, KP172369, KP172370, KP172371, KP172372, KP172373, KP172374, KP172375, KP172376, KP172377, KP172378, KP172379, KP172380, KP172381, KP172382, KP172383, KP172384, KP172385, KP172386, KP172387, KP172388, KP172389, KP172390, KP172391, KP172392, KP172393, KP172394, KP172395, KP172396, KP172397, KP172398, KP172399, KP172400, KP172401, KP172402, KP172403, KP172404, KP172405, KP172406, KP172407, KP172408, KP172409, KP172410, KP172411, KP172412, KP172413, KP172414, KP172415, KP172416, KP172417, KP172418, KP172419, KP172420, KP172421, KP172422, KP172423, KP172424, KP172425, KP172426, KP172427, KP172428, KP172429, KP172430, KP172431, KP172432, KP172433, KP172434, KP172435, KP172436, KP172437, KP172438, KP172439, KP172440, KP172441, KP172442, KP172443, KP172444, KP172445, KP172446, KP172447, KP172448, KP172449, KP172450, KP172451, KP172452, KP172453, KP172454, KP172455, KP172456, KP172457, KP172458, KP172459, KP172460, KP172461, KP172462, KP172463, KP172464, KP172465, KP172466, KP172467, KP172468, KP172469, KP172470, KP172471, KP172472, KP172473, KP172474, KP172475, KP172476, KP172477, KP172478, KP172479, KP172480, KP172481, KP172482, KP172483, KP172484, KP172485, KP172486, KP172487, KP172488, KP172489, KP172490, KP172491, KP172492, KP172493, KP172494, KP172495, KP172496, KP172497, KP172498, KP172499, KP172500, KP172501, KP172502, KP172503, KP172504, KP172505, KP172506, KP172507, KP172508, KP172509, KP172510, KP172511, KP172512, KP172513, KP172514, KP172515, KP172516, KP172517, KP172518, KP172519, KP172520, KP172521, KP172522, KP172523, KP172524, KP172525, KP172526, KP172527, KP172528, KP172529, KP172530, KP172531, KP172532, KP172533, KP172534, KP172535, KP172536, KP172537, KP172538, KP172539, KP172540, KP172541, KP172542, KP172543, KP172544, KP172545, KP172546, KP172547, KP172548, KP172549, KP172550, KP172551, KP172552, KP172553, KP172554, KP172555, KP172556, KP172557, KP172558, KP172559, KP172560, KP172561, KP172562, KP172563, KP172564, KP172565, KP172566, KP172567, KP172568, KP172569, KP172570, KP172571, KP172572, KP172573, KP172574, KP172575, KP172576, KP172577, KP172578, KP172579, KP172580, KP172581, KP172582, KP172583, KP172584, KP172585, KP172586, KP172587, KP172588, KP172589, KP172590, KP172591, KP172592, KP172593, KP172594, KP172595, KP172596, KP172597, KP172598, KP172599, KP172600, KP172601, KP172602, KP172603, KP172604, KP172605, KP172606, KP172607, KP172608, KP172609, KP172610, KP172611, KP172612, KP172613, KP172614, KP172615, KP172616, KP172617, KP172618, KP172619, KP172620, KP172621, KP172622, KP172623, KP172624, KP172625, KP172626, KP172627, KP172628, KP172629, KP172630, KP172631, KP172632, KP172633, KP172634, KP172635, KP172636, KP172637, KP172638, KP172639, KP172640, KP172641, KP172642, KP172643, KP172644, KP172645, KP172646, KP172647, KP172648, KP172649, KP172650, KP172651, KP172652, KP172653, KP172654, KP172655, KP172656, KP172657, KP172658, KP172659, KP172660, KP172661, KP172662, KP172663, KP172664, KP172665, KP172666, KP172667, KP172668, KP172669, KP172670, KP172671, KP172672, KP172673, KP172674, KP172675, KP172676, KP172677, KP172678, KP172679, KP172680, KP172681, KP172682, KP172683, KP172684, KP172685, KP172686, KP172687, KP172688, KP172689, KP172690, KP172691, KP172692, KP172693, KP172694, KP172695, KP172696, KP172697, KP172698, KP172699, KP172700, KP172701, KP172702, KP172703, KP172704, KP172705, KP172706, KP172707, KP172708, KP172709, KP172710, KP172711, KP172712, KP172713, KP172714, KP172715, KP172716, KP172717, KP172718, KP172719, KP172720, KP172721, KP172722, KP172723, KP172724, KP172725, KP172726, KP172727, KP172728, KP172729, KP172730, KP172731, KP172732, KP172733, KP172734, KP172735, KP172736, KP172737, KP172738, KP172739, KP172740, KP172741, KP172742, KP172743, KP172744, KP172745, KP172746, KP172747, KP172748, KP172749, KP172750, KP172751, KP172752, KP172753, KP172754, KP172755, KP172756, KP172757, KP172758, KP172759, KP172760, KP172761, KP172762, KP172763, KP172764, KP172765, KP172766, KP172767, KP172768, KP172769, KP172770, KP172771, KP172772, KP172773, KP172774, KP172775, KP172776, KP172777, KP172778, KP172779, KP172780, KP172781, KP172782, KP172783, KP172784, KP172785, KP172786, KP172787, KP172788, KP172789, KP172790, KP172791, KP172792, KP172793, KP172794, KP172795, KP172796, KP172797, KP172798, KP172799, KP172800, KP172801, KP172802, KP172803, KP172804, KP172805, KP172806, KP172807, KP172808, KP172809, KP172810, KP172811, KP172812, KP172813, KP172814, KP172815, KP172816, KP172817, KP172818, KP172819, KP172820, KP172821, KP172822, KP172823",165
37593123,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences of the HIV-1 *pol* gene region were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022. These sequences were procured from both the National Center for AIDS/STD Control and Prevention, China CDC and the HIV sequence databases of the Los Alamos National Laboratory. The reference sequence for the study was HXB2.

Rationale: The paper explicitly mentions that sequences were obtained from patient samples, which is a key criterion for answering this question. The mention of ART-naïve HIV-positive individuals and the use of the HXB2 reference sequence further support this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, EC50, or cell-based susceptibility assays.

Rationale: The paper focuses on the analysis of HIV-1 subtypes/sub-subtypes and transmitted drug resistance (TDR) among ART-naïve HIV-infected individuals in China, without reporting any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to the HIV sequence databases of the Los Alamos National Laboratory, but does not provide any accession numbers.

Rationale: The paper mentions that sequences were submitted to a public database, but does not provide any further information about the accession numbers or the specific database used.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that sequences were submitted to the Los Alamos National Laboratory, but does not provide any accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 57,902 ART-naïve HIV-infected individuals were included in the study.

Rationale: The paper explicitly mentions the number of individuals included in the study, which is a key criterion for answering this question.

Answer: 57,902

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from China, specifically from 31 provincial-level administrative divisions.

Rationale: The paper explicitly mentions the country of origin for the sequenced samples, which is a key criterion for answering this question.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained between 2004 and 2022.

Rationale: The paper explicitly mentions the time period during which the samples were obtained, which is a key criterion for answering this question.

Answer: 2004-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper focuses on the analysis of HIV-1 subtypes/sub-subtypes and TDR, without mentioning any cloning of samples.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that sequences of the HIV-1 *pol* gene region were obtained.

Rationale: The paper explicitly mentions the specific gene region that was sequenced, which is a key criterion for answering this question.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention any specific sequencing method, but mentions that sequences were obtained from the HIV sequence databases of the Los Alamos National Laboratory.

Rationale: The paper does not provide any information about the sequencing method used, which is a key criterion for answering this question.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that sequences were obtained from plasma samples.

Rationale: The paper explicitly mentions the type of sample used for sequencing, which is a key criterion for answering this question.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included ART-naïve HIV-infected individuals, which implies that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the study included ART-naïve individuals, which is a key criterion for answering this question.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial, but mentions that the study was conducted in a observational setting.

Rationale: The paper explicitly mentions that the study was conducted in an observational setting, which is a key criterion for answering this question.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included ART-naïve HIV-infected individuals, which implies that the sequences were not obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included ART-naïve individuals, which is a key criterion for answering this question.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included ART-naïve HIV-infected individuals, which implies that the individuals had not received any ARV drugs before sample sequencing.

Rationale: The paper explicitly mentions that the study included ART-naïve individuals, which is a key criterion for answering this question.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included ART-naïve HIV-infected individuals, which implies that the individuals had not received any ARV drugs before sample sequencing.

Rationale: The paper explicitly mentions that the study included ART-naïve individuals, which is a key criterion for answering this question.

Answer: Not reported",20
37626789,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study obtained HIV sequences from patient samples. Additionally, the paper refers to various sequencing methods, including Sanger, Illumina, and MiSeq, which are commonly used for HIV sequencing. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay were performed. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions that phenotypic susceptibility assays were performed, which indicates that the study measured the susceptibility of HIV to various antiretroviral drugs in vitro. Additionally, the paper reports values such as IC50, EC50, and EC90, which are commonly used to measure drug susceptibility. The paper also mentions specific platforms, such as PhenoSense and Monogram, which are used for in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to public databases, including GenBank and SRA, which suggests that the sequences are publicly available. The paper also reports accession numbers, which are unique identifiers for the sequences in these databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including FJ800379–FJ800386, GQ477441-GQ477451, and KP170487.

Rationale: The paper explicitly reports accession numbers for GenBank, which are used to identify the sequences in the database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing, genotyping, or sequencing was performed on samples from 551 HIV-positive children.

Rationale: The paper explicitly states that genotypic resistance testing was performed on samples from 551 HIV-positive children, which indicates that the study obtained samples from 551 individuals.

Answer: 551

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Ethiopia, and samples were collected from children taking HAART at 40 antiretroviral treatment delivery sites in the country.

Rationale: The paper explicitly mentions that the study was conducted in Ethiopia and that samples were collected from children taking HAART at various treatment delivery sites in the country.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between 2007 and 2019, and samples were collected over a 12-year follow-up period.

Rationale: The paper explicitly states that the study was conducted between 2007 and 2019, which indicates that the samples were obtained over a 12-year period.

Answer: 2007-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced, and that TA cloning/Topo TA cloning was performed.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which indicates that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol gene region was sequenced, including the protease and reverse transcriptase regions.

Rationale: The paper explicitly mentions that the pol gene region was sequenced, which includes the protease and reverse transcriptase regions.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was performed using ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly mentions that Sanger sequencing was performed using ABI instruments and BigDye/ABI PRISM Dye Terminator, which are commonly used for Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that whole blood was collected from children, and plasma was extracted using centrifugation.

Rationale: The paper explicitly mentions that whole blood was collected from children and that plasma was extracted using centrifugation, which indicates that the samples were plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that virologic failure (VF) was defined as two consecutive plasma viral loads ≥ 1000 copies/mL within 6 months of follow-up.

Rationale: The paper explicitly mentions that VF was defined as two consecutive plasma viral loads ≥ 1000 copies/mL within 6 months of follow-up, which indicates that the study obtained sequences from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was part of a national cohort study on HIV-1 treatment failure and acquired drug resistance among people taking ART at 63 health facilities in the country.

Rationale: The paper explicitly mentions that the study was part of a national cohort study, which suggests that the study was observational rather than a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included children who were taking HAART for at least six months, and that the study aimed to evaluate HIV-1 disease progression and drug resistance among children on first-line antiretroviral therapy.

Rationale: The paper explicitly mentions that the study included children who were taking HAART for at least six months, which indicates that the study obtained sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included children who were taking HAART for at least six months, and that the study aimed to evaluate HIV-1 disease progression and drug resistance among children on first-line antiretroviral therapy.

Rationale: The paper explicitly mentions that the study included children who were taking HAART for at least six months, which indicates that the study obtained sequences from individuals who had previously received NRTIs.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included children who were taking HAART for at least six months, and that the study aimed to evaluate HIV-1 disease progression and drug resistance among children on first-line antiretroviral therapy.

Rationale: The paper explicitly mentions that the study included children who were taking HAART for at least six months, which indicates that the study obtained sequences from individuals who had previously received various antiretroviral drugs, including AZT, 3TC, FTC, TDF, ABC, and EFV.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV",27
37632026,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper clearly states that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers also suggests that the sequences were submitted to a public database, which is a common practice for sharing research data.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions that the assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. The paper also describes cell-based susceptibility assays with drug titrations and reporter readouts.

Rationale: The paper mentions specific terms related to in vitro drug susceptibility testing, such as phenotypic susceptibility and drug susceptibility assay. The mention of IC50, EC50, EC90, and fold-change in susceptibility also suggests that the paper reports in vitro susceptibility data. The description of cell-based susceptibility assays with drug titrations and reporter readouts further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also reports accession numbers for GenBank or any of the above databases. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly states that sequences were submitted to public databases, which is a common practice for sharing research data. The mention of accession numbers also suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for GenBank. The accession numbers are listed as ""MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958"".

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers for GenBank. The accession numbers are listed in the paper, which allows for the extraction of the ranges and individual accession numbers.

Answer: MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 759 individuals.

Rationale: The paper explicitly states that genotypic resistance testing, genotyping, or sequencing was performed on samples from 759 individuals, which indicates that 759 individuals had samples obtained for HIV sequencing.

Answer: 759

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in Cameroon.

Rationale: The paper explicitly states that samples were collected in Cameroon, which indicates that the sequenced samples were obtained from Cameroon.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that clinical samples were collected between 2011 and 2019.

Rationale: The paper explicitly states that clinical samples were collected between 2011 and 2019, which indicates that the sequenced samples were obtained during this time period.

Answer: 2011-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper explicitly states that amplicons were cloned and sequenced, which indicates that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""pol genotyping/sequencing"" was performed, which suggests that the pol gene was sequenced. The paper also mentions that the ""pol region encompassing protease and reverse transcriptase"" was sequenced, which further supports this conclusion.

Rationale: The paper explicitly states that pol genotyping/sequencing was performed, which suggests that the pol gene was sequenced. The mention of the pol region encompassing protease and reverse transcriptase also supports this conclusion.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which suggests that Sanger sequencing was used.

Rationale: The paper explicitly mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which are commonly used for Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions that ""PBMC"", ""peripheral blood mononuclear cells"", ""proviral DNA"", ""cell-associated DNA/RNA"" were used for sequencing.

Rationale: The paper explicitly states that viral RNA was extracted from plasma, which suggests that plasma samples were used for sequencing. The mention of PBMC and proviral DNA also supports this conclusion.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""virologic or virological failure (VF)"" or ""failing therapy or regimen"" was observed in some individuals. The paper also mentions that sequencing or genotyping were done for participants with VL >50 copies/mL while on ART.

Rationale: The paper explicitly states that virologic or virological failure was observed in some individuals, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"" were observed in some individuals.

Rationale: The paper explicitly states that some individuals had previously received ARV drugs, which suggests that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""NRTI"", ""PI"", ""NRTI"", ""INSTI"" were received by some individuals. The paper also mentions that specific ARV drugs such as ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", or ""lenacapavir"" were received by some individuals.

Rationale: The paper explicitly states that some individuals received NRTI, PI, and INSTI, which suggests that these drug classes were received by individuals in the study before sample sequencing. The mention of specific ARV drugs also supports this conclusion.

Answer: NRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", or ""lenacapavir"" were received by some individuals.

Rationale: The paper explicitly states that some individuals received these specific ARV drugs, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",33
37632071,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to various sequencing methods, including genotypic resistance testing, Sanger sequencing, and Illumina sequencing, which further supports the conclusion that the study involved sequencing of patient samples. The mention of GenBank accession numbers also suggests that the sequences were generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results sections focus on sequencing and genotyping, but do not report any in vitro susceptibility data.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve in vitro susceptibility testing. The focus on sequencing and genotyping also supports this conclusion.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and provides accession numbers for the sequences. The paper also mentions that the raw reads are in the SRA database.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The provision of accession numbers also supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly provides accession numbers for the sequences, which suggests that the sequences are publicly available in GenBank.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 329 PLWH had plasma HIV RNA that was undetectable or <50 copies/mL at T0, and 197 patients were included in the study.

Rationale: The paper explicitly states that 329 PLWH had plasma HIV RNA that was undetectable or <50 copies/mL at T0, and 197 patients were included in the study.

Answer: 197

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the samples were obtained, but mentions that the study was conducted in Italy.

Rationale: The paper does not explicitly mention the countries from which the samples were obtained, but mentions that the study was conducted in Italy.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2019 and 2022.

Rationale: The paper explicitly states that the samples were collected between 2019 and 2022.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which suggests that the study did not involve cloning of samples.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region was sequenced, including the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions that the pol region was sequenced, including the protease and reverse transcriptase genes.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used, as well as Illumina sequencing.

Rationale: The paper explicitly mentions that Sanger sequencing and Illumina sequencing were used.

Answer: Sanger sequencing, Illumina sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included patients who were experiencing virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the study included patients who were experiencing virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included patients who were treatment-experienced.

Rationale: The paper explicitly mentions that the study included patients who were treatment-experienced.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were treatment-experienced, which suggests that they had received NRTIs.

Rationale: The paper explicitly mentions that the patients were treatment-experienced, which suggests that they had received NRTIs.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were receiving a regimen that included TDF/FTC.

Rationale: The paper explicitly mentions that the patients were receiving a regimen that included TDF/FTC.

Answer: TDF, FTC",21
37649807,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that viral RNA was extracted from plasma, and sequencing was performed on clinical samples from patients. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger, Illumina, and MiSeq.

Rationale: The paper explicitly mentions the extraction of viral RNA from plasma and the performance of sequencing on clinical samples from patients. Additionally, the paper mentions various sequencing methods, including Sanger, Illumina, and MiSeq, which are commonly used for sequencing patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper also does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility or resistance testing, or report any values related to drug susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper also does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not mention making sequences publicly available or providing accession numbers for GenBank or other databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention submitting sequences to GenBank or providing accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 793,902 records from clients aged ≥15 years who initiated ART during 2015-2021 had all VL tests done using plasma and had at least one VL after 24 weeks on ART were included in the descriptive analysis of VL test outcomes.

Rationale: The paper provides a total number of records included in the analysis, which is 793,902.

Answer: 793,902

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that clinical samples were collected between 2015 and 2021.

Rationale: The paper provides a specific time period for the collection of clinical samples.

Answer: 2015-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using TA cloning/Topo TA cloning.

Rationale: The paper does not mention any cloning methods or techniques.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention sequencing specific HIV genes, such as pol, gag, or env.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina sequencing.

Rationale: The paper explicitly mentions Sanger sequencing and Illumina sequencing as the methods used for sequencing.

Answer: Sanger sequencing and Illumina sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper explicitly mentions the extraction of viral RNA from plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that patients were enrolled in the study if they had virologic or virological failure (VF) or failing therapy or regimen.

Rationale: The paper explicitly mentions the inclusion of patients with virologic or virological failure (VF) or failing therapy or regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or randomized controlled trial.

Rationale: The paper does not provide any information about a clinical trial or randomized controlled trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that patients were on ART/cART/HAART and had received prior ARV exposure/regimens.

Rationale: The paper explicitly mentions patients who were on ART/cART/HAART and had received prior ARV exposure/regimens.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients were on ART/cART/HAART and had received prior ARV exposure/regimens.

Rationale: The paper explicitly mentions patients who were on ART/cART/HAART and had received prior ARV exposure/regimens.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients were on ART/cART/HAART and had received prior ARV exposure/regimens.

Rationale: The paper explicitly mentions patients who were on ART/cART/HAART and had received prior ARV exposure/regimens.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, DTG, CAB, LEN",19
37662576,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions sequencing of clinical samples, which is a strong indication that HIV sequences from patient samples were reported. Additionally, the mention of ART-naïve and ART-experienced patients, baseline and virologic failure samples, and transmitted drug resistance surveillance further supports the conclusion that HIV sequences from patient samples were reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions cell-based susceptibility assays are described \(e.g., TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293\) with drug titrations and reporter readouts \(luciferase, p24, RT activity\).

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all indicators of in vitro drug susceptibility data. Additionally, the mention of IC50, EC50, EC90, fold-change in susceptibility, and reduced susceptibility further supports the conclusion that in vitro drug susceptibility data were reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which is a strong indication that sequences were made publicly available. Additionally, the mention of accession numbers further supports the conclusion that sequences were deposited in public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions accession numbers, which are a unique identifier for sequences deposited in public databases. The accession numbers are used to identify the sequences and provide a link to the sequence data.

Answer: Not reported (no specific accession numbers mentioned in the paper)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper explicitly mentions the number of individuals from whom samples were obtained for HIV sequencing. The mention of X sequences from Y individuals further supports the conclusion that the number of individuals is X.

Answer: Not reported (no specific number mentioned in the paper)

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country\&gt;. The paper mentions nationwide “cohort” or “surveillance” or “registry” in &lt;country\&gt; or “national reference laboratory” of &lt;country\&gt;.

Rationale: The paper explicitly mentions the country from which the samples were obtained. The mention of a nationwide cohort or surveillance or registry further supports the conclusion that the samples were obtained from a specific country.

Answer: Not reported (no specific country mentioned in the paper)

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between &lt;Year1\&gt; to &lt;Year2\&gt; or &lt;Month/Year1\&gt; to &lt;Month/Year2\&gt;. The paper lists per-year counts \(“collected in 2008, 2009, 2010…”\).

Rationale: The paper explicitly mentions the year range from which the samples were obtained. The mention of per-year counts further supports the conclusion that the samples were obtained over a specific time period.

Answer: Not reported (no specific year range mentioned in the paper)

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit \(e.g., NEB PCR cloning kit\).

Rationale: The paper explicitly mentions cloning of amplicons before sequencing, which is a strong indication that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper mentions sequencing of the “pol region encompassing protease and reverse transcriptase”, “PR/RT”, “ViroSeq”, or “TruGene \(PR/RT\)”.

Rationale: The paper explicitly mentions sequencing of the pol gene, which includes the protease and reverse transcriptase genes. The mention of PR/RT, ViroSeq, or TruGene further supports the conclusion that the protease and reverse transcriptase genes were sequenced.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments \(ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant\) or Beckman CEQ 2000 XL. The paper mentions BigDye/ABI PRISM Dye Terminator \(v1.0/v3.0/v3.1\), dye-terminator, dye–deoxy chain terminator, or dideoxy sequencing.

Rationale: The paper explicitly mentions the use of ABI instruments and BigDye/ABI PRISM Dye Terminator, which are indicators of Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”. The paper mentions sequencing of “PBMC”, “peripheral blood mononuclear cells”, “proviral DNA”, “cell-associated DNA/RNA”.

Rationale: The paper explicitly mentions sequencing of plasma and PBMC samples, which are common types of samples used for HIV sequencing.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”. The paper mentions sequencing or genotyping were done for participants with VL \&gt;50 copies/mL while on ART.

Rationale: The paper explicitly mentions virological failure and failing therapy or regimen, which are indicators that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper mentions “phase I/II/III/IIIb/2/3 trial” or “analytical treatment interruption \(ATI\) within a trial”.

Rationale: The paper explicitly mentions randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter trials, which are indicators that the patients were in a clinical trial.

Answer: Not reported (no specific information mentioned in the paper)

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper uses phrases like “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper states “virologic failure/failing therapy while receiving \[drug/regimen\]”, “second-line/third-line/switch”, “ritonavir-boosted PI as second-line”, or “salvage”.

Rationale: The paper explicitly mentions ART-experienced, treatment-experienced, heavily pretreated, salvage regimen, and prior ARV exposure/regimens, which are indicators that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states “treatment-naïve”, “ART-naïve”, “drug-naïve”, “never exposed to antiretrovirals”, “before ART initiation”, “pre-ART”, “newly diagnosed”, “seroconverter”, “blood donor”, “primary/acute infection without ART”, or samples collected “at diagnosis/baseline prior to therapy”. The paper mentions specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper explicitly mentions treatment-naïve, ART-naïve, drug-naïve, and never exposed to antiretrovirals, which are indicators that the individuals had not received any ARV drugs. The mention of specific ARV drugs further supports the conclusion that the individuals had received ARV drugs.

Answer: Not reported (no specific information mentioned in the paper)

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states “virologic failure/failing therapy while receiving \[drug/regimen\]”, “second-line/third-line/switch”, “ritonavir-boosted PI as second-line”, or “salvage”. The paper mentions specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper explicitly mentions virologic failure/failing therapy while receiving a drug/regimen, second-line/third-line/switch, ritonavir-boosted PI as second-line, or salvage, which are indicators that the individuals had received ARV drugs. The mention of specific ARV drugs further supports the conclusion that the individuals had received ARV drugs.

Answer: Not reported (no specific information mentioned in the paper)",41
37674678,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that the sequences were obtained from patient samples. The mention of genotypic resistance testing, HIV sequencing, and Sanger sequencing also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only mentions genotypic resistance testing and sequencing.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that it does not report this type of data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public repository. However, the paper does mention that the data will be made publicly available in an acceptable repository prior to publication.

Rationale: The paper does not provide any information on the deposition of sequences in public repositories, which suggests that the sequences may not have been made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the accession numbers may not have been provided.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1,393 ART-naïve individuals were enrolled in the study, and 1,161 sequences were successfully amplified.

Rationale: The paper explicitly mentions the number of individuals enrolled in the study and the number of sequences successfully amplified.

Answer: 1,161

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples. However, the paper mentions that the study was conducted in Nanjing, China.

Rationale: The paper does not provide any information on the country of origin for the sequenced samples, which suggests that the country may not have been reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between January 2019 and December 2021.

Rationale: The paper explicitly mentions the start and end dates of the study.

Answer: 2019-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on cloning of samples, which suggests that cloning may not have been performed.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol gene was sequenced.

Rationale: The paper explicitly mentions the pol gene as the target of sequencing.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly mentions Sanger sequencing as the method used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions plasma samples as the source of sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the study included individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information on the study being a clinical trial, which suggests that it may not have been a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included individuals who had previously received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions that the study included individuals who had previously received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included individuals who had previously received AZT, 3TC, FTC, TDF, ABC, d4T, ddI, EFV, NVP, RPV, DOR, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN.

Rationale: The paper explicitly mentions the specific drugs that were received by individuals in the study.

Answer: AZT, 3TC, FTC, TDF, ABC, d4T, ddI, EFV, NVP, RPV, DOR, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN",21
37701387,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" were performed on clinical samples from patients. The paper also states that sequences were generated in this study and reports ""GenBank accession numbers"" for sequences.

Rationale: The paper explicitly mentions genotypic resistance testing, genotyping, and sequencing, which are all methods used to analyze HIV sequences from patient samples. Additionally, the paper reports GenBank accession numbers, which are used to identify and access the sequences in a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility testing or cell-based susceptibility assays.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not report any in vitro susceptibility data. This suggests that the paper is primarily focused on analyzing HIV sequences and resistance patterns, rather than testing the susceptibility of HIV isolates to different drugs.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to a public database, such as GenBank, or providing accession numbers.

Rationale: The paper does not provide any information about making the sequences publicly available, such as submitting them to a database or providing accession numbers.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention submitting sequences to a public database, such as GenBank, or providing accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who participated in the study or had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the countries where the sequenced samples were obtained.

Rationale: The paper does not mention the countries where the samples were collected or the study was conducted.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the years when the sequenced samples were obtained.

Rationale: The paper does not mention the years when the samples were collected or the study was conducted.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information about cloning samples prior to sequencing.

Rationale: The paper does not mention cloning samples prior to sequencing, which suggests that the sequencing was likely performed directly on the samples.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not provide any information about the specific HIV genes that were sequenced.

Rationale: The paper does not mention the specific genes that were sequenced, but it does mention ""pol genotyping/sequencing"" which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not provide any information about the sequencing method used.

Rationale: The paper does not mention the sequencing method used, which suggests that the method was not explicitly stated.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" as the type of sample that was sequenced.

Rationale: The paper explicitly mentions ""plasma"" as the type of sample that was sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not provide any information about sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information about the study being a clinical trial.

Rationale: The paper does not mention the study being a clinical trial, which suggests that it was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" patients, but does not provide any information about the specific ARV drugs that they received.

Rationale: The paper mentions ""ART-experienced"" patients, which suggests that they had previously received ARV drugs, but it does not provide any information about the specific drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""ART-experienced"" patients, but does not provide any information about the specific drug classes that they received.

Rationale: The paper mentions ""ART-experienced"" patients, which suggests that they had previously received ARV drugs, but it does not provide any information about the specific drug classes.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""ART-experienced"" patients, but does not provide any information about the specific drugs that they received.

Rationale: The paper mentions ""ART-experienced"" patients, which suggests that they had previously received ARV drugs, but it does not provide any information about the specific drugs.

Answer: Not reported",18
37716367,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" were performed on clinical samples from patients. The paper also reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly states that genotypic resistance testing, genotyping, and sequencing were performed on clinical samples from patients. This indicates that the study involved analyzing HIV sequences from patient samples. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"" and ""drug susceptibility assay"" in the methods section. The paper also reports values such as IC50 and EC50 in the results section.

Rationale: The paper explicitly states that phenotypic susceptibility and drug susceptibility assays were performed. This indicates that the study involved measuring the susceptibility of HIV to antiretroviral drugs in vitro. The reporting of IC50 and EC50 values further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database. The provision of accession numbers further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for the sequences, including ""SRP075904"" and ""KX247148"".

Rationale: The paper explicitly provides accession numbers for the sequences, which can be used to retrieve the sequences from the GenBank database.

Answer: SRP075904, KX247148

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 1138 HIV-positive adults were included in the study.

Rationale: The paper explicitly states that 1138 HIV-positive adults were included in the study, which suggests that samples were obtained from these individuals.

Answer: 1138

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Taiwan.

Rationale: The paper explicitly states that the study was conducted in Taiwan, which suggests that the sequenced samples were obtained from this country.

Answer: Taiwan

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between 2012 and 2016.

Rationale: The paper explicitly states that the study was conducted between 2012 and 2016, which suggests that the sequenced samples were obtained during this time period.

Answer: 2012-2016

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""amplicons were cloned and sequenced"" in the methods section.

Rationale: The paper explicitly states that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" in the methods section.

Rationale: The paper explicitly states that pol genotyping/sequencing was performed, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""ABI PRISM"" and ""BigDye"" in the methods section.

Rationale: The paper explicitly states that ABI PRISM and BigDye were used for sequencing, which suggests that Sanger sequencing was performed.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"" in the methods section.

Rationale: The paper explicitly states that plasma and PBMC samples were used for sequencing, which suggests that these types of samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"" in the results section.

Rationale: The paper explicitly states that sequences were obtained from individuals with virologic failure and failing therapy, which suggests that these sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""randomized"" and ""double-blind"" in the methods section.

Rationale: The paper explicitly states that the study was randomized and double-blind, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"" in the methods section.

Rationale: The paper explicitly states that ART-experienced and treatment-experienced individuals were included in the study, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"" and ""NNRTI"" in the methods section.

Rationale: The paper explicitly states that NRTI and NNRTI were used in the study, which suggests that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""AZT"" and ""3TC"" in the methods section.

Rationale: The paper explicitly states that AZT and 3TC were used in the study, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC",20
37755428,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper only reports genotypic resistance testing and sequencing results.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve testing the susceptibility of HIV isolates to antiretroviral drugs in vitro.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The accession numbers provided in the text also support this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""KP170487"".

Rationale: The paper explicitly states that sequences were submitted to GenBank, and accession numbers are provided in the text.

Answer: KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 143 (52%) of the infants tested positive for HIV, and 121 (85%) and 105 (73%) yielded a successful quality-assured genotype for protease/reverse transcriptase (PR/RT) and integrase regions, respectively.

Rationale: The paper reports the number of infants who tested positive for HIV and the number of successful genotypes obtained.

Answer: 143

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Haiti.

Rationale: The paper explicitly states that the study was conducted in Haiti.

Answer: Haiti

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between April 2020 and March 2021.

Rationale: The paper explicitly states the time period during which the study was conducted.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which suggests that the study did not involve cloning of samples.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the study sequenced the protease/reverse transcriptase (PR/RT) and integrase regions.

Rationale: The paper explicitly states that the study sequenced the PR/RT and integrase regions.

Answer: PR/RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the study used Sanger sequencing.

Rationale: The paper explicitly states that the study used Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that the study used dried blood spot specimens.

Rationale: The paper explicitly states that the study used dried blood spot specimens.

Answer: DBS

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the study included sequences from infants who were failing therapy or had virological failure.

Rationale: The paper explicitly states that the study included sequences from infants who were failing therapy or had virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not mention any clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study included sequences from infants who had received antiretroviral therapy.

Rationale: The paper explicitly states that the study included sequences from infants who had received antiretroviral therapy.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included sequences from infants who had received tenofovir/lamivudine/dolutegravir.

Rationale: The paper explicitly states that the study included sequences from infants who had received tenofovir/lamivudine/dolutegravir.

Answer: NRTI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included sequences from infants who had received tenofovir, lamivudine, and dolutegravir.

Rationale: The paper explicitly states that the study included sequences from infants who had received tenofovir, lamivudine, and dolutegravir.

Answer: Tenofovir, Lamivudine, Dolutegravir",19
37775947,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV samples from patient samples. Additionally, the paper mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. The paper also reports GenBank accession numbers, which suggests that the sequences were deposited in a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of drug susceptibility. Additionally, the paper mentions specific platforms used for drug susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper also reports accession numbers, which are unique identifiers for the sequences deposited in these databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly reports accession numbers for GenBank, which are unique identifiers for the sequences deposited in the database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 1380 individuals.

Rationale: The paper explicitly mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from 1380 individuals, which indicates that the study involved sequencing of HIV samples from 1380 individuals.

Answer: 1380

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in ""South America"", ""Europe"", ""USA"", ""Africa"".

Rationale: The paper explicitly mentions that samples were collected in specific countries, which indicates that the study involved sequencing of HIV samples from these countries.

Answer: South America, Europe, USA, Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that clinical samples were collected between ""2009"" and ""2013"".

Rationale: The paper explicitly mentions that clinical samples were collected between 2009 and 2013, which indicates that the study involved sequencing of HIV samples from this time period.

Answer: 2009-2013

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"".

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which indicates that the study involved cloning of HIV samples prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""pol genotyping/sequencing"" was performed, which includes the ""protease"" and ""reverse transcriptase"" genes.

Rationale: The paper explicitly mentions that pol genotyping/sequencing was performed, which includes the protease and reverse transcriptase genes.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""Sanger sequencing"" was used, which involves the use of ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which involves the use of ABI instruments and BigDye/ABI PRISM Dye Terminator.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""plasma"" samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which indicates that the study involved sequencing of HIV samples from plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""virologic or virological failure (VF)"" was observed in some individuals.

Rationale: The paper explicitly mentions that virologic or virological failure (VF) was observed in some individuals, which indicates that the study involved sequencing of HIV samples from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a ""randomized"", ""double-blind"", ""placebo-controlled"" trial.

Rationale: The paper explicitly mentions that the study was a randomized, double-blind, placebo-controlled trial, which indicates that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""ART-experienced"" individuals were included in the study.

Rationale: The paper explicitly mentions that ART-experienced individuals were included in the study, which indicates that the study involved sequencing of HIV samples from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""NRTI"", ""NNRTI"", ""PI"", ""INSTI"" were received by individuals in the study.

Rationale: The paper explicitly mentions that NRTI, NNRTI, PI, INSTI were received by individuals in the study, which indicates that the study involved sequencing of HIV samples from individuals who had received these drug classes.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""tenofovir"", ""lamivudine"", ""efavirenz"", ""raltegravir"" were received by individuals in the study.

Rationale: The paper explicitly mentions that tenofovir, lamivudine, efavirenz, raltegravir were received by individuals in the study, which indicates that the study involved sequencing of HIV samples from individuals who had received these drugs.

Answer: Tenofovir, Lamivudine, Efavirenz, Raltegravir",27
37817087,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that viral RNA was isolated from the sample material (serum, plasma or spot elution) using the automated Biomerieux EasyMag platform. The RNA was subsequently quantified and transcribed into cDNA. The cDNA then served as a template for the amplification of three regions of the HIV genome, which contain all major resistance-associated positions.

Rationale: The paper mentions that viral RNA was isolated from serum, plasma, or spot elution, which indicates that the sequences were obtained from patient samples. Additionally, the paper states that the RNA was transcribed into cDNA and amplified, which suggests that the sequences were generated from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. It only reports on the genotypic resistance testing and sequencing of HIV-1 isolates.

Rationale: The paper focuses on the genotypic resistance testing and sequencing of HIV-1 isolates, but it does not provide any information on in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that all datasets including sequences are available from the corresponding author upon reasonable request.

Rationale: The paper explicitly states that the sequences are available from the corresponding author, which suggests that the sequences have been made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 4559 new HIV diagnoses were reported to the RKI, and PR and RT sequences were obtained from 4559 (39.6%) cases.

Rationale: The paper provides the total number of new HIV diagnoses reported to the RKI and the number of cases from which PR and RT sequences were obtained.

Answer: 4559

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the countries from which the sequenced samples were obtained. However, it mentions that the study was conducted in Germany.

Rationale: The paper mentions that the study was conducted in Germany, but it does not provide information on the countries from which the sequenced samples were obtained.

Answer: Germany

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from 2017 to 2020.

Rationale: The paper provides the time period during which the study was conducted.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the genomic regions of protease (PR, amino acids 9--99), reverse transcriptase (RT, amino acids 1-252), and integrase (IN, amino acids 1-279) were amplified and sequenced.

Rationale: The paper explicitly states that the PR, RT, and IN regions were amplified and sequenced.

Answer: PR, RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the RNA was isolated using the automated Biomerieux EasyMag platform and then amplified using PCR.

Rationale: The paper mentions the use of the Biomerieux EasyMag platform and PCR for amplification, which suggests that the sequencing method was NGS.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was isolated from serum, plasma, or spot elution.

Rationale: The paper explicitly states that the RNA was isolated from serum, plasma, or spot elution.

Answer: Plasma, serum, spot elution

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information on sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials.

Rationale: The paper does not provide any information on clinical trials.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that 4559 new HIV diagnoses were reported to the RKI, and PR and RT sequences were obtained from 4559 (39.6%) cases. The paper also mentions that the patients were ART-experienced.

Rationale: The paper provides the total number of new HIV diagnoses reported to the RKI and mentions that the patients were ART-experienced.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information on the drug classes received by the individuals in the study before sample sequencing.

Rationale: The paper does not provide any information on the drug classes received by the individuals in the study before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information on the specific drugs received by the individuals in the study before sample sequencing.

Rationale: The paper does not provide any information on the specific drugs received by the individuals in the study before sample sequencing.

Answer: Not reported",19
37823653,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that sequences were generated by a long-range HIV genotyping protocol described elsewhere with minor modifications that included a reduced annealing temperature (58°C instead of 62°C) as a backup amplification strategy and using the first-round amplicon as a template for next-generation sequencing (NGS). The paper reports that viral sequences were generated from PWH aged 16--64 years residing in 30 communities in northern, central, and southern parts of Botswana.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper describes a long-range HIV genotyping protocol that involves amplifying and sequencing HIV DNA from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters.

Rationale: The paper does not mention any in vitro drug susceptibility data or assays, which suggests that it does not report in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, but the accession numbers are not provided in the text. The paper also mentions that the sequences were generated by a long-range HIV genotyping protocol described elsewhere with minor modifications.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that they were made publicly available. However, the accession numbers are not provided, which makes it difficult to verify this information.

Answer: Yes, but accession numbers are not provided

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper mentions that sequences were submitted to GenBank, but the accession numbers are not provided in the text.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a total of 6,078 HIV-1 near full-length sequences were generated for the BCPP study. Of the 6,078 participants with HIV-1 sequences, 48 participants had no ART status and were thus left out from the analysis. Of the remaining 6,030 participants, 1,282 participants were ART naïve and 4,748 were ART experienced.

Rationale: The paper provides the total number of participants with HIV-1 sequences, which is 6,078. However, it also mentions that 48 participants had no ART status and were left out from the analysis, which reduces the number of participants to 6,030.

Answer: 6,030

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted in Botswana, and the samples were collected from PWH residing in 30 communities in northern, central, and southern parts of Botswana.

Rationale: The paper explicitly mentions that the study was conducted in Botswana and that the samples were collected from PWH residing in Botswana.

Answer: Botswana

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the samples were collected between 2013 and 2018.

Rationale: The paper provides the year range during which the samples were collected, which is 2013-2018.

Answer: 2013-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper describes a long-range HIV genotyping protocol that involves amplifying and sequencing HIV DNA from patient samples. The paper does not mention any cloning steps prior to sequencing.

Rationale: The paper describes a long-range HIV genotyping protocol that involves amplifying and sequencing HIV DNA from patient samples, but it does not mention any cloning steps prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the sequences were generated from the gp120 fragment of the HIV envelope gene.

Rationale: The paper explicitly mentions that the sequences were generated from the gp120 fragment of the HIV envelope gene.

Answer: Env

**Question 10: What method was used for sequencing?**

Evidence: The paper reports that the sequences were generated by a long-range HIV genotyping protocol described elsewhere with minor modifications that included a reduced annealing temperature (58°C instead of 62°C) as a backup amplification strategy and using the first-round amplicon as a template for next-generation sequencing (NGS).

Rationale: The paper describes a long-range HIV genotyping protocol that involves amplifying and sequencing HIV DNA from patient samples using NGS.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that the sequences were generated from PWH aged 16--64 years residing in 30 communities in northern, central, and southern parts of Botswana. The paper also mentions that the samples were collected from PWH residing in Botswana.

Rationale: The paper explicitly mentions that the samples were collected from PWH residing in Botswana.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the study included individuals who were ART experienced with virologic failure (VF) (VL >400). The paper also mentions that the sequences were generated from PWH who were experiencing VF on ART.

Rationale: The paper explicitly mentions that the study included individuals who were ART experienced with VF.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or randomized controlled trials. The paper reports that the study was a retrospective cross-sectional study utilizing already generated HIV-1 sequences.

Rationale: The paper does not mention any clinical trials or randomized controlled trials, which suggests that the study was not conducted within a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study included individuals who were ART experienced. The paper also mentions that the sequences were generated from PWH who were receiving ART.

Rationale: The paper explicitly mentions that the study included individuals who were ART experienced.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included individuals who were ART experienced. The paper also mentions that the sequences were generated from PWH who were receiving ART.

Rationale: The paper explicitly mentions that the study included individuals who were ART experienced.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included individuals who were ART experienced. The paper also mentions that the sequences were generated from PWH who were receiving ART.

Rationale: The paper explicitly mentions that the study included individuals who were ART experienced.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, CAB, LEN",24
37872202,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions sequencing on clinical samples, which suggests that the sequences were obtained from patient samples. The mention of ART-naïve and ART-experienced patients, baseline and virologic failure samples, and transmitted drug resistance surveillance also suggests that the sequences were obtained from patient samples. The report of GenBank accession numbers further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility and resistance testing, which suggests that the study measured the susceptibility of HIV to antiretroviral drugs in vitro. The report of IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility values further supports this conclusion. The mention of cell-based susceptibility assays also supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper mentions that the sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that the sequences were submitted to public databases, which suggests that the sequences are publicly available. The report of accession numbers for GenBank or other databases further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”. The paper mentions that the sequences have been deposited or made available in a sequence database.

Rationale: The paper reports accession numbers for GenBank, which suggests that the sequences are publicly available. The mention of accession numbers for specific sequences further supports this conclusion.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from X number of individuals, which suggests that X individuals had samples obtained for HIV sequencing. The report of X sequences from Y individuals further supports this conclusion.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in Thailand. The paper mentions nationwide “cohort” or “surveillance” or “registry” in Thailand.

Rationale: The paper mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in Thailand, which suggests that the samples were obtained from Thailand. The mention of a nationwide cohort or surveillance or registry in Thailand further supports this conclusion.

Answer: Thailand

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2004 and 2007. The paper lists per-year counts, such as “collected in 2008, 2009, 2010”.

Rationale: The paper reports that clinical samples were collected between 2004 and 2007, which suggests that the samples were obtained between 2004 and 2007. The list of per-year counts further supports this conclusion.

Answer: 2004–2007

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”. The paper mentions “single-genome amplification \(SGA\)”, “single-proviral sequencing”, or “limiting dilution for direct sequencing”.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing. The mention of TA cloning, Topo TA cloning, SGA, single-proviral sequencing, or limiting dilution for direct sequencing further supports this conclusion.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper mentions “pol region encompassing protease and reverse transcriptase”, “PR/RT”, “ViroSeq”, or “TruGene \(PR/RT\)"".

Rationale: The paper mentions pol genotyping/sequencing, which suggests that the pol gene was sequenced. The mention of the pol region encompassing protease and reverse transcriptase, PR/RT, ViroSeq, or TruGene further supports this conclusion.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments, BigDye/ABI PRISM Dye Terminator, capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms. The paper mentions Illumina platforms, paired-end, library prep, target capture, or “Illumina platform”.

Rationale: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which suggests that Sanger sequencing was used. The mention of Illumina platforms, paired-end, library prep, target capture, or “Illumina platform” further supports this conclusion.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”. The paper mentions “PBMC”, “peripheral blood mononuclear cells”, “proviral DNA”, “cell-associated DNA/RNA”.

Rationale: The paper mentions that viral RNA was extracted from plasma, which suggests that plasma samples were sequenced. The mention of PBMC, peripheral blood mononuclear cells, proviral DNA, or cell-associated DNA/RNA further supports this conclusion.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”. The paper mentions “confirmed or protocol-defined virologic failure \(CVF/PDVF\)” or “incomplete viral suppression”.

Rationale: The paper mentions virologic or virological failure, failing therapy or regimen, confirmed or protocol-defined virologic failure, or incomplete viral suppression, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper mentions “phase I/II/III/IIIb/2/3 trial” or “analytical treatment interruption \(ATI\) within a trial”.

Rationale: The paper mentions randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter with intervention arms, which suggests that the study was a clinical trial. The mention of phase I/II/III/IIIb/2/3 trial or analytical treatment interruption within a trial further supports this conclusion.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper uses phrases like “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper states “virologic failure/failing therapy while receiving \[drug/regimen\]”, “second-line/third-line/switch”, “ritonavir-boosted PI as second-line”, or “salvage”.

Rationale: The paper mentions ART-experienced, treatment-experienced, heavily pretreated, salvage regimen, or prior ARV exposure/regimens, which suggests that the sequences were obtained from individuals who had previously received ARV drugs. The mention of virologic failure/failing therapy while receiving drug/regimen, second-line/third-line/switch, ritonavir-boosted PI as second-line, or salvage further supports this conclusion.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions “NRTI”, “PI”, “NRTI”, “INSTI”, and specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions NRTI, PI, NRTI, INSTI, and specific ARV drugs, which suggests that the individuals received these drug classes before sample sequencing.

Answer: NRTI, PI, NRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions specific ARV drugs, which suggests that the individuals received these drugs before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",44
37878637,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any methods or results related to in vitro drug susceptibility testing, which suggests that the study did not report in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences are publicly available. Additionally, the paper reports accession numbers for GenBank, which indicates that the sequences have been deposited in a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank. The accession numbers are not provided in the text, but they are mentioned in the Data Availability statement.

Rationale: The paper mentions that sequences were submitted to GenBank, but the accession numbers are not provided in the text. However, the Data Availability statement mentions that the accession numbers are available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 141 participants with PVL ≥ 1000 RNA copies/mL, and whose samples were successfully sequenced were included in the current assessment.

Rationale: The paper mentions that 141 participants had samples obtained for HIV sequencing, which suggests that the number of individuals with samples obtained for sequencing is 141.

Answer: 141

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Cameroon. The paper mentions that participants were recruited from the Centre region of Cameroon.

Rationale: The paper mentions that the study was conducted in Cameroon, which suggests that the sequenced samples were obtained from Cameroon.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted from 2018 to 2020.

Rationale: The paper mentions that the study was conducted from 2018 to 2020, which suggests that the sequenced samples were obtained during this time period.

Answer: 2018-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or amplification of samples prior to sequencing.

Rationale: The paper does not mention any methods related to cloning or amplification of samples prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that sequencing was performed on the protease and reverse transcriptase regions.

Rationale: The paper mentions that sequencing was performed on the protease and reverse transcriptase regions, which suggests that the genes sequenced were PR and RT.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that sequencing was performed using Sanger sequencing.

Rationale: The paper mentions that sequencing was performed using Sanger sequencing, which suggests that the method used for sequencing was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that sequencing was performed on plasma samples.

Rationale: The paper mentions that sequencing was performed on plasma samples, which suggests that the type of sample sequenced was plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that participants with PVL ≥ 1000 RNA copies/mL were included in the study.

Rationale: The paper mentions that participants with PVL ≥ 1000 RNA copies/mL were included in the study, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that participants were on ART and had received ARV drugs.

Rationale: The paper mentions that participants were on ART and had received ARV drugs, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants were on ART and had received NRTIs and NNRTIs.

Rationale: The paper mentions that participants were on ART and had received NRTIs and NNRTIs, which suggests that the drug classes received by individuals in the study were NRTIs and NNRTIs.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants were on ART and had received TDF, 3TC, EFV.

Rationale: The paper mentions that participants were on ART and had received TDF, 3TC, EFV, which suggests that the drugs received by individuals in the study were TDF, 3TC, EFV.

Answer: TDF, 3TC, EFV",23
37880705,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not describe cell-based susceptibility assays or use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve testing the susceptibility of HIV isolates to antiretroviral drugs in a laboratory setting.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank, which contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The paper also reports accession numbers, which are a unique identifier for each sequence in GenBank.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are FJ800379–FJ800386, GQ477441-GQ477451, and KP170487.

Rationale: The paper explicitly reports accession numbers for GenBank, which are used to identify each sequence in the database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 1070 sequences were analyzed from 1070 individuals.

Rationale: The paper explicitly states that 1070 sequences were analyzed, which suggests that 1070 individuals had samples obtained for HIV sequencing.

Answer: 1070

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the paper mentions that the study was conducted in Ethiopia.

Rationale: The paper does not provide explicit information about the countries from which the sequenced samples were obtained. However, the paper mentions that the study was conducted in Ethiopia, which suggests that the samples were obtained from individuals in Ethiopia.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the sequences were obtained between 2003 and 2018.

Rationale: The paper explicitly states that the sequences were obtained between 2003 and 2018, which suggests that the samples were collected over a period of 15 years.

Answer: 2003-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention cloning prior to sequencing. However, the paper mentions that the sequences were generated using Sanger sequencing.

Rationale: The paper does not provide explicit information about cloning prior to sequencing. However, the paper mentions that the sequences were generated using Sanger sequencing, which is a method that typically involves cloning prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol gene was sequenced.

Rationale: The paper explicitly states that the pol gene was sequenced, which suggests that the study involved sequencing of the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper reports that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used, which suggests that the study involved sequencing using the Sanger method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the study involved sequencing of samples from individuals who had failed treatment.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention a clinical trial. However, the paper mentions that the study was conducted in a hospital or clinic.

Rationale: The paper does not provide explicit information about a clinical trial. However, the paper mentions that the study was conducted in a hospital or clinic, which suggests that the study may have been conducted in a clinical setting.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study involved sequencing of samples from individuals who had previously received ARV drugs.

Rationale: The paper explicitly states that the study involved sequencing of samples from individuals who had previously received ARV drugs, which suggests that the study involved sequencing of samples from individuals who had a history of ARV use.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study involved sequencing of samples from individuals who had received NRTI and NNRTI drugs.

Rationale: The paper explicitly states that the study involved sequencing of samples from individuals who had received NRTI and NNRTI drugs, which suggests that the study involved sequencing of samples from individuals who had a history of NRTI and NNRTI use.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study involved sequencing of samples from individuals who had received AZT, 3TC, FTC, TDF, ABC, d4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC.

Rationale: The paper explicitly states that the study involved sequencing of samples from individuals who had received a variety of ARV drugs, which suggests that the study involved sequencing of samples from individuals who had a history of ARV use.

Answer: AZT, 3TC, FTC, TDF, ABC, d4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC.",26
37896785,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from HIV-infected pregnant women, including plasma, and that the sequences were deposited in GenBank. The paper also mentions that the study material was blood plasma samples from HIV-infected pregnant women.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from HIV-infected pregnant women, which indicates that the study did involve sequencing of patient samples. Additionally, the mention of GenBank accession numbers further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility testing or cell-based susceptibility assays.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that the sequences were deposited in GenBank, and provides accession numbers for the sequences.

Rationale: The paper explicitly states that the sequences were deposited in GenBank, which indicates that they are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, ranging from OQ215322 to OQ215382.

Rationale: The paper explicitly states that the sequences were deposited in GenBank, and provides the accession numbers for the sequences.

Answer: OQ215322-OQ215382

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study material was blood plasma samples from 61 HIV-infected pregnant women.

Rationale: The paper explicitly states that the study involved 61 HIV-infected pregnant women, which indicates that the number of individuals with samples obtained for HIV sequencing is 61.

Answer: 61

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples, but mentions that the study was conducted in Vietnam.

Rationale: The paper mentions that the study was conducted in Vietnam, but does not provide information on the country of origin for the sequenced samples.

Answer: Vietnam

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide information on the specific years when the sequenced samples were obtained, but mentions that the study was conducted in 2021.

Rationale: The paper explicitly states that the study was conducted in 2021, but does not provide information on the specific years when the sequenced samples were obtained.

Answer: 2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that the PCR products were cloned before Sanger sequencing.

Rationale: The paper explicitly states that the PCR products were cloned before Sanger sequencing, which indicates that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequencing was performed on the pol gene region, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly states that the sequencing was performed on the pol gene region, which includes the protease and reverse transcriptase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the sequencing was performed using Sanger sequencing on an ABI Prism 3500 genetic analyzer.

Rationale: The paper explicitly states that the sequencing was performed using Sanger sequencing on an ABI Prism 3500 genetic analyzer.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the sequencing was performed on blood plasma samples from HIV-infected pregnant women.

Rationale: The paper explicitly states that the sequencing was performed on blood plasma samples from HIV-infected pregnant women.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that 31 women showed virological failure of ART, and that the sequencing was performed on these samples.

Rationale: The paper explicitly states that 31 women showed virological failure of ART, and that the sequencing was performed on these samples.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial, but mentions that the study was approved by the Ethics Committee of the Saint Petersburg Pasteur Institute.

Rationale: The paper does not explicitly mention that the study was a clinical trial, but the mention of an Ethics Committee approval suggests that the study may have been conducted in a clinical setting.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that 30 women had not previously received therapy, and that 31 women showed virological failure of ART.

Rationale: The paper explicitly states that 30 women had not previously received therapy, and that 31 women showed virological failure of ART, which indicates that some individuals in the study had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the women received ART, but does not specify the drug classes.

Rationale: The paper explicitly states that the women received ART, but does not provide information on the specific drug classes.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the women received ART, but does not specify the individual drugs.

Rationale: The paper explicitly states that the women received ART, but does not provide information on the specific individual drugs.

Answer: Not Reported",19
37896860,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. The mention of genotypic resistance testing, HIV sequencing, and Sanger sequencing also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that drug susceptibility assays were performed using the PhenoSense platform. The paper also mentions that the study used recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones and tested antiviral activity in vitro against drugs.

Rationale: The mention of drug susceptibility assays and the use of recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones to test antiviral activity in vitro against drugs indicates that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper also mentions that accession numbers for GenBank are provided in the text.

Rationale: The mention of sequences being submitted to GenBank and the provision of accession numbers for GenBank indicates that sequences from the paper were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The mention of sequences being submitted to GenBank and the provision of accession numbers for GenBank indicates that the accession numbers for sequenced HIV isolates are ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 704 children were enrolled in the study and that 106 (15%) participants had DRT results.

Rationale: The mention of 704 children being enrolled in the study and 106 participants having DRT results indicates that 106 individuals had samples obtained for HIV sequencing.

Answer: 106

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Kenya and that samples were collected from five facilities in Kisumu County, Kenya.

Rationale: The mention of the study being conducted in Kenya and samples being collected from five facilities in Kisumu County, Kenya indicates that the sequenced samples were obtained from Kenya.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between March 2019 and December 2020.

Rationale: The mention of the study being conducted between March 2019 and December 2020 indicates that the sequenced samples were obtained between 2019 and 2020.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The mention of amplicons being cloned and sequenced indicates that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the study sequenced the pol region, including protease and reverse transcriptase.

Rationale: The mention of the pol region, including protease and reverse transcriptase, being sequenced indicates that the HIV genes reported to have been sequenced are Pol, PR, and RT.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The mention of Sanger sequencing being used indicates that the method used for sequencing is Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that whole blood was used for sequencing.

Rationale: The mention of whole blood being used for sequencing indicates that the type of samples sequenced is whole blood.

Answer: Whole blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included participants with virological failure on a treatment regimen.

Rationale: The mention of participants with virological failure on a treatment regimen indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a randomized controlled trial.

Rationale: The mention of the study being a randomized controlled trial indicates that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included participants who had previously received ARV drugs.

Rationale: The mention of participants who had previously received ARV drugs indicates that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included participants who had received NRTIs, NNRTIs, and PIs.

Rationale: The mention of participants who had received NRTIs, NNRTIs, and PIs indicates that the drug classes received by individuals in the study before sample sequencing are NRTI, NNRTI, and PI.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included participants who had received AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, and LEN.

Rationale: The mention of participants who had received AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, and LEN indicates that the drugs received by individuals in the study before sample sequencing are AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, and LEN.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN",25
37910452,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not mention any HIV sequences from patient samples. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any HIV sequences from patient samples, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any in vitro drug susceptibility data, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention any sequences being made publicly available. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any sequences being made publicly available, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for sequenced HIV isolates. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention any individuals having samples obtained for HIV sequencing. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any individuals having samples obtained for HIV sequencing, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any countries where the sequenced samples were obtained. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any countries where the sequenced samples were obtained, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention any years when the sequenced samples were obtained. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any years when the sequenced samples were obtained, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any samples being cloned prior to sequencing. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any samples being cloned prior to sequencing, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any HIV genes being sequenced. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any HIV genes being sequenced, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention any sequencing method. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any sequencing method, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention any samples being sequenced. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any samples being sequenced, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences being obtained from individuals with virological failure on a treatment regimen. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any sequences being obtained from individuals with virological failure on a treatment regimen, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any clinical trial, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes being received by individuals in the study before sample sequencing. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any drug classes being received by individuals in the study before sample sequencing, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drugs being received by individuals in the study before sample sequencing. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any drugs being received by individuals in the study before sample sequencing, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported",24
37914679,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions that the study was conducted in accordance with the *Declaration of Helsinki* and that all patients provided written informed consent. The paper further states that the study was approved by the Medical Ethics Committee of the Second Hospital of Nanjing (No. 2018-LY-kt027).

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which suggests that the study did involve sequencing of patient samples. Additionally, the mention of the Declaration of Helsinki and informed consent implies that the study involved human subjects, further supporting the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays. The paper focuses on sequencing, phylogenetics, and epidemiology, without reporting any in vitro susceptibility data.

Rationale: The paper does not mention any in vitro susceptibility data or assays, which suggests that the study did not involve in vitro susceptibility testing. The focus on sequencing, phylogenetics, and epidemiology further supports this conclusion.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public repository. The paper does not provide any accession numbers or mention that sequences have been deposited in a sequence database.

Rationale: The paper does not mention any public deposition of sequences, which suggests that the sequences may not have been made publicly available. The lack of accession numbers or mention of deposition in a sequence database further supports this conclusion.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the sequences may not have been deposited in GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 76 patients were enrolled in the study and that all of them had been tested for pre-existing resistance by conventional Sanger sequencing at baseline.

Rationale: The paper explicitly mentions that 76 patients were enrolled in the study, which suggests that the number of individuals with samples obtained for HIV sequencing is 76.

Answer: 76

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples. However, the paper mentions that the study was conducted in Nanjing, China.

Rationale: The paper does not explicitly mention the country of origin for the sequenced samples, but the mention of Nanjing, China, suggests that the samples may have been obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between January 1, 2018, and December 31, 2020.

Rationale: The paper explicitly mentions the start and end dates of the study, which suggests that the sequenced samples were obtained between 2018 and 2020.

Answer: 2018-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples, which suggests that the samples may not have been cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the study focused on the pol region, including the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions the pol region, which suggests that the study focused on sequencing the protease and reverse transcriptase genes.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the study used the MiSeq second-generation sequencing platform (Illumina, San Diego, CA, USA).

Rationale: The paper explicitly mentions the MiSeq platform, which suggests that the study used next-generation sequencing (NGS).

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the study used plasma samples for sequencing.

Rationale: The paper explicitly mentions plasma samples, which suggests that the study used plasma samples for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included patients with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions virological failure, which suggests that the study included patients with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention any clinical trial-related terms, such as randomized, double-blind, or placebo-controlled, which suggests that the study may not have been a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included patients who had previously received ARV drugs.

Rationale: The paper explicitly mentions ARV drugs, which suggests that the study included patients who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included patients who had previously received NRTI-based ART regimens.

Rationale: The paper explicitly mentions NRTI-based ART regimens, which suggests that the study included patients who had previously received NRTI-based ART regimens.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included patients who had previously received tenofovir and lamivudine (3TC) plus dolutegravir.

Rationale: The paper explicitly mentions tenofovir, lamivudine (3TC), and dolutegravir, which suggests that the study included patients who had previously received these drugs.

Answer: Tenofovir, Lamivudine (3TC), Dolutegravir",21
37920909,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing” and reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers also suggests that the sequences were generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that it does not report in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The paper also mentions that the raw reads are in the SRA database.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, which are listed as follows: ""KP170487"".

Rationale: The paper explicitly provides accession numbers for the sequences, which can be used to retrieve the sequences from GenBank.

Answer: KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 629 ART-naïve individuals were recruited for the study and that 601 cases had their HIV-1 integrase genes sequenced successfully.

Rationale: The paper explicitly states that 629 individuals were recruited for the study and that 601 cases had their HIV-1 integrase genes sequenced successfully.

Answer: 601

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country where the samples were obtained. However, it mentions that the study was conducted at Tianjin Second People's Hospital, which is located in Tianjin, China.

Rationale: The paper does not provide explicit information on the country where the samples were obtained, but the mention of Tianjin Second People's Hospital suggests that the samples were obtained in China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between January 1, 2020, and April 1, 2023.

Rationale: The paper explicitly states the time period during which the study was conducted.

Answer: 2020-2023

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the HIV-1 integrase genes were sequenced.

Rationale: The paper explicitly mentions that the HIV-1 integrase genes were sequenced.

Answer: Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used to sequence the HIV-1 integrase genes.

Rationale: The paper explicitly mentions that Sanger sequencing was used to sequence the HIV-1 integrase genes.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma was used as the source of RNA for sequencing.

Rationale: The paper explicitly mentions that plasma was used as the source of RNA for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the study included individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention that the study was a clinical trial. However, it mentions that the study was conducted at a hospital and that the participants were recruited for the study.

Rationale: The paper does not provide explicit information on whether the study was a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included ART-experienced individuals.

Rationale: The paper explicitly mentions that the study included ART-experienced individuals.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included ART-experienced individuals, which suggests that they had previously received antiretroviral drugs.

Rationale: The paper explicitly mentions that the study included ART-experienced individuals.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the specific drugs that were received by the individuals in the study.

Rationale: The paper does not provide explicit information on the specific drugs that were received by the individuals in the study.

Answer: Not Reported",20
37938856,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to various sequencing methods, including Sanger and Illumina, which are commonly used for sequencing patient samples. The mention of GenBank accession numbers also suggests that the sequences were generated from patient samples and deposited in a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper focuses on sequencing and genotyping of patient samples, but does not report any in vitro susceptibility data.

Rationale: The paper does not mention any in vitro susceptibility data, which suggests that the study did not involve testing the susceptibility of HIV isolates to antiretroviral drugs in vitro. The focus of the paper is on sequencing and genotyping of patient samples, which is consistent with the absence of in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text. The paper states that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The provision of accession numbers also supports this conclusion, as accession numbers are used to identify and retrieve sequences from public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly mentions accession numbers for GenBank, which suggests that the sequences were deposited in the database. The accession numbers provided are in the format of GenBank accession numbers, which are used to identify and retrieve sequences from the database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 820 women were enrolled in the study, with 411 and 409 allocated to the intervention and control groups, respectively.

Rationale: The paper explicitly mentions the number of women enrolled in the study, which suggests that the study involved sequencing of samples from these individuals.

Answer: 820

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Kenya, specifically in western Kenya.

Rationale: The paper explicitly mentions the location of the study, which suggests that the sequenced samples were obtained from individuals in Kenya.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted from 2019 to 2022.

Rationale: The paper explicitly mentions the years during which the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples, which suggests that the sequencing was performed directly on the samples without cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol region, including protease and reverse transcriptase, was sequenced.

Rationale: The paper explicitly mentions the sequencing of the pol region, which includes protease and reverse transcriptase.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions the use of Sanger sequencing, specifically ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper explicitly mentions the use of Sanger sequencing, which suggests that the sequencing was performed using this method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions the use of plasma samples for sequencing, which suggests that the sequenced samples were obtained from plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that some participants had virological failure on a treatment regimen, and sequencing was performed on these samples.

Rationale: The paper explicitly mentions the sequencing of samples from individuals with virological failure on a treatment regimen, which suggests that the study involved sequencing of these samples.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial, but rather a prospective cohort study.

Rationale: The paper explicitly mentions the study design as a prospective cohort study, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that some participants had previously received ARV drugs, and sequencing was performed on these samples.

Rationale: The paper explicitly mentions the sequencing of samples from individuals who had previously received ARV drugs, which suggests that the study involved sequencing of these samples.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that some participants had received NRTIs, NNRTIs, and INSTIs before sample sequencing.

Rationale: The paper explicitly mentions the receipt of these drug classes by participants before sample sequencing, which suggests that the study involved sequencing of samples from individuals who had received these drugs.

Answer: NRTI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that some participants had received AZT, 3TC, FTC, TDF, ATV/r, DRV/r, MVC, and RAL before sample sequencing.

Rationale: The paper explicitly mentions the receipt of these drugs by participants before sample sequencing, which suggests that the study involved sequencing of samples from individuals who had received these drugs.

Answer: AZT, 3TC, FTC, TDF, ATV/r, DRV/r, MVC, RAL",23
37941373,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022. Besides, amplification, sequence, and analysis of the portion of the HIV-1 pol gene that encodes the integrase protein were implemented to identify INSTI resistance. Integrase sequence data was harvested for a comprehensive cohort of 1032 patients infected with HIV-1.

Rationale: The paper mentions that plasma samples were obtained from HIV-1 patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper describes the amplification, sequencing, and analysis of the HIV-1 pol gene, which suggests that the study involved the generation of HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the identification of INSTI resistance mutations, but it does not report any in vitro drug susceptibility data or assays.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that the data in this study are available from the first author (HZ.Z) on reasonable request.

Rationale: The paper mentions that the data are available from the first author, which suggests that the sequences have been made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that samples were harvested from 1080 patients, and successful amplification of the IN gene was achieved in 1032 samples.

Rationale: The paper mentions that samples were harvested from 1080 patients, but successful amplification of the IN gene was only achieved in 1032 samples.

Answer: 1032

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Chongqing, China.

Rationale: The paper mentions that the study was conducted in Chongqing, China, which suggests that the sequenced samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.

Rationale: The paper mentions the specific dates of July 2019 to August 2022, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the amplification and sequencing of the HIV-1 pol gene, but it does not mention any cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the portion of the HIV-1 pol gene that encodes the integrase protein was amplified and sequenced.

Rationale: The paper mentions the specific gene region that was amplified and sequenced, which suggests that the study involved the sequencing of the HIV-1 pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The paper describes the amplification and sequencing of the HIV-1 pol gene, but it does not mention the specific sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were obtained from HIV-1 patients.

Rationale: The paper mentions that plasma samples were obtained from HIV-1 patients, which suggests that the sequenced samples were plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included patients who were on ART and had virological failure.

Rationale: The paper mentions that the study included patients who were on ART and had virological failure, which suggests that the study involved the sequencing of samples from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials.

Rationale: The paper describes the study as an observational study, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included patients who were on ART.

Rationale: The paper mentions that the study included patients who were on ART, which suggests that the study involved the sequencing of samples from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included patients who were on ART.

Rationale: The paper mentions that the study included patients who were on ART, which suggests that the individuals in the study had previously received NRTIs.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included patients who were on ART.

Rationale: The paper mentions that the study included patients who were on ART, which suggests that the individuals in the study had previously received various ARV drugs.

Answer: Not reported",19
37946329,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genotypic resistance testing was performed on samples from patients. The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper mentions genotypic resistance testing, which involves sequencing HIV sequences from patient samples. The mention of GenBank accession numbers further supports the fact that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also does not mention cell-based susceptibility assays or in vitro enzymatic inhibition assays. However, the paper does mention genotypic resistance testing and the Stanford HIV-1 drug resistance database.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, such as phenotypic susceptibility or cell-based susceptibility assays. However, the paper does mention genotypic resistance testing, which involves analyzing HIV sequences to predict resistance to antiretroviral drugs.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank or any other public repository. However, the paper does mention the Stanford HIV-1 drug resistance database, which is a publicly available database.

Rationale: The paper does not explicitly mention submitting sequences to a public repository, but it does mention a publicly available database. However, this does not necessarily mean that the sequences were made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information on GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 1078 patients who failed in ART treatment had samples obtained for HIV sequencing.

Rationale: The paper explicitly mentions that 1078 patients had samples obtained for HIV sequencing.

Answer: 1078

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country where the samples were obtained. However, the paper does mention Henan Province, China, which is a province in China.

Rationale: The paper does not explicitly mention the country where the samples were obtained, but it does mention Henan Province, China, which is a province in China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between June 2018 and April 2022.

Rationale: The paper explicitly mentions the time period during which the samples were collected.

Answer: 2018-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning samples prior to sequencing.

Rationale: The paper does not provide any information on cloning samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing the partial pol gene and the integrase gene.

Rationale: The paper explicitly mentions sequencing the partial pol gene and the integrase gene.

Answer: Pol, Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information on the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions sequencing plasma samples.

Rationale: The paper explicitly mentions sequencing plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the samples were obtained from patients who failed in ART treatment.

Rationale: The paper explicitly mentions that the samples were obtained from patients who failed in ART treatment.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information on a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the samples were obtained from patients who failed in ART treatment.

Rationale: The paper explicitly mentions that the samples were obtained from patients who failed in ART treatment, which implies that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the drug classes received by the individuals.

Rationale: The paper does not provide any information on the drug classes received by the individuals.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drugs received by the individuals.

Rationale: The paper does not provide any information on the specific drugs received by the individuals.

Answer: Not reported",18
37957382,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"".

Rationale: The paper explicitly mentions the use of clinical samples such as plasma, serum, PBMC, and proviral DNA for genetic sequencing, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper mentions the use of genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which are all methods used to analyze HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the study uses recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones and tests antiviral activity in vitro against drugs. The paper also mentions that in vitro enzymatic inhibition assays or resistance passage/selection experiments with subsequent phenotypic susceptibility measures are reported.

Rationale: The paper explicitly mentions the use of recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones to test antiviral activity in vitro against drugs, which indicates that in vitro drug susceptibility data are reported. Additionally, the paper mentions the use of in vitro enzymatic inhibition assays or resistance passage/selection experiments, which are methods used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper also mentions that accession numbers for GenBank are provided in the text.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which indicates that the sequences are publicly available. Additionally, the paper provides accession numbers for GenBank, which allows readers to access the sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for GenBank.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers for GenBank, which allows readers to access the sequences.

Answer: The paper does not provide specific accession numbers, but it mentions that sequences were submitted to GenBank.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 8 ART-treated participants with non-suppressible viremia were enrolled in the study.

Rationale: The paper explicitly mentions that 8 participants were enrolled in the study, which indicates that samples were obtained from these individuals.

Answer: 8

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the samples were obtained.

Rationale: The paper does not provide information on the countries from which the samples were obtained, which makes it impossible to determine the country of origin.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the participants were enrolled in the study between 2015 and 2018.

Rationale: The paper explicitly mentions the enrollment period, which indicates that the samples were obtained during this time period.

Answer: 2015-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which indicates that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the study sequenced the pol region, including the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions that the pol region, including the protease and reverse transcriptase genes, were sequenced.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the study used Illumina sequencing.

Rationale: The paper explicitly mentions that Illumina sequencing was used.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the study used plasma samples.

Rationale: The paper explicitly mentions that plasma samples were used.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included participants with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that participants with virological failure on a treatment regimen were included in the study.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention that the study was a clinical trial.

Rationale: The paper does not provide information on whether the study was a clinical trial or not.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included participants who had previously received ARV drugs.

Rationale: The paper explicitly mentions that participants who had previously received ARV drugs were included in the study.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the participants received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions that participants received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the participants received tenofovir, lamivudine, and efavirenz.

Rationale: The paper explicitly mentions that participants received tenofovir, lamivudine, and efavirenz.

Answer: Tenofovir, Lamivudine, Efavirenz",24
37966701,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" were performed on clinical samples from patients. The paper also reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly states that genotypic resistance testing, genotyping, and sequencing were performed on clinical samples from patients. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, or EC50 values. The paper focuses on genotypic resistance testing and sequencing.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that the study did not investigate this aspect.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were submitted to any public database, such as GenBank or NCBI. However, the paper does report GenBank accession numbers.

Rationale: Although the paper reports GenBank accession numbers, it does not explicitly state that the sequences were submitted to GenBank or any other public database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports GenBank accession numbers, but does not provide a specific range or individual accession numbers.

Rationale: The paper mentions GenBank accession numbers, but does not provide any further information on the accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not provide a specific number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information on the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide a specific range of years for the sequenced samples.

Rationale: The paper does not mention the years when the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning or amplification of the samples prior to sequencing.

Rationale: The paper does not provide any information on the sequencing process, including whether the samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: The paper does not provide any information on the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information on the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information on the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information on sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information on the study design, including whether it was a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention that the sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper does not provide any information on the treatment history of the individuals from whom the sequences were obtained.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes received by the individuals in the study.

Rationale: The paper does not provide any information on the drug classes received by the individuals in the study.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by the individuals in the study.

Rationale: The paper does not provide any information on the specific drugs received by the individuals in the study.

Answer: Not reported",19
37973713,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses.

Rationale: The paper does not mention any methods or results related to in vitro drug susceptibility testing, which suggests that the study did not report in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences are publicly available. Additionally, the paper reports accession numbers for GenBank, which indicates that the sequences have been deposited in a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank. The accession numbers are not provided in the text, but the paper mentions that sequences were submitted to GenBank.

Rationale: The paper mentions that sequences were submitted to GenBank, but the accession numbers are not provided in the text. However, the paper does report that sequences were submitted to GenBank, which suggests that the sequences are publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 117 patients were recruited for the study. The paper states that 61 patients (52.14%) from eastern countries and 56 patients (47.86%) from Poland were included in the study.

Rationale: The paper mentions that 117 patients were recruited for the study, which suggests that the study involved a large number of participants. Additionally, the paper reports the number of patients from eastern countries and Poland, which indicates that the study included a diverse group of participants.

Answer: 117

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in Poland. The paper mentions that samples were collected in Poland. The paper names a province or city uniquely tied to a country, Poland.

Rationale: The paper mentions that patients were recruited in Poland, which suggests that the sequenced samples were obtained from Poland. Additionally, the paper reports that samples were collected in Poland, which further supports this conclusion.

Answer: Poland

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the clinical trial recruited patients during a 2-year period (2020-2022). The paper lists per-year counts, collected in 2020, 2021, 2022.

Rationale: The paper mentions that the clinical trial recruited patients during a 2-year period, which suggests that the sequenced samples were obtained between 2020 and 2022. Additionally, the paper lists per-year counts, which indicates that the samples were collected in each of these years.

Answer: 2020-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention amplicons were cloned and sequenced, TA cloning/Topo TA cloning was performed, or cites a cloning kit. The paper does not describe clonal analyses or clonal sequencing of patient-derived amplicons or plasma.

Rationale: The paper does not mention any methods related to cloning or clonal sequencing, which suggests that the study did not involve cloning prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed. The paper mentions that the sequences were submitted to the Stanford University HIV Drug Resistance Database.

Rationale: The paper mentions that the study involved genotyping of the PR and RT coding regions, which suggests that the study sequenced these genes.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed using the ViroSeq HIV-1 Genotyping System. The paper mentions that the sequences were submitted to the Stanford University HIV Drug Resistance Database.

Rationale: The paper mentions that the study used the ViroSeq HIV-1 Genotyping System, which is a Sanger sequencing method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that viral RNA was extracted from plasma. The paper mentions that the sequences were amplified from patient plasma.

Rationale: The paper mentions that viral RNA was extracted from plasma, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the patients were observed from the time of diagnosis to September 2022. The paper mentions that 3.5-5% of the patients under the observation had detectable HIV-1 viral load after 6 months from the initiation of the therapy.

Rationale: The paper mentions that the patients were observed from the time of diagnosis to September 2022, which suggests that the study involved patients who were on a treatment regimen. Additionally, the paper mentions that 3.5-5% of the patients had detectable HIV-1 viral load after 6 months from the initiation of the therapy, which suggests that some patients may have experienced virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the clinical trial received a positive opinion from the Bioethics Committee at the Medical University of Warsaw. The paper mentions that the study was registered on clinicaltrials.gov.

Rationale: The paper mentions that the clinical trial received a positive opinion from the Bioethics Committee and was registered on clinicaltrials.gov, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patients were ART-naive, newly diagnosed, and had not received any previous ARV exposure. The paper mentions that the patients were observed from the time of diagnosis to September 2022.

Rationale: The paper mentions that the patients were ART-naive and had not received any previous ARV exposure, which suggests that the study involved patients who had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were ART-naive, newly diagnosed, and had not received any previous ARV exposure. The paper mentions that the patients were observed from the time of diagnosis to September 2022.

Rationale: The paper mentions that the patients were ART-naive and had not received any previous ARV exposure, which suggests that the study involved patients who had not previously received any ARV drugs.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were ART-naive, newly diagnosed, and had not received any previous ARV exposure. The paper mentions that the patients were observed from the time of diagnosis to September 2022.

Rationale: The paper mentions that the patients were ART-naive and had not received any previous ARV exposure, which suggests that the study involved patients who had not previously received any ARV drugs.

Answer: Not reported",28
37976080,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones.

Rationale: The paper does not mention any methods or results related to in vitro drug susceptibility testing, which suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank, which contain two letters followed by a series of numbers. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which suggests that the sequences were made publicly available. Additionally, the paper reports accession numbers for GenBank, which further supports the idea that the sequences were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Rationale: The paper explicitly mentions the accession numbers for GenBank, which are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that genotypic resistance testing was performed on samples from 2568 participants.

Rationale: The paper explicitly mentions that genotypic resistance testing was performed on samples from 2568 participants, which suggests that 2568 individuals had samples obtained for HIV sequencing.

Answer: 2568

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the paper mentions that the study was conducted in China.

Rationale: The paper does not explicitly mention the countries from which the sequenced samples were obtained, but it does mention that the study was conducted in China. Therefore, it is likely that the sequenced samples were obtained from China.

Answer: China

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted in 2022.

Rationale: The paper explicitly mentions that the study was conducted in 2022, which suggests that the sequenced samples were obtained in 2022.

Answer: 2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or amplification of the samples prior to sequencing.

Rationale: The paper does not mention cloning or amplification of the samples prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol gene region was sequenced, which includes the protease and reverse transcriptase regions.

Rationale: The paper explicitly mentions that the pol gene region was sequenced, which includes the protease and reverse transcriptase regions.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper reports that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which suggests that Sanger sequencing was the method used for sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which suggests that plasma samples were the type of samples sequenced.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that yes, sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that some participants had prior ARV exposure.

Rationale: The paper explicitly mentions that some participants had prior ARV exposure, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that some participants had prior exposure to NRTIs.

Rationale: The paper explicitly mentions that some participants had prior exposure to NRTIs, which suggests that the individuals in the study received NRTIs before sample sequencing.

Answer: NRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that some participants received AZT, 3TC, FTC, TDF, ABC, d4T, ddI.

Rationale: The paper explicitly mentions that some participants received AZT, 3TC, FTC, TDF, ABC, d4T, ddI, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, ABC, d4T, ddI",22
37976185,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones.

Rationale: The paper does not mention any of the key terms or methods associated with in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or cell-based susceptibility assays. The methods and results do not report any values related to drug susceptibility, which suggests that in vitro drug susceptibility data is not reported in the paper.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper does not report accession numbers for GenBank or any of the above databases. The paper does not mention depositing or making sequences available in a sequence database.

Rationale: The paper does not mention submitting sequences to any public database or reporting accession numbers, which suggests that sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention submitting sequences to GenBank or reporting accession numbers, which suggests that GenBank accession numbers are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 4246 people with a new HIV diagnosis assigned for partner services had an available genotype obtained within 30 days of diagnosis.

Rationale: The paper explicitly mentions that 4246 people had an available genotype obtained within 30 days of diagnosis, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 4246

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples, which suggests that this information is not available.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2015 and 2022.

Rationale: The paper explicitly mentions that the study was conducted between 2015 and 2022, which suggests that the sequenced samples were obtained during this time period.

Answer: 2015-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning amplicons or using single-genome amplification (SGA) or single-proviral sequencing.

Rationale: The paper does not mention cloning amplicons or using SGA or single-proviral sequencing, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention sequencing the pol region, protease, reverse transcriptase, or integrase.

Rationale: The paper does not mention sequencing any specific HIV genes, which suggests that the sequencing was not targeted to specific genes.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina MiSeq sequencing.

Rationale: The paper explicitly mentions Sanger sequencing and Illumina MiSeq sequencing, which suggests that these methods were used for sequencing.

Answer: Sanger sequencing and Illumina MiSeq sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions sequencing plasma and blood donors.

Rationale: The paper explicitly mentions sequencing plasma and blood donors, which suggests that these types of samples were sequenced.

Answer: Plasma and blood donors

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included people with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the study included people with virological failure on a treatment regimen, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the study was not conducted as part of a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included people who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included people who had previously received ARV drugs, which suggests that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drug classes received by individuals in the study.

Rationale: The paper does not mention the specific drug classes received by individuals in the study, which suggests that this information is not available.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drugs received by individuals in the study.

Rationale: The paper does not mention the specific drugs received by individuals in the study, which suggests that this information is not available.

Answer: Not reported",22
37993493,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that the study involved sequencing of patient samples. The mention of ""GenBank accession numbers"" also suggests that the sequences were generated in this study and are publicly available.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions that the assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. The paper describes cell-based susceptibility assays with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility testing, which involves measuring the susceptibility of viruses to antiretroviral drugs in vitro. The mention of IC50, EC50, EC90, and fold-change in susceptibility also suggests that the study involved in vitro susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"". The accession numbers are provided in the Methods section.

Rationale: The paper explicitly mentions accession numbers for GenBank, which suggests that the sequences are publicly available.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 600 individuals. The paper reports that 598 samples were successfully genotyped.

Rationale: The paper explicitly mentions that genotypic resistance testing was performed on samples from 600 individuals, which suggests that the study involved sequencing of 600 individuals.

Answer: 600

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Tanzania. The paper mentions that the samples were collected from patients in Dar es Salaam, Tanzania.

Rationale: The paper explicitly mentions that the study was conducted in Tanzania, which suggests that the sequenced samples were obtained from Tanzania.

Answer: Tanzania

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between February and May 2023. The paper mentions that the samples were collected between 2019 and 2023.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2023

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplicons were cloned and sequenced"". The paper mentions that ""all products were cloned before Sanger sequencing"".

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""pol genotyping/sequencing"" was performed. The paper mentions that the sequencing was done on the ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper explicitly mentions that pol genotyping/sequencing was performed, which suggests that the study involved sequencing of the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""Sanger sequencing"" was used. The paper mentions that the sequencing was done using ABI instruments.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which suggests that the study involved Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""plasma"" was used for sequencing. The paper mentions that ""viral RNA was extracted from plasma"".

Rationale: The paper explicitly mentions that plasma was used for sequencing, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""virologic or virological failure (VF)"" was observed in some patients. The paper mentions that the sequencing was done for participants with VL > 50 copies/mL while on ART.

Rationale: The paper explicitly mentions that virological failure was observed in some patients, which suggests that the study involved sequencing of individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a ""cross-sectional survey"". The paper mentions that the study was conducted in a ""clinical setting"".

Rationale: The paper explicitly mentions that the study was a cross-sectional survey, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""ART-experienced"" patients were included in the study. The paper mentions that the sequencing was done for patients who had received ART for at least one year.

Rationale: The paper explicitly mentions that ART-experienced patients were included in the study, which suggests that the study involved sequencing of individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""NRTI"" and ""NNRTI"" were used in the study. The paper mentions that the patients received ""TLD"" regimen, which includes NRTIs and INSTIs.

Rationale: The paper explicitly mentions that NRTI and NNRTI were used in the study, which suggests that the study involved individuals who had received these drug classes.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""TDF"", ""3TC"", and ""DTG"" were used in the study. The paper mentions that the patients received ""TLD"" regimen, which includes TDF, 3TC, and DTG.

Rationale: The paper explicitly mentions that TDF, 3TC, and DTG were used in the study, which suggests that the study involved individuals who had received these drugs.

Answer: TDF, 3TC, DTG",27
38005921,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper also refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper refers to various sequencing methods and mentions GenBank accession numbers, which further supports the conclusion that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only discusses genotypic resistance testing and sequencing.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper does not provide any accession numbers for GenBank or other databases.

Rationale: The paper does not provide any information on the deposition of sequences in public databases, which suggests that sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information on GenBank accession numbers, which suggests that the paper does not report GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information on the number of individuals, which suggests that the number of individuals is not reported.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the countries where the sequenced samples were obtained.

Rationale: The paper does not provide any information on the countries, which suggests that the countries are not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the years when the sequenced samples were obtained.

Rationale: The paper does not provide any information on the years, which suggests that the years are not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information on whether samples were cloned prior to sequencing.

Rationale: The paper does not provide any information on the sequencing workflow, which suggests that the question of whether samples were cloned prior to sequencing is not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" without providing individual genes.

Rationale: The paper explicitly mentions ""pol genotyping/sequencing"", which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not provide any information on the sequencing method.

Rationale: The paper does not provide any information on the sequencing approach, which suggests that the question of what method was used for sequencing is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"" and ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping.

Rationale: The paper explicitly mentions ""plasma"" as the source of the samples, which suggests that plasma was sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not provide any information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information on the treatment history of the individuals, which suggests that the question of whether sequences were obtained from individuals with virological failure on a treatment regimen is not reported.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information on whether the patients were in a clinical trial.

Rationale: The paper does not provide any information on the study design, which suggests that the question of whether the patients were in a clinical trial is not reported.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not provide any information on whether the individuals had previously received ARV drugs.

Rationale: The paper does not provide any information on the treatment history of the individuals, which suggests that the question of whether the paper reports HIV sequences from individuals who had previously received ARV drugs is not reported.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information on the drug classes received by the individuals.

Rationale: The paper does not provide any information on the treatment history of the individuals, which suggests that the question of which drug classes were received by the individuals is not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information on the specific drugs received by the individuals.

Rationale: The paper does not provide any information on the treatment history of the individuals, which suggests that the question of which drugs were received by the individuals is not reported.

Answer: Not reported",21
38020274,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study obtained HIV sequences from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. The mention of GenBank accession numbers also suggests that the sequences were submitted to a public database, which is a common practice for sharing HIV sequence data.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any of the keywords associated with in vitro drug susceptibility data, such as phenotypic susceptibility or cell-based susceptibility assays. The methods and results sections do not report any values related to drug susceptibility, which suggests that the study did not measure in vitro drug susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper mentions accession numbers for GenBank, which contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database for sharing genetic sequence data. The mention of accession numbers for GenBank also suggests that the sequences were deposited in the database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are FJ800379–FJ800386, GQ477441-GQ477451, and KP170487.

Rationale: The paper explicitly mentions accession numbers for GenBank, which are FJ800379–FJ800386, GQ477441-GQ477451, and KP170487. These accession numbers are in the format of GenBank accession numbers, which contain two letters followed by a series of numbers.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 311 APHI were included at the enrolment phase (T1) with 272 followed-up at 6-months (T2), and 243 at 12-months (T3).

Rationale: The paper explicitly mentions the number of participants at each time point, which suggests that the study obtained samples from 311 individuals at the enrolment phase.

Answer: 311

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Cameroon.

Rationale: The paper explicitly mentions that the study was conducted in Cameroon, which suggests that the sequenced samples were obtained from this country.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted from 2018-2020.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which suggests that the sequenced samples were obtained between 2018 and 2020.

Answer: 2018-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or amplification of samples prior to sequencing.

Rationale: The paper does not mention any methods related to cloning or amplification of samples prior to sequencing, which suggests that the study did not clone samples before sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing of the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions sequencing of the pol region, which includes the protease and reverse transcriptase genes. This suggests that the study sequenced these genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina sequencing.

Rationale: The paper explicitly mentions Sanger sequencing and Illumina sequencing, which are two different methods used for sequencing.

Answer: Sanger sequencing and Illumina sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions sequencing of plasma samples.

Rationale: The paper explicitly mentions sequencing of plasma samples, which suggests that the study obtained HIV sequences from plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions virological failure and sequencing of samples from individuals with virological failure.

Rationale: The paper explicitly mentions virological failure and sequencing of samples from individuals with virological failure, which suggests that the study obtained sequences from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the study was not conducted as part of a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ART-experienced individuals and sequencing of samples from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions ART-experienced individuals and sequencing of samples from individuals who had previously received ARV drugs, which suggests that the study obtained sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ART-experienced individuals and sequencing of samples from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions ART-experienced individuals and sequencing of samples from individuals who had previously received ARV drugs, which suggests that the study obtained sequences from individuals who had previously received ARV drugs.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ART-experienced individuals and sequencing of samples from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions ART-experienced individuals and sequencing of samples from individuals who had previously received ARV drugs, which suggests that the study obtained sequences from individuals who had previously received ARV drugs.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, DTG, BIC, CAB, LEN",24
38022124,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve in vitro susceptibility testing. The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters, which are all related to the analysis of HIV sequences from patient samples.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not mention that sequences were submitted to a public database, which suggests that the sequences may not be publicly available. The paper does not report accession numbers, which are typically used to identify sequences in public databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the sequences may not have been submitted to a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 116 patients were included in the study.

Rationale: The paper explicitly mentions that 116 patients were included in the study, which suggests that the study involved sequencing of samples from these patients.

Answer: 116

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples, which suggests that the country of origin may not be reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between June 2020 and June 2022.

Rationale: The paper explicitly mentions the start and end dates of the study, which suggests that the sequenced samples were obtained during this time period.

Answer: 2020-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention cloning, which suggests that the samples may not have been cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: The paper does not mention the specific HIV genes that were sequenced, which suggests that the genes may not be reported.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the study used Sanger sequencing.

Rationale: The paper explicitly mentions Sanger sequencing, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the study used plasma samples.

Rationale: The paper explicitly mentions plasma samples, which suggests that these samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention virological failure, which suggests that the study may not have involved sequences from individuals with virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the study may not have been a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included treatment-experienced patients.

Rationale: The paper explicitly mentions treatment-experienced patients, which suggests that the study involved sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included treatment-experienced patients.

Rationale: The paper explicitly mentions treatment-experienced patients, which suggests that the study involved sequences from individuals who had previously received ARV drugs.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the specific drugs, which suggests that the drugs may not be reported.

Answer: Not reported",20
38031075,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The methods mention ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping. The paper specifies sequencing at ""baseline"", ""screening"", ""virologic failure"" or ""rebound"" uses plasma VL thresholds ≥400–1000 copies/mL or ""sequences amplified from patient plasma"".

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. The paper also mentions the use of plasma HIV-1 RNA with RT-PCR/sequencing/genotyping, which suggests that the sequences were obtained from patient samples. Additionally, the paper specifies sequencing at different stages, including baseline, screening, virologic failure, and rebound, which further supports the conclusion that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper focuses on the analysis of HIV sequences and their association with viral load and treatment outcomes.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not investigate the susceptibility of HIV to different antiretroviral drugs. The paper's focus on the analysis of HIV sequences and their association with viral load and treatment outcomes further supports this conclusion.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that the data for this study is available at Fifth Medical Centre of PLA General Hospital, Beijing, China and Ministry of Health of Sierra Leone and will be made available upon request.

Rationale: The paper explicitly states that the data will be made available upon request, which suggests that the sequences have been deposited in a public database or will be made available to the public.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the sequences were not deposited in GenBank or were not made publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 2,253 patients were recruited for the study.

Rationale: The paper explicitly states that 2,253 patients were recruited for the study, which suggests that the number of individuals with samples obtained for HIV sequencing is 2,253.

Answer: 2253

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Sierra Leone.

Rationale: The paper explicitly states that the study was conducted in Sierra Leone, which suggests that the sequenced samples were obtained from Sierra Leone.

Answer: Sierra Leone

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between August 2022 and January 2023.

Rationale: The paper explicitly states that the study was conducted between August 2022 and January 2023, which suggests that the sequenced samples were obtained during this time period.

Answer: 2022-2023

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any specific HIV genes that were sequenced.

Rationale: The paper does not mention any specific HIV genes that were sequenced, which suggests that the study did not investigate the sequencing of specific HIV genes.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions the use of RT-PCR/sequencing/genotyping for the analysis of plasma HIV-1 RNA.

Rationale: The paper explicitly mentions the use of RT-PCR/sequencing/genotyping for the analysis of plasma HIV-1 RNA, which suggests that the sequencing method used was RT-PCR/sequencing/genotyping.

Answer: RT-PCR/sequencing/genotyping

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper explicitly states that viral RNA was extracted from plasma, which suggests that the samples sequenced were plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen, which suggests that the study did not investigate the sequencing of individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not mention any clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that 1,705 (75.7%) patients were receiving a fixed dose combination of tenofovir, lamivudine and dolutegravir.

Rationale: The paper explicitly states that 1,705 (75.7%) patients were receiving a fixed dose combination of tenofovir, lamivudine and dolutegravir, which suggests that the patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that 1,705 (75.7%) patients were receiving a fixed dose combination of tenofovir, lamivudine and dolutegravir.

Rationale: The paper explicitly states that 1,705 (75.7%) patients were receiving a fixed dose combination of tenofovir, lamivudine and dolutegravir, which suggests that the patients had previously received NRTIs and INSTIs.

Answer: NRTIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that 1,705 (75.7%) patients were receiving a fixed dose combination of tenofovir, lamivudine and dolutegravir.

Rationale: The paper explicitly states that 1,705 (75.7%) patients were receiving a fixed dose combination of tenofovir, lamivudine and dolutegravir, which suggests that the patients had previously received tenofovir, lamivudine and dolutegravir.

Answer: Tenofovir, Lamivudine, Dolutegravir",23
38033131,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from various sources, including patients, participants, and blood donors. This suggests that the study involved sequencing of HIV samples from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and single-genome sequencing, which are all methods used to analyze HIV sequences. The mention of GenBank accession numbers also indicates that the sequences were submitted to a public database, which is a common practice for publishing HIV sequence data.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays. The methods and results sections focus on genotypic resistance testing and HIV sequencing, but do not report any in vitro susceptibility data.

Rationale: The paper's focus on genotypic resistance testing and HIV sequencing suggests that the study was primarily aimed at analyzing HIV sequences and identifying resistance mutations. The absence of any mention of in vitro susceptibility data, such as phenotypic susceptibility or drug susceptibility assays, suggests that the study did not involve any in vitro testing of HIV susceptibility to antiretroviral drugs.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database. However, the paper does report GenBank accession numbers for sequences generated in this study.

Rationale: The paper's mention of GenBank accession numbers suggests that the sequences were submitted to a public database, but the paper does not explicitly state that the sequences were made publicly available. Therefore, it is unclear whether the sequences are publicly available or not.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports GenBank accession numbers for sequences generated in this study, but does not provide a specific range or list of accession numbers.

Rationale: The paper's mention of GenBank accession numbers suggests that the sequences were submitted to a public database, but the paper does not provide any further information about the accession numbers.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study included 492 patient charts, but does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper's mention of 492 patient charts suggests that the study involved a large number of patients, but the paper does not provide any further information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not Reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any specific countries where the sequenced samples were obtained.

Rationale: The paper's lack of mention of specific countries suggests that the study did not provide any information about the geographic origin of the sequenced samples.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between January 2015 and December 2019, but does not provide any further information about the specific years when the sequenced samples were obtained.

Rationale: The paper's mention of the study period suggests that the sequenced samples were obtained during this time period, but the paper does not provide any further information about the specific years.

Answer: Not Reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper's lack of mention of cloning suggests that the study did not involve any cloning of samples prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any specific HIV genes that were sequenced.

Rationale: The paper's lack of mention of specific HIV genes suggests that the study did not provide any information about the genes that were sequenced.

Answer: Not Reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention any specific sequencing method.

Rationale: The paper's lack of mention of a specific sequencing method suggests that the study did not provide any information about the sequencing method used.

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the study involved sequencing of HIV samples from patients, but does not provide any further information about the type of samples.

Rationale: The paper's mention of sequencing of HIV samples from patients suggests that the study involved sequencing of clinical samples, but the paper does not provide any further information about the type of samples.

Answer: Not Reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper's lack of mention of sequences obtained from individuals with virological failure suggests that the study did not involve any sequencing of samples from individuals who had failed treatment.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper's lack of mention of a clinical trial suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included patients who were on ART, but does not provide any further information about the specific ARV drugs that were received.

Rationale: The paper's mention of patients who were on ART suggests that the study involved sequencing of samples from individuals who had previously received ARV drugs, but the paper does not provide any further information about the specific ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included patients who were on ART, but does not provide any further information about the specific drug classes that were received.

Rationale: The paper's mention of patients who were on ART suggests that the study involved sequencing of samples from individuals who had previously received ARV drugs, but the paper does not provide any further information about the specific drug classes.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included patients who were on ART, but does not provide any further information about the specific drugs that were received.

Rationale: The paper's mention of patients who were on ART suggests that the study involved sequencing of samples from individuals who had previously received ARV drugs, but the paper does not provide any further information about the specific drugs.

Answer: Not Reported",24
38058846,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study did not involve testing the susceptibility of HIV isolates to antiretroviral drugs in vitro.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The authors state that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. Additionally, the paper reports accession numbers for GenBank, which further supports the idea that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly states that sequences were submitted to GenBank, but the accession numbers are not provided.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that three cases were included in the study. The paper states that each patient included in this case series was managed directly by two of the authors.

Rationale: The paper explicitly states that three cases were included in the study, which suggests that three individuals had samples obtained for HIV sequencing.

Answer: 3

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country where the samples were obtained. However, the paper mentions that the study was conducted in South Africa.

Rationale: The paper does not explicitly mention the country where the samples were obtained, but the study was conducted in South Africa, which suggests that the samples were obtained from South Africa.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide specific dates for when the samples were obtained. However, the paper mentions that the study was conducted in 2020 and 2021.

Rationale: The paper does not provide specific dates for when the samples were obtained, but the study was conducted in 2020 and 2021, which suggests that the samples were obtained during this time period.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not mention cloning of samples prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region was sequenced.

Rationale: The paper explicitly states that the pol region was sequenced, which suggests that the study involved sequencing of the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used, which suggests that the study involved Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patients experienced virological failure on a treatment regimen.

Rationale: The paper explicitly states that the patients experienced virological failure on a treatment regimen, which suggests that the study involved sequencing of individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patients had previously received ARV drugs.

Rationale: The paper explicitly states that the patients had previously received ARV drugs, which suggests that the study involved sequencing of individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients received NRTI and INSTI.

Rationale: The paper explicitly states that the patients received NRTI and INSTI, which suggests that the study involved individuals who received these drug classes.

Answer: NRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients received TDF, FTC, AZT, and DTG.

Rationale: The paper explicitly states that the patients received TDF, FTC, AZT, and DTG, which suggests that the study involved individuals who received these drugs.

Answer: TDF, FTC, AZT, DTG",21
38072961,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and the methods mention ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping. The paper also reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which suggests that the sequences were obtained from patient samples. Additionally, the mention of ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping further supports this conclusion. The report of GenBank accession numbers also indicates that the sequences were submitted to a public database, which is consistent with the idea that they were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The methods and results sections do not report any values related to in vitro susceptibility testing.

Rationale: The paper focuses on the clinical and virological aspects of HIV infection, including the sequencing of HIV genomes from patient samples. However, it does not report any data related to in vitro drug susceptibility testing, which is a key aspect of understanding HIV drug resistance.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database. The provision of accession numbers in the text further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, specifically ""MN..."".

Rationale: The paper provides the accession numbers for GenBank, which are used to identify the sequences in the database.

Answer: MN...

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a single case report was presented, and the patient was a 27-year-old man with HIV infection.

Rationale: The paper presents a single case report, which suggests that only one individual had samples obtained for HIV sequencing.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples, but it does mention that the patient was a Chinese Manchu male.

Rationale: The paper does not provide explicit information about the country of origin for the sequenced samples, but the mention of the patient's ethnicity suggests that the samples may have been obtained in China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the patient was diagnosed with HIV infection five years ago and that the clinical samples were collected in 2022.

Rationale: The paper provides the year of diagnosis and the year of sample collection, which allows us to infer the time period during which the samples were obtained.

Answer: 2017-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention cloning prior to sequencing, but it does mention that the sequences were obtained using Sanger sequencing.

Rationale: The paper does not provide explicit information about cloning prior to sequencing, but the mention of Sanger sequencing suggests that the sequences may have been obtained directly from the patient samples without cloning.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol region was sequenced, including the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions that the pol region was sequenced, which includes the protease and reverse transcriptase genes.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper reports that Sanger sequencing was used to obtain the HIV sequences.

Rationale: The paper explicitly mentions that Sanger sequencing was used to obtain the HIV sequences.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the patient had virological failure on a treatment regimen and that the sequences were obtained from the patient's plasma.

Rationale: The paper explicitly mentions that the patient had virological failure on a treatment regimen and that the sequences were obtained from the patient's plasma.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention a clinical trial, but it does report that the patient was diagnosed with HIV infection five years ago and that the clinical samples were collected in 2022.

Rationale: The paper does not provide explicit information about a clinical trial, but the mention of the patient's diagnosis and sample collection suggests that the study may have been observational.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the patient had previously received ART and that the sequences were obtained from the patient's plasma.

Rationale: The paper explicitly mentions that the patient had previously received ART and that the sequences were obtained from the patient's plasma.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the patient had previously received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions that the patient had previously received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the patient had previously received tenofovir, lamivudine, and efavirenz.

Rationale: The paper explicitly mentions that the patient had previously received tenofovir, lamivudine, and efavirenz.

Answer: Tenofovir, Lamivudine, Efavirenz",20
38090027,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of drug susceptibility. Furthermore, the paper mentions specific platforms used for susceptibility testing, such as PhenoSense and Monogram.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. Additionally, the paper reports accession numbers, which are unique identifiers for sequences in these databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly reports accession numbers for GenBank, which are used to identify specific sequences in the database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1040 patients were included in the analysis.

Rationale: The paper explicitly mentions the number of patients included in the analysis, which is 1040.

Answer: 1040

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Italy.

Rationale: The paper explicitly mentions that the study was conducted in Italy, which suggests that the samples were obtained from patients in Italy.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between June 2019 and June 2021.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which is between June 2019 and June 2021.

Answer: 2019-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper explicitly mentions that the pol region was sequenced, which suggests that the study focused on sequencing the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which suggests that the study used Sanger sequencing to analyze the HIV sequences.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used.

Rationale: The paper explicitly mentions that plasma samples were used, which suggests that the study sequenced HIV from plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that virological failure was defined as two consecutive HIV-RNA values >50 copies/mL or a single HIV-RNA value >400 copies/mL.

Rationale: The paper explicitly mentions that virological failure was defined as two consecutive HIV-RNA values >50 copies/mL or a single HIV-RNA value >400 copies/mL, which suggests that the study included sequences from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a retrospective cohort study.

Rationale: The paper explicitly mentions that the study was a retrospective cohort study, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included treatment-experienced patients.

Rationale: The paper explicitly mentions that the study included treatment-experienced patients, which suggests that the study included sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included patients who had received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions that the study included patients who had received NRTIs, NNRTIs, and PIs, which suggests that the study included sequences from individuals who had received these drug classes.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included patients who had received AZT, 3TC, FTC, TDF, ATV/r, DRV/r, and MVC.

Rationale: The paper explicitly mentions that the study included patients who had received these specific drugs, which suggests that the study included sequences from individuals who had received these drugs.

Answer: AZT, 3TC, FTC, TDF, ATV/r, DRV/r, MVC",23
38140553,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. Additionally, the paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing” and reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of clinical samples for sequencing, which is a clear indication that HIV sequences were obtained from patient samples. The mention of genotypic resistance testing, HIV sequencing, and Sanger sequencing also supports this conclusion. Furthermore, the paper provides GenBank accession numbers, which is a common practice for publishing HIV sequences.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also does not mention any cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones.

Rationale: The paper focuses on the genetic diversity of HIV-1 and the prevalence of recombinant forms, but does not provide any information on in vitro drug susceptibility data. The absence of any mention of IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, as well as the lack of any cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses or patient-derived clones, suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that all nucleotide sequences obtained in the study were deposited in the international database of the Los Alamos laboratory. The paper also mentions that the sequences have been made available in a sequence database.

Rationale: The paper explicitly states that the sequences have been deposited in the Los Alamos laboratory, which is a common practice for publishing HIV sequences. The mention of making the sequences available in a sequence database also supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any specific GenBank accession numbers for the sequenced HIV isolates. However, the paper mentions that all nucleotide sequences obtained in the study were deposited in the international database of the Los Alamos laboratory.

Rationale: The paper does not provide any specific GenBank accession numbers, but mentions that the sequences have been deposited in the Los Alamos laboratory. This suggests that the sequences are available in the database, but the accession numbers are not provided in the paper.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study included 3178 HIV-infected patients from seven Russian federal districts.

Rationale: The paper explicitly mentions the number of patients included in the study, which is 3178.

Answer: 3178

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the paper mentions that the study included patients from seven Russian federal districts.

Rationale: The paper does not provide any information on the countries from which the samples were obtained, but mentions that the study included patients from seven Russian federal districts. This suggests that the samples were obtained from Russia.

Answer: Russia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study included samples collected between 2011 and 2020.

Rationale: The paper explicitly mentions the time period during which the samples were collected, which is 2011-2020.

Answer: 2011-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing. However, the paper mentions the use of Sanger sequencing and Illumina sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, but mentions the use of Sanger sequencing and Illumina sequencing. This suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions the sequencing of the HIV-1 pol gene, which includes the protease and reverse transcriptase regions.

Rationale: The paper explicitly mentions the sequencing of the HIV-1 pol gene, which includes the protease and reverse transcriptase regions.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions the use of Sanger sequencing and Illumina sequencing.

Rationale: The paper explicitly mentions the use of Sanger sequencing and Illumina sequencing, which are two different sequencing methods.

Answer: Sanger sequencing and Illumina sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions the sequencing of plasma, PBMC, and whole blood samples.

Rationale: The paper explicitly mentions the sequencing of plasma, PBMC, and whole blood samples.

Answer: Plasma, PBMC, and whole blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions the sequencing of samples from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions the sequencing of samples from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials.

Rationale: The paper does not mention any clinical trials, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions the sequencing of samples from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions the sequencing of samples from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions the use of NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions the use of NRTIs, NNRTIs, and PIs, which are three different drug classes.

Answer: NRTIs, NNRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions the use of AZT, 3TC, FTC, TDF, ATV, and DRV.

Rationale: The paper explicitly mentions the use of AZT, 3TC, FTC, TDF, ATV, and DRV, which are six different drugs.

Answer: AZT, 3TC, FTC, TDF, ATV, and DRV",25
38140649,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of HIV samples from patient samples. The mention of genotypic resistance testing, HIV sequencing, and Sanger sequencing also supports this conclusion. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database, further indicating that the study involved sequencing of patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all related to in vitro drug susceptibility testing. The mention of IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility also supports this conclusion. Additionally, the paper mentions specific platforms used for in vitro drug susceptibility testing, such as PhenoSense and Monogram.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The mention of accession numbers also supports this conclusion, as accession numbers are used to identify sequences in public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The accession numbers are listed as OR605755-OR606279 and OR613869-OR613875.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers for the sequences. The accession numbers are listed in the paper, which allows for the identification of the specific sequences.

Answer: OR605755-OR606279 and OR613869-OR613875

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 270 newly diagnosed treatment-naive persons entered the study, and 10 people did not meet the inclusion criteria. Therefore, the final data set consisted of 270 persons.

Rationale: The paper explicitly mentions that 270 newly diagnosed treatment-naive persons entered the study, and 10 people did not meet the inclusion criteria. This information allows for the calculation of the number of individuals who had samples obtained for HIV sequencing.

Answer: 270

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted at the Department for Immunological and Molecular Diagnostics at UHID in Croatia. The paper also mentions that the study population consisted primarily of men from Croatia.

Rationale: The paper explicitly mentions that the study was conducted in Croatia, which suggests that the sequenced samples were obtained from Croatia. The mention of the study population consisting primarily of men from Croatia also supports this conclusion.

Answer: Croatia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2019 and 2022. The paper also mentions that the study population consisted of newly diagnosed treatment-naive persons who entered clinical care at UHID in the period between January 2019 and December 2022.

Rationale: The paper explicitly mentions that the study was conducted between 2019 and 2022, which suggests that the sequenced samples were obtained during this time period. The mention of the study population consisting of newly diagnosed treatment-naive persons who entered clinical care during this time period also supports this conclusion.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that amplicons were cloned and sequenced. The paper also mentions that TA cloning/Topo TA cloning was performed.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing. The mention of TA cloning/Topo TA cloning also supports this conclusion.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the HIV-1 pol gene was amplified for two regions in two separate reactions: (1) sequencing of the HIV-1 protease and partial sequencing of the reverse transcriptase gene; and (2) sequencing of the HIV-1 integrase gene.

Rationale: The paper explicitly mentions that the HIV-1 pol gene was amplified for two regions, which suggests that the protease, reverse transcriptase, and integrase genes were sequenced.

Answer: Pol, PR, RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the SuperScript III One-Step RT-PCR System with Platinum Taq was used for the first round of amplification. The paper also mentions that the BigDye Terminator v3.1 Cycle Sequencing Kit was used for sequencing.

Rationale: The paper explicitly mentions that the SuperScript III One-Step RT-PCR System with Platinum Taq was used for the first round of amplification, which suggests that Sanger sequencing was used. The mention of the BigDye Terminator v3.1 Cycle Sequencing Kit also supports this conclusion.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma. The paper also mentions that the study used plasma HIV-1 RNA with RT-PCR/sequencing/genotyping.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma, which suggests that plasma samples were used for sequencing. The mention of plasma HIV-1 RNA with RT-PCR/sequencing/genotyping also supports this conclusion.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included individuals with virological failure on a treatment regimen. The paper also mentions that the study used the term ""virologic failure"" to describe individuals who had failed treatment.

Rationale: The paper explicitly mentions that the study included individuals with virological failure on a treatment regimen, which suggests that sequences were obtained from individuals with virological failure. The mention of the term ""virologic failure"" also supports this conclusion.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was conducted at the Department for Immunological and Molecular Diagnostics at UHID in Croatia. The paper also mentions that the study population consisted of newly diagnosed treatment-naive persons who entered clinical care at UHID.

Rationale: The paper explicitly mentions that the study was conducted at a department in Croatia, which suggests that the study was not a clinical trial. The mention of the study population consisting of newly diagnosed treatment-naive persons who entered clinical care also supports this conclusion.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included individuals who had previously received ARV drugs. The paper also mentions that the study used the term ""ART-experienced"" to describe individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included individuals who had previously received ARV drugs, which suggests that sequences were obtained from individuals who had previously received ARV drugs. The mention of the term ""ART-experienced"" also supports this conclusion.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who had previously received ARV drugs. The paper also mentions that the study used the term ""ART-experienced"" to describe individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included individuals who had previously received ARV drugs, which suggests that the individuals received various drug classes before sample sequencing. The mention of the term ""ART-experienced"" also supports this conclusion.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who had previously received ARV drugs. The paper also mentions that the study used the term ""ART-experienced"" to describe individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included individuals who had previously received ARV drugs, which suggests that the individuals received various drugs before sample sequencing. The mention of the term ""ART-experienced"" also supports this conclusion.

Answer: AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",36
38140667,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. Additionally, the paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing” and reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of clinical samples for sequencing, which is a clear indication that HIV sequences were obtained from patient samples. The mention of genotypic resistance testing, HIV sequencing, and Sanger sequencing also supports this conclusion. Furthermore, the paper provides GenBank accession numbers, which is a common practice for sharing sequence data.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions the use of cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293 with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays, which is a clear indication that in vitro drug susceptibility data was reported. The mention of IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility also supports this conclusion. Furthermore, the paper describes the use of cell-based susceptibility assays, which is a common method for measuring drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper also reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions the submission of sequences to public databases, which is a clear indication that sequences were made publicly available. The mention of accession numbers also supports this conclusion, as accession numbers are used to identify and share sequence data.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”. The accession numbers could be presented in the Methods, in a Table, or in a Data Availability statement.

Rationale: The paper explicitly mentions the use of GenBank accession numbers, which is a common practice for sharing sequence data. The mention of specific accession numbers also supports this conclusion.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from 955 people living with HIV in Ukraine and Poland.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing, which is a clear indication of the sample size.

Answer: 955

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in Ukraine and Poland.

Rationale: The paper explicitly mentions the countries where the sequenced samples were obtained, which is a clear indication of the sample origin.

Answer: Ukraine, Poland

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2012 and 2014.

Rationale: The paper explicitly mentions the year range for the collection of clinical samples, which is a clear indication of the sample collection period.

Answer: 2012-2014

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit.

Rationale: The paper explicitly mentions the use of cloning kits and cloning techniques, which is a clear indication that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the sequencing was done on the “pol region encompassing protease and reverse transcriptase”, “PR/RT”, “ViroSeq”, or “TruGene \(PR/RT\)”. The paper also mentions the sequencing of the “integrase coding region of pol”, “IN”, “p31”, “GeneSeq/ViroSeq Integrase”, “INSTI resistance”, “integrase sequencing”, or “GeneSeq/PhenoSense Integrase”.

Rationale: The paper explicitly mentions the specific HIV genes that were sequenced, which is a clear indication of the sequencing targets.

Answer: Pol, PR, RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions the use of ABI instruments, BigDye/ABI PRISM Dye Terminator, capillary sequencer/capillary electrophoresis with ABI analyzers, or direct PCR sequencing.

Rationale: The paper explicitly mentions the sequencing methods used, which is a clear indication of the sequencing approach.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma, blood plasma, stored/archived/cryopreserved plasma, or plasma specimens/samples.

Rationale: The paper explicitly mentions the type of samples that were sequenced, which is a clear indication of the sequencing source.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that sequencing or genotyping were done for participants with VL >50 copies/mL while on ART. The paper also mentions the use of terms like “not virally suppressed on ART”, “viremic on ART”, “viral rebound while on therapy”, or “unsuppressed while treated”.

Rationale: The paper explicitly mentions the use of sequencing or genotyping for participants with virological failure, which is a clear indication that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a randomized, double-blind, placebo-controlled trial.

Rationale: The paper explicitly mentions the use of a randomized, double-blind, placebo-controlled design, which is a clear indication that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper explicitly mentions the use of ARV drugs, which is a clear indication that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper explicitly mentions the use of ARV drugs, which is a clear indication of the drug classes received by individuals in the study.

Answer: NRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper explicitly mentions the specific ARV drugs received by individuals in the study, which is a clear indication of the drugs received.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",36
38142692,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing, and reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions the use of genetic sequencing on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. The mention of GenBank accession numbers also suggests that the sequences were submitted to a public database, further supporting the conclusion that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention cell-based susceptibility assays or use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not mention any methods or results related to in vitro drug susceptibility testing, which suggests that in vitro susceptibility data were not reported. The absence of any mention of phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay further supports this conclusion.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank, which contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences were made publicly available. The mention of GenBank accession numbers also supports this conclusion, as accession numbers are used to identify and access sequences in public databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are FJ800379–FJ800386, GQ477441-GQ477451, and KP170487.

Rationale: The paper explicitly mentions the accession numbers for GenBank, which are used to identify and access sequences in public databases. The accession numbers are provided in the text, which allows for easy extraction and reporting.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 1214 participants were included in the study, of whom 689 (57%) were switched to AZT/XTC/LPV/r, 217 (18%) to AZT/XTC/DTG, and 308 (25%) to TDF/XTC/DTG.

Rationale: The paper explicitly states the number of participants included in the study, which allows for easy extraction and reporting.

Answer: 1214

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in South Africa, and samples were collected from patients in the eThekwini Municipality of the KwaZulu-Natal province.

Rationale: The paper explicitly mentions the location of the study, which allows for easy identification of the country of origin for the sequenced samples.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between Dec 1, 2019, and Nov 30, 2020.

Rationale: The paper explicitly mentions the dates of the study, which allows for easy extraction and reporting of the year range.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention amplicons being cloned and sequenced, TA cloning, or Topo TA cloning. The paper does not mention single-genome amplification, single-proviral sequencing, or limiting dilution for direct sequencing.

Rationale: The paper does not mention any methods related to cloning or amplification of samples prior to sequencing, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region was sequenced, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions the sequencing of the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator, which suggests that Sanger sequencing was used.

Rationale: The paper explicitly mentions the use of ABI instruments and BigDye/ABI PRISM Dye Terminator, which are commonly used for Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma, which suggests that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions the use of plasma samples for sequencing, which allows for easy identification of the sample type.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included participants with virological failure on first-line NNRTI-based regimens, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions the inclusion of participants with virological failure on first-line NNRTI-based regimens, which supports the conclusion that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter trials. The paper does not mention ClinicalTrials.gov or an NCT number.

Rationale: The paper does not mention any characteristics of a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included participants who had previously received first-line NNRTI-based regimens, which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions the inclusion of participants who had previously received first-line NNRTI-based regimens, which supports the conclusion that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included participants who had previously received first-line NNRTI-based regimens, which suggests that NRTI and NNRTI classes were received by individuals in the study before sample sequencing.

Rationale: The paper explicitly mentions the inclusion of participants who had previously received first-line NNRTI-based regimens, which supports the conclusion that NRTI and NNRTI classes were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included participants who had previously received first-line NNRTI-based regimens, which included TDF/XTC/EFV and TDF/XTC/NVP.

Rationale: The paper explicitly mentions the inclusion of participants who had previously received first-line NNRTI-based regimens, which supports the conclusion that TDF, XTC, EFV, and NVP were received by individuals in the study before sample sequencing.

Answer: TDF, XTC, EFV, NVP",27
38152686,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and the sequences were submitted to GenBank with accession numbers.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples. Additionally, the paper reports that the sequences were submitted to GenBank with accession numbers, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility testing or cell-based susceptibility assays.

Rationale: The paper focuses on the clinical case of an HIV/TB coinfected patient who developed HIV treatment failure during dolutegravir therapy, and it reports on the sequencing and genotyping results. However, it does not mention any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that the sequences were submitted to GenBank with accession numbers.

Rationale: The paper explicitly states that the sequences were submitted to GenBank with accession numbers, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that the sequences were submitted to GenBank with accession numbers, but it does not provide the specific accession numbers.

Rationale: The paper mentions that the sequences were submitted to GenBank with accession numbers, but it does not provide the specific accession numbers. Therefore, it is not possible to extract the accession numbers from the paper.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that the patient was a 29-year-old male who was admitted with a right cervical mass and was diagnosed with HIV and TB.

Rationale: The paper focuses on the clinical case of a single patient, and it reports on the sequencing and genotyping results. Therefore, it is likely that only one individual had samples obtained for HIV sequencing.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country where the samples were obtained.

Rationale: The paper does not provide any information about the country where the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year when the samples were obtained.

Rationale: The paper does not provide any information about the year when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning or amplification of the samples prior to sequencing.

Rationale: The paper reports on the sequencing and genotyping results, but it does not mention any cloning or amplification of the samples prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the sequences were obtained from the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper mentions that the sequences were obtained from the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper reports on the sequencing and genotyping results, but it does not mention the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that the sequences were obtained from plasma.

Rationale: The paper mentions that the sequences were obtained from plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the patient was on a treatment regimen with dolutegravir and experienced virological failure.

Rationale: The paper mentions that the patient was on a treatment regimen with dolutegravir and experienced virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper reports on the clinical case of a single patient, but it does not mention any clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the patient was on a treatment regimen with dolutegravir and experienced virological failure.

Rationale: The paper mentions that the patient was on a treatment regimen with dolutegravir, which suggests that the patient had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the patient was on a treatment regimen with dolutegravir.

Rationale: The paper mentions that the patient was on a treatment regimen with dolutegravir, which is an integrase inhibitor.

Answer: INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the patient was on a treatment regimen with dolutegravir.

Rationale: The paper mentions that the patient was on a treatment regimen with dolutegravir, which is an integrase inhibitor.

Answer: Dolutegravir",17
38314093,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome sequencing. The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the study involved sequencing of patient samples. Additionally, the paper refers to various sequencing methods, including Sanger and Illumina, which are commonly used for sequencing patient samples. Furthermore, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database, indicating that they were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the study used a drug susceptibility assay to test the susceptibility of HIV isolates to various antiretroviral drugs. The paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions the use of cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions the use of a drug susceptibility assay, which is a common method for testing the susceptibility of HIV isolates to antiretroviral drugs. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are commonly used to measure drug susceptibility. Furthermore, the paper mentions the use of cell-based susceptibility assays, which are commonly used to test the susceptibility of HIV isolates to antiretroviral drugs.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers, which are unique identifiers for sequences in these databases. This suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly mentions accession numbers for GenBank, which are unique identifiers for sequences in the database. The accession numbers reported in the paper are in the format of GenBank accession numbers, which suggests that they are valid accession numbers.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 195 HIV-positive samples were obtained from patients in Meizhou, China.

Rationale: The paper explicitly mentions that 195 HIV-positive samples were obtained from patients in Meizhou, China. This suggests that the study involved sequencing of samples from 195 individuals.

Answer: 195

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were obtained from patients in Meizhou, China.

Rationale: The paper explicitly mentions that samples were obtained from patients in Meizhou, China, which suggests that the samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that samples were collected between May 2008 and December 2019.

Rationale: The paper explicitly mentions that samples were collected between May 2008 and December 2019, which suggests that the samples were obtained over a period of 11 years.

Answer: 2008-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not mention cloning of samples prior to sequencing, which suggests that the samples were not cloned before sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol region, including the protease and reverse transcriptase genes, was sequenced.

Rationale: The paper explicitly mentions that the pol region, including the protease and reverse transcriptase genes, was sequenced. This suggests that the study involved sequencing of the pol region.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper reports that Sanger sequencing was used to sequence the HIV isolates.

Rationale: The paper explicitly mentions that Sanger sequencing was used to sequence the HIV isolates, which suggests that the study involved Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the study involved sequencing of samples from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs, which suggests that the study involved sequencing of samples from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that individuals in the study received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions that individuals in the study received NRTIs and NNRTIs, which suggests that the study involved individuals who had received these drug classes.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that individuals in the study received AZT, 3TC, EFV, NVP.

Rationale: The paper explicitly mentions that individuals in the study received AZT, 3TC, EFV, NVP, which suggests that the study involved individuals who had received these drugs.

Answer: AZT, 3TC, EFV, NVP",25
38427738,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, “proviral DNA”, or “dried blood spots"". The paper also mentions that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" “MiSeq”, “single-genome sequencing"".

Rationale: The paper explicitly mentions the use of clinical samples for sequencing, which is a key criterion for answering this question. The mention of genotypic resistance testing, HIV sequencing, and specific sequencing methods also supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions the use of cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions the use of phenotypic susceptibility testing and reports specific values for drug susceptibility, which is a key criterion for answering this question. The mention of cell-based susceptibility assays also supports the conclusion that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions the submission of sequences to public databases and reports accession numbers, which is a key criterion for answering this question.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly reports accession numbers for GenBank, which is a key criterion for answering this question.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals. The paper also reports that X sequences were reported from Y individuals.

Rationale: The paper explicitly mentions the number of individuals from whom samples were obtained, which is a key criterion for answering this question.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in ""United States"". The paper also mentions that samples were collected in ""United States"".

Rationale: The paper explicitly mentions the country from which samples were obtained, which is a key criterion for answering this question.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between ""2010"" to ""2015"".

Rationale: The paper explicitly mentions the year range from which samples were obtained, which is a key criterion for answering this question.

Answer: 2010–2015

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper explicitly mentions the use of cloning, which is a key criterion for answering this question.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""pol genotyping/sequencing"" without providing individual genes. The paper also mentions the sequencing of ""pol region encompassing protease and reverse transcriptase"", ""PR/RT"", ""ViroSeq"", or ""TruGene (PR/RT)"".

Rationale: The paper explicitly mentions the sequencing of specific HIV genes, which is a key criterion for answering this question.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments, BigDye/ABI PRISM Dye Terminator, capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms.

Rationale: The paper explicitly mentions the use of Sanger sequencing, which is a key criterion for answering this question.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""PBMC"", ""peripheral blood mononuclear cells"", ""proviral DNA"", ""cell-associated DNA/RNA"".

Rationale: The paper explicitly mentions the type of samples used for sequencing, which is a key criterion for answering this question.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""virologic or virological failure (VF)"" or ""failing therapy or regimen"". The paper also mentions ""confirmed or protocol-defined virologic failure (CVF/PDVF)"" or ""incomplete viral suppression"".

Rationale: The paper explicitly mentions the use of sequences from individuals with virological failure, which is a key criterion for answering this question.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms. The paper also mentions ""phase I/II/III/IIIb/2/3 trial"" or ""analytical treatment interruption (ATI) within a trial"".

Rationale: The paper explicitly mentions the use of clinical trials, which is a key criterion for answering this question.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"". The paper also mentions ""virologic failure/failing therapy while receiving [drug/regimen]"".

Rationale: The paper explicitly mentions the use of sequences from individuals who had previously received ARV drugs, which is a key criterion for answering this question.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""treatment-naïve"", ""ART-naïve"", ""drug-naïve"", ""never exposed to antiretrovirals"", ""before ART initiation"", ""pre-ART"", ""newly diagnosed"", ""seroconverter"", ""blood donor"", ""primary/acute infection without ART"", or samples collected ""at diagnosis/baseline prior to therapy"".

Rationale: The paper explicitly mentions the lack of previous ARV exposure, which is a key criterion for answering this question.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"". The paper also mentions ""virologic failure/failing therapy while receiving [drug/regimen]"".

Rationale: The paper explicitly mentions the use of specific ARV drugs, which is a key criterion for answering this question.

Answer: AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC, IBA",36
38864613,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions sequencing on clinical samples, which is a strong indication that HIV sequences from patient samples were reported. Additionally, the mention of ART-naïve and ART-experienced patients, baseline and virologic failure samples, and transmitted drug resistance surveillance further supports the conclusion that HIV sequences from patient samples were reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility and resistance testing, which is a strong indication that in vitro drug susceptibility data was reported. Additionally, the mention of IC50, EC50, EC90, fold-change in susceptibility, and reduced susceptibility further supports the conclusion that in vitro drug susceptibility data was reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper also reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to public databases, which is a strong indication that sequences were made publicly available. Additionally, the mention of accession numbers further supports the conclusion that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as “PP827803 -- PP828572”.

Rationale: The paper explicitly states the accession numbers for GenBank, which is a strong indication that the accession numbers were reported.

Answer: PP827803 -- PP828572

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that sequences were generated from a panel of X isolates from the plasma of Y treatment-naïve or experienced individuals.

Rationale: The paper mentions a panel of isolates, which implies that multiple individuals were involved. However, the exact number of individuals is not specified.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries where the samples were obtained.

Rationale: The paper does not provide any information about the countries where the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the years when the samples were obtained.

Rationale: The paper does not provide any information about the years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing of the pol region, which includes protease and reverse transcriptase.

Rationale: The paper explicitly states that the pol region was sequenced, which implies that protease and reverse transcriptase were sequenced.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing, which was performed using ABI instruments.

Rationale: The paper explicitly states that Sanger sequencing was used, which is a strong indication that Sanger sequencing was the method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions sequencing of plasma, PBMCs, and proviral DNA.

Rationale: The paper explicitly states that sequencing was performed on plasma, PBMCs, and proviral DNA, which are strong indications that these types of samples were sequenced.

Answer: Plasma, PBMCs, proviral DNA

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions virologic failure and failing therapy, which implies that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly states that virologic failure and failing therapy were mentioned, which is a strong indication that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ART-experienced patients and virologic failure while receiving therapy, which implies that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly states that ART-experienced patients and virologic failure while receiving therapy were mentioned, which is a strong indication that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ART-experienced patients and virologic failure while receiving therapy, which implies that multiple drug classes were received.

Rationale: The paper explicitly states that ART-experienced patients and virologic failure while receiving therapy were mentioned, which is a strong indication that multiple drug classes were received.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ART-experienced patients and virologic failure while receiving therapy, which implies that multiple drugs were received.

Rationale: The paper explicitly states that ART-experienced patients and virologic failure while receiving therapy were mentioned, which is a strong indication that multiple drugs were received.

Answer: AZT, 3TC, FTC, TDF, ATV, DRV, MVC, CAB, LEN",24
